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“The reasonable man adapts himself to the world; 
the unreasonable one persists in trying to adapt the world to himself. 
Therefore all progress depends on the unreasonable man.” 
 
- George Bernard Shaw, Man and Superman, 1903 
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COVER 
 
FRONT: 
The front cover shows the application of an imine reductase for the reduction of cyclic imines and for 
the reductive amination of a ketone to generate primary or secondary chiral amines.  
 
BACK:  
The back cover illustrates the combination of an amine oxidase and an imine reductase in cascade 
reactions to transform polyamines into heterocyclic amines. In the first reaction the polyamine is 
transformed into an aminoaldehyde by the amine oxidase, thereby triggering its spontaneous cyclization 
to a cyclic imine which is in the second step reduced by the imine reductase.   
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VI ABSTRACT 
 
Chiral amines are an ubiquitously distributed class of bioactive compounds, what turns them into 
preferred scaffolds for pharmaceuticals. The high chemical and enantiomerical purities required for such 
an application are ideally suited for biocatalysis as enzymatic methods routinely display high 
specificities. The established methods for chiral amine synthesis with lipases, ω-transaminases and 
amine oxidases, however have considerable limitations regarding their access to pharmaceutically 
relevant chiral secondary and tertiary amines. Recently the new enzyme class of imine reductases 
(IREDs) was described, offering an attractive extension to the currently used techniques as the 
preparation of imines by chemical methods in organic solvents is a well established and widely 
applicable method. 
As the number of IREDs known initially was limited to only three enzymes, this project started with a 
database search for the discovery of novel enzymes. For the first time it was shown that the IRED family 
is much larger than assumed and over 350 novel, putative IREDs were identified. A sequence analysis 
of the database members revealed (R)- type and (S)- type superfamilies and led after an update to the 
identification of IRED specific sequence motifs. These criteria allowed to define this new enzyme family 
on a sequence level and discriminate them from the closest related homologues.  
Based on the biochemical information about the three published IREDs and a conservation analysis of 
the database members, three new enzymes from Streptosporangium roseum DSM43021, Streptomyces 
turgidiscabies and Paenibacillus elgii were selected for characterization. The enzymes were shown to 
encode for functional IREDs with much higher activity than the previously known IREDs. By site directed 
mutagenesis the mechanism of the IREDs was probed and the importance of a conserved Tyr for 
catalysis of an (S)- type IRED shown, while the crucial role of the proposed Asp residue for catalysis in 
the (R)- type IREDs was questioned. The characterization of the new IREDs revealed their pH optima 
and confirmed the suspected dimerization. The thermostability of the IREDs was investigated and the 
selected (S)- type IRED identified as the most stable enzyme known to date. Further the activity in the 
presence of water miscible organic solvents was tested and high tolerance versus MeOH found. In 
biotransformations all IREDs showed high activity and a broad panel of cyclic imines was fully converted 
to piperidines and tetrahydroisoquinolines with enantioselectivities up to 99% ee. With purified IREDs 
kinetic constants for these substrates were recorded and their substrate preference investigated. This 
indicated a preference of the (S)- type IRED for more bulky substrates, compared to the (R)- type IREDs. 
After optimization of the reaction conditions, with purified IREDs also high activities and chemo- as well 
as enantioselectivities for very labile exocyclic imines were detected. The possibility to effectively reduce 
already low levels of such imines led to the application of one (R)- type IRED for the generation of novel 
C-N bonds by reductive aminations. The established methodology revealed the crucial influence, 
conditions that favor imine formation (high molar excess of the amine nucleophile and high pH) display 
on the conversion rates. Under optimized conditions, different carbonyls could efficiently be transformed 
with a variety of amines in the aqueous buffer system with moderate to good conversions into primary 
and secondary (chiral) amines with very high selectivities (ee up to 98%). 
Finally, an application of IREDs in cascade reactions to produce saturated N-heterocyclic compounds 
was envisioned. A microbial putrescine oxidase (PuO) was chosen to selectively oxidize polyamines to 
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aminoaldehydes, thereby triggering their spontaneous cyclization to an imine. To target a broad range 
of heterocycles, PuO was characterized with a range of unnatural polyamines. The results indicated a 
narrow substrate scope and low activity for these compounds. To enhance the activity for such 
substrates directed evolution of PuO with epPCR was performed and led to the identification of a Glu 
residue, representing a hotspot for mutagenesis. This residue aligns to one of the multiple channels that 
lead into the deeply buried active site of PuO and it is located in the second shell around the active site. 
By site-saturation mutagenesis further mutants in the active site and this channel were generated and 
many mutants with smaller amino acids demonstrated the influence of this hotspot position to increase 
the activity of the enzyme. The best mutant exhibited considerably increased activities (up to 25-fold) 
for unnatural polyamines and also for natural polyamines the substrate spectrum was strongly shifted 
from putrescine towards longer polyamines like spermidine which is now transformed with a 10-fold 
increased catalytic efficiency (kcat/KM).  
The combination of both enzymes in purified form as well as in whole cells enabled the production of 
heterocyclic amines relying on the consecutive transformation of the substrate by both enzymes. While 
with the whole cell system only low amounts of the N-heterocyclic compounds were produced, the 
utilization of purified enzymes led in case of all three IREDs to high conversions of different polyamines 
into pyrrolines and piperidines.  
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VII ZUSAMMENFASSUNG 
 
Chirale Amine stellen eine allgegenwärtige Klasse an bioaktiven Verbindungen dar, weshalb sie auch 
bevorzugte Leitstrukturen für Pharmazeutika ausmachen. Die sehr hohen chemischen- und 
enantiomeren Reinheiten die für einen solchen Einsatz erforderlich sind, stellen ideale Vorrausetzungen 
für biokatalytische Herstellungsmethoden dar, da enzymatische Methoden oft hohe Spezifitäten 
aufweisen. Jedoch besitzen die derzeit etablierten Methoden die zur Synthese chiraler Amine eingesetzt 
werden können und auf Lipasen, ω-Transaminasen und Aminoxidasen basieren, beträchtliche 
Limitierungen was ihren Einsatz zur Darstellung pharmazeutisch relevanter chiraler sekundärer und 
tertiärer Amine betrifft. Kürzlich wurde mit den Iminreduktasen (IREDs) eine neue Enzymklasse 
beschrieben die eine attraktive Erweiterung zu den derzeit verwendeten Biokatalysatoren darstellt, da 
die chemische Synthese von Iminen in organischen Lösemitteln eine etablierte und breit anwendbare 
Methode repräsentiert. 
Da die Anzahl bekannter IREDs mit nur drei beschriebenen Enzymen zunächst sehr gering war, startete 
dieses Projekt mit einer Datenbankanalyse zur Entdeckung neuer Enzyme. Zum ersten Mal wurde 
hierbei gezeigt, dass die IRED Familie wesentlich größer ist als angenommen und über 350 neue, 
putative IREDs wurden identifiziert. Über eine Sequenzanalyse wurden die Datenbankvertreter in (R)- 
Typ und (S)- Typ Familien eingeteilt und nach einem Datenbankupdate wurden IRED spezifische 
Sequenzmotive identifiziert. Diese Kriterien ermöglichten die Definition von IREDs auf Sequenzebene 
und ihre Unterscheidung von den nächstverwandten Enzymen.  
Basierend auf publizierten biochemischen Daten der drei bekannten Enzyme und einer 
Konservierungsanalyse der Datenbankvertreter wurden drei neue Enzyme aus Streptosporangium 
roseum DSM43021, Streptomyces turgidiscabies und Paenibacillus elgii zur Charakterisierung 
ausgewählt. Es wurde gezeigt, dass diese Sequenzen für funktionale IREDs kodieren welche wesentlich 
höhere Aktivitäten besitzen als die bisher bekannten IREDs. Über ortsgerichtete Mutagenese wurde der 
Mechanismus der IREDs untersucht und der Einfluss eines konservierten Tyr auf die Aktivität der (S)- 
Typ IRED gezeigt, während gleichzeitig die essentielle Rolle des Asp Restes, welcher für die (R)- Typ 
IREDs als katalytisch wichtig vorgeschlagen wurde, hinterfragt wurde. Zur Charakterisierung der drei 
IREDs wurden deren pH Optima untersucht und die vermutete Dimerisierung bestätigt. Die 
Thermostabilität wurde untersucht und die ausgewählte (S)- Typ IRED als die stabilste der derzeit 
bekannten IREDs ausgemacht. Weiterhin wurde die Aktivität der IREDs in Gegenwart Wasser 
mischbarer organischer Lösemittel untersucht und eine hohe Toleranz gegenüber MeOH festgestellt. In 
Biotransformationen zeigten alle IREDs hohe Aktivitäten und eine breite Auswahl an zyklischen Iminen 
wurde vollständig umgesetzt und sowohl Piperidine als auch Tetrahydroisochinoline wurden mit sehr 
hohen Enantioselektivitäten von bis zu 99% ee erhalten. Mit den aufgereinigten IREDs wurden die 
kinetischen Konstanten für diese Substrate bestimmt und die Substratpräferenz der IREDs untersucht. 
Dies deutete auf ein breiteres Substratspektrum der (S)- Typ IRED hinsichtlich sperriger Substrate hin 
im Vergleich zu den (R)- Typ IREDs.  
Nach Optimierung der Reaktionsbedingungen mit aufgereinigten IREDs wurden zudem hohe Aktivitäten 
und sowohl Chemo- als auch Enantioselektivitäten für den Umsatz von sehr labilen exozyklischen 
Iminen gezeigt. Die Möglichkeit auch sehr geringe Mengen solcher Imine effektiv umsetzen zu können 
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führte zur Anwendung einer (R)- Typ IRED für die Generierung neuer Kohlenstoff-Stickstoff Bindungen 
durch reduktive Aminierung. Die entwickelte Methodik enthüllte den elementaren Einfluss welchen 
Reaktionsbedingungen die die Iminbildung begünstigen (hoher molarer Überschuss an Aminnukleophil 
und hohe pH Werte) auf die Umsatzraten besitzen. Unter optimierten Bedingungen konnte die effiziente 
Umsetzung verschiedener Carbonyle mit einer Auswahl an unterschiedlichen Aminen im wässrigen 
Puffersystem mit moderaten bis guten Umsetzungen und sehr hohen Selektivitäten (bis zu 98% ee) in 
primäre und sekundäre (chirale) Amine gezeigt werden. 
Des Weiteren wurde eine Anwendung der IREDs in Kaskadenreaktionen untersucht, die die Produktion 
von gesättigten, stickstoffhaltigen Heterozyklen ermöglicht. Eine mikrobielle Putrescinoxidase (PuO) 
wurde für die selektive Oxidation von Polyaminen zu Aminoaldehyden ausgewählt um deren spontane 
Zyklisierung zu einem Imin zu induzieren. Um dies auf ein breites Spektrum an Heterozyklen anwenden 
zu können, wurde die Aktivität der PuO mit einer Auswahl an nicht-natürlichen Polyaminen untersucht. 
Die Ergebnisse deuteten auf ein beschränktes Substratspektrum mit geringen Aktivitäten für diese 
Verbindungen hin. Zur Verbesserung der Aktivitäten für solche Substrate, wurde durch gerichtete 
Evolution über epPCR ein Glu Aminosäurerest identifiziert, welcher ein Hotspot für die Mutagenese 
darstellt. Die Seitenkette dieser Aminosäure befindet sich in einem der zahlreichen Kanäle die in die tief 
im Inneren des Enzyms liegende aktive Tasche führen, zudem befindet sich diese Aminosäure in der 
sogenannten zweiten Schale um das aktive Zentrum. Über ortsgerichtete Sättigungsmutagenese 
wurden weitere Mutanten im aktiven Zentrum des Enzyms und in diesem Kanal generiert; hierbei 
verdeutlichten mehrere Mutanten mit kleinere Aminosäureseitenketten den Einfluss der Hotspot 
Position darauf, die Aktivität des Enzyms zu erhöhen. Die beste Mutante wies beträchtlich gestiegene 
Aktivitäten (bis zu einer 25-fachen Erhöhung) für nicht-natürliche Polyamine auf und zeigte auch für 
natürliche Polyaminsubstrate eine starke Veränderung im Substratspektrum des Enzyms von Putrescin 
hin zu längeren Polyaminen wie Spermidin, die jetzt mit einer über 10-fach höheren katalytischen 
Effizienz (kcat/KM) umgesetzt wurden.  
Die Kombination aus beiden Enzymen sowohl in aufgereinigter Form, als auch in ganzen Zellen 
ermöglichte dann die Produktion von heterozyklischen Aminen welche auf die aufeinanderfolgende 
Transformation des Substrates durch beide Enzyme angewiesen war. Während mit dem 
Ganzzellsystem nur geringe Mengen der stickstoffhaltigen Heterozyklen gebildet wurden, resultierte die 
Verwendung von aufgereinigten Enzymen im Fall aller drei IREDs in hohen Umsätzen von 
verschiedenen Polyaminen zu Pyrrolinen und Piperidinen.  
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1 INTRODUCTION 
1.1 The importance of chiral amines in natural products and pharmaceuticals 
 
Optically active amines and amino acids play central roles in all living systems and the general 
importance these molecules and thereof derived heterocycles have for all organisms is directly reflected 
by their ubiquitous distribution in nature.1–4 As an example amino acids are the universal element of 
proteins and next to this they also function as precursors for DNA and RNA bases, so they are directly 
involved in the biosynthesis of all of the most important biological macromolecules.5 In addition, they 
also play crucial roles in the signaling in metabolic pathways and are part of many secondary metabolites 
like alkaloids.5–7 Following terpenes, alkaloids like nicotine represent the second largest class of natural 
products and most of them are also derived from amino acids (Scheme 1).6–8  
 
 
Scheme 1: Chiral amines in natural products derived from amino acids.  
The top row shows the proposed biosynthetic pathway for (S)-nicotine, the main alkaloid of tobacco plants.7 (S)-nicotine binds to 
acetylcholine receptors, making it a powerful stimulating drug that can lead to addiction.7 In contrast, (R)-nicotine is not active.7 
Decarboxylation of L-ornithine leads to diaminobutane, which is in the next step methylated at one of the amine moieties.6,7 
Oxidation of the other amine group to an aldehyde triggers the spontaneous cyclization.6,7 The cyclic imine is proposed to further 
react with an intermediate of the NAD biosynthesis, thereby introducing the dihydropyridine ring.6,7 The final step represents the 
oxidation to the pyridine.6,7  
Bottom row: One of the potential ephedrine biosynthesis pathways is shown. Ephedrine and other substituted amphetamines have 
various applications as precursors for pharmaceuticals.8 The biosynthesis of ephedrine starts from L-phenylalanine, but depending 
on the organism different metabolic routes are possible.8 In the one shown above after deamination, cinnamic acid is coupled to 
Coenzyme A by a cinnamyl-CoA ligase.8 In a biosynthetic route similar to the β-oxidation the carbon chain is shortened and later 
by a thiamine diphosphate-dependent enzyme with pyruvate again elongated, introducing the diketone motif.8 One of the carbonyl 
groups is transformed into the chiral amine by a ω-transaminase (ω-TA) and the other one is reduced.8 The last step represents 
the further modification by N-methylation.8  
 
The high biological activity provoked by many of these compounds is thought to be based on the 
structural information that is introduced by the ability of the chiral amines to build up numerous hydrogen 
bonds with adjacent (macro-) molecules.4,9 Hence, it is not surprising that such amines are prominent 
scaffolds for the synthesis of natural products including their analogs, pharmaceuticals and 
agrochemicals.3,4,9 Their leading role is underlined by the estimation that over 40% of all current 
pharmaceuticals contain chiral amines.2 The different biological activity chiral molecules display was 
already known for long but this importance tragically recollected during the early 1960’s with the 
insomnia drug thalidomide.2,10,11 Whereas the (R)- enantiomer of the drug had the desired effect, the 
(S)- enantiomer showed teratogenic outcomes (Figure 1), but the drug can also easily racemize 
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in vivo.2,11 Another example for the different effects the individual enantiomers of a drug can display are 
the two isomers of ethambutol (Figure 1). The (S,S)- enantiomer is an effective antituberculosis agent 
but the (R,R)- enantiomer causes blindness.3,10  
 
 
Figure 1: (R)- and (S)- enantiomers of thalidomide (left) and the (R,R)- and the (S,S)- forms of ethambutol (right). In both cases 
each enantiomer of the drug has very different effects. For thalidomide the (R)- enantiomer is the active drug, whereas the (S)- 
enantiomer showed teratogenic effects2,10,11 and in case of ethambutol the (S,S)- form is effective against tuberculosis, but the 
(R,R)- form can lead to blindness.3,10  
 
Following the thalidomide scandal, the American Food and Drug Administration and its European 
counterpart set strict rules for the approval of new pharmaceuticals and by 1992 toxicological tests for 
each single enantiomer of a racemic drug were required.2,3 Also for already licensed pharmaceuticals 
the reapproval in their enantiopure form resulted in attractive concessions, speeding up the chiral switch 
and leading to a boost of chiral chemistry in the pharmaceutical industry.3,11 The agrochemical industry 
followed up this trend as thereby also the economic effect is improved and the environmental impact 
reduced.3 In a study from the pharmaceutical industry by Carey et al. the importance of amines in the 
synthesis of pharmaceuticals was illuminated.12 More than 90% of all heterocyclic small molecule 
pharmaceuticals contain nitrogen atoms and the numbers for protections and deprotections of amino 
groups exceed by far the ones for hydroxyl-, carboxyl- and thiol groups.12 Chirality is often supplied in 
form of chiral building blocks and in these synthesis routes introduced as early as possible to maintain 
flexibility and reduce the number of steps.3,12 For compounds to serve as enantiopure building blocks 
however optical purities of > 99.5% ee are required.12 As it allows to approach higher yields asymmetric 
synthesis would be the desired strategy for the production of such building blocks, but on an industrial 
scale also the resolution of racemic materials is still a profitable process.3,10 Next to their direct use as 
building blocks chiral amines also have additional important roles for the synthesis of other enantiopure 
compounds. They are frequently used as chiral auxiliaries for stereoselective organic synthesis and can 
be used as resolving agents for the preparation of chiral carboxylic acids.3,13  
 
1.2 Chemical and biocatalytic methods for the preparation of chiral amines 
1.2.1 Chemical methods for the resolution of racemic amines and asymmetric 
synthesis for the stereoselective formation of amines 
 
Due to their prominent roles and many applications the demand for chiral amines is steadily 
increasing.2,3 Synthetic organic chemistry has harnessed much progress in every decade, but especially 
the above mentioned chiral switch resulted in the fast development of novel enantioselective synthesis 
routes for the production of chiral amines.14 The diastereomeric crystallization of chiral amines or 
carboxylic acids with amines and the use of chiral amines as auxiliaries seems therefore somehow 
outdated compared to sophisticated methods in asymmetric synthesis and although their impact is 
1 INTRODUCTION 
20 
decreasing in latest years, these methods still have some validation today.15 Frequently both methods 
lead to a rapid, reliable and highly selective way for production of the target molecule.3,13,16 The 
application of chiral auxiliaries often is straightforward and the setting of selectivity by such a strategy is 
relatively universal.13,16 Additionally, even for an imperfect selective outcome, the diastereomeric 
character of the intermediate allows an easy separation.13,16 Due to its simplicity and the ease of use 
the diastereomeric crystallization of amines was also on an industrial scale a popular method some time 
ago.3,10,15 In the last years however, the trend was rather to use this method as a second step for 
enantioenrichment in case asymmetric synthesis did not result in the desired purity, than for the 
crystallization of racemic mixtures.9,15 Nevertheless established processes are still running and for 
example the resolution of (S)-2-aminobutanol, which is the key chiral intermediate for one of the most 
important tuberculosis drugs (ethambutol), is still performed by resolution with L-(+)-tartaric acid.3,10,17 
 
 
Scheme 2: Diastereomeric crystallization of (S)-2-aminobutanl with L-(+)-tartaric acid to produce the chiral precursor for the 
tuberculosis drug ethambutol. 
 
Nevertheless asymmetric synthesis has made tremendous improvements for the preparation of chiral 
amines driven by the recent progress in organocatalysis and by the development of chiral ligands for 
transition metal catalysts.14 The enantioselective hydrogenation of enamides and enamines is a way to 
generate chiral amines and radical- and nucleophilic addition reactions to (activated) imines, catalyzed 
by metals or chiral phosphoric acids, are also intensively investigated.1,9,16,18 In contrast, the 
metallonitrene catalyzed C-H amination and the asymmetric hydroamination of unsaturated carbon-
carbon bonds are a rather new fields of research.1,16 However, the broad availability of alkynes, allenes 
and dienes and the high atom economy of the latter process render it an attractive target, albeit 
especially the amination of alkenes remains challenging due to the high energetic activation barrier that 
has to be overcome.1,16 The detailed reviewing of all of these methods is beyond the scope of this 
introduction and therefore only the (asymmetric) reductive amination, which is regarded as the most 
popular and broadly applicable method for the enantioselective synthesis of chiral amines will be 
introduced.9,14,19,20  
The basic principle for the reductive amination is the condensation of a carbonyl and an amine. This 
versatile and widely applicable coupling reaction directly leads to the imine intermediate of the reaction, 
which is in the next step reduced to the amine.9 A strict definition of this process would be the direct one 
pot transformation of a ketone or aldehyde into an amine, without the isolation of the imine intermediate 
which is sometimes described as an indirect reductive amination.9 Two-step processes that involve 
previous imine formation (but not isolation), before the reducing agent is applied are however covered.1,9 
Challenges that are arising for such direct reductive amination procedures are related to the choices of 
suitable and highly selective catalysts and reducing reagents.9,14 Chemoselectivity is crucial, as the 
undesired reduction of the starting carbonyl to an alcohol has to be avoided, but the imine must efficiently 
be targeted.9,14 Further, other reducible intermediates like hemiaminals and enamines that are arising 
during imine formation or from isomerizations should also not be reduced.9,14 To achieve a highly 
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enantioselective outcome in this reaction is also difficult and sets special requirements to the catalysts. 
Acyclic imines form mixtures of E/Z intermediates, complicating the stereoselective reduction.9,14 Finally, 
the elimination of water is an essential step to shift the equilibrium of the carbonyl and amine 
condensation towards the side of the imine.1,9,14,16,20 
For reductive aminations, the asymmetric hydrogenation of the imine intermediate with stoichiometric 
amounts of H2 gas is particularly attractive.1,16,21 Unfortunately the high pressure required and the 
leaching of the expensive metals (in most cases Ru, Rh and Ir are employed) hampers large scale 
applications.1,16,21 Nevertheless such methods are viable for industrial production and one of the world’s 
largest enantioselective catalytic processes is the chiral Ir-Xyliphos catalyzed imine hydrogenation to 
produce the herbicide (S)-metolachlor (Scheme 3).1,16,22,23 
 
 
Scheme 3: Ir-catalyzed enantioselective hydrogenation to produce the chiral intermediate for the synthesis of the herbicide 
(S)-metolachlor.23 This process is performed on an industrial scale and with > 10 000 t per year one of the largest enantioselective 
catalytic processes.23  
 
Inspired by the fact that the majority of chiral molecules is not produced by organometallic catalysis but 
by nature, the groups of List and MacMillan, amongst others, have pioneered organocatalytic methods 
with Hantzsch esters (HEH) as hydrogen source for enantioselective imine reduction.24–26 Hantzsch 
esters can be seen as an organocatalytic mimic to the biological reducing agents NAD(P)H and the use 
of chiral phosphoric acids results in the coordination and activation of the HEH and the imine.24,25 By 
this method the direct reductive amination of a broad range of (aromatic) ketones and aromatic amines 
was shown with quite high selectivities (Scheme 4).24–27  
 
 
Scheme 4: Overview about some of the reductive aminations performed by Storer et al..25 Various acetophenone derivatives were 
reacted with p-anisidine to form the imine intermediates.25 The addition of the molecular sieve (MS) was critical to shift the 
equilibrium.25 An example for one of the chiral phosphoric acid catalysts that were investigated is shown on the right side.25 Also 
shown is the Hantzsch ester (HEH) that was employed as reducing agent.  
 
Heterocyclic amines like pyridines, piperidines and pyrrolidines have important roles as solvents, but 
especially the chiral derivatives of the saturated heterocyclic compounds find also numerous 
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applications as building blocks for pharmaceuticals.28,29 They are usually obtained by hydrogenation of 
pyridines at elevated temperatures and pressure in the presence of metal catalysts like nickel, palladium 
or ruthenium.28,30 In combination with chiral auxiliaries this can be used for an asymmetric 
hydrogenation, directly leading to enantioenriched products.31 In other cases crystallizations or kinetic 
resolution were investigated32,33 and in some cases also asymmetric reductive amination reactions have 
been developed.34 Nevertheless, their preparation in high yields with high enantiomeric excess amounts 
remains challenging.29 For example, for the rather simple (R)-2-methylpyrrolidine, which finds 
applications in histamine H3-receptor antagonistic drugs35,36 or as part of HIV reverse transcriptase 
inhibitors,37 Merck has published an optimized synthesis route.29 It starts from the readily available 
N-Boc-protected L-proline and within 4 steps the product is obtained in about 80% yield with > 99% ee.29 
This represented a tremendous improvement to the previously reported crystallization process of 
racemic 2-methylpyrrolidine that required several recrystallizations, diminishing the yield to only 28%29 
and at the same time reveals the potential the asymmetric reduction of cyclic imines has to improve the 
synthesis for such important pharma precursors.  
 
1.2.2 Strategies and challenges for the biocatalytic generation of chiral amines  
 
The importance of biocatalysis to solve synthetic challenges is steadily increasing as it becomes more 
and more a facile usable technology.38–40 Biocatalysis is therefore regarded as an important extension 
to currently established techniques in the chemical industry.38–40 These changes are driven by the 
immense technological progress in biochemistry and molecular biology.38–41 The vast availability of 
genetic information, combined with high throughput screening methods and novel bioinformatics tools 
have considerably facilitated the identification and production of novel enzymes.38–41 These 
combinations have led to numerous examples for novel enzymes and their application for the generation 
of chiral intermediates.2,38,41–45 The high chemo-, regio- and enantioselectivities enzymes often display 
are one of the driving forces for this development.3,38–40 Next to that biocatalysis benefits also from mild 
reaction conditions and is generally regarded as “green”.3,38–40 
Maybe less focused are some of the still remaining drawbacks of biocatalysis. Current chemistry focuses 
mainly on rather unpolar aliphatic hydrocarbons that display in contrast to the natural sugar based 
feedstock only limited solubility in aqueous solvents.40,46,47 Under a space-time yield perspective 
however the low concentrations that are accessible represent a significant challenge, further do they 
complicate the downstream processing of the final products.47 Yet, the shift to unphysiological conditions 
to overcome these limitations by increasing the temperature or the addition of organic solvents often 
results in low stability of the biocatalyst.48,49 The engineering of enzyme stability is therefore an important 
task next to increasing the activity and selectivity.48,49 Another drawback for biocatalysis is that many 
reactions that are performed in synthetic chemistry are not available to enzymes.50 The discovery of 
novel enzymes and the improvements in computational enzyme design and engineering, however also 
resulted in first noticeable advances for non-natural reactions catalyzed by protein scaffolds.38,41,51–56  
A recently published and highly respectable example illustrating many of the above mentioned 
tremendous proceedings is the engineering of a (R)- selective ω-transaminase (ω-TA), performed by 
Codexis Inc. and Merck for the preparation of the anti-diabetic drug sitagliptin (Scheme 5).57 Structure 
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guided and random approaches were combined and in 11 rounds of mutagenesis the final biocatalyst 
acquired 27 mutations, showing now enhanced activity (~ 40000-fold) and stability under conditions 
applicable for an industrial process.38,57 Compared to the chemical Rh-catalyzed process the yields 
would be over 10% increased, the productivity over 50% increased and at the same time the produced 
waste reduced by about 19%.38,57 
 
 
Scheme 5: Highly selective ω-TA-catalyzed amination of prositagliptin to produce the chiral amine of the drug. Over 11 rounds of 
mutagenesis the activity and stability of the biocatalysts was optimized.57 The evolved enzyme is stable and active in 50% DMSO 
at 45 °C and tolerates high substrate loadings.57 To shift the reaction equilibrium towards the amination, isopropylamine is used 
as amine donor and the coproduct acetone removed by evaporation at the elevated temperatures and reduced pressure.57  
 
1.2.3 Enzymes and enzymatic cascade reactions for the preparation of primary 
α-chiral amines 
 
The possibility to use ω-TAs for the preparation of chiral amines was already shown above at the 
example of the drug sitagliptin, however also other enzymatic methods for the production of chiral 
primary amines are available and have been commercialized. In Figure 2 an overview about some of 
the most widely applicable enzymatic methods for the generation of primary α-chiral amines is given 
and these enzymes might hence be summarized as an enzymatic toolbox for chiral amine synthesis.  
 
 
Figure 2: Biocatalyst toolbox comprising the most popular enzymes for the production of primary chiral amines by kinetic resolution 
or asymmetric synthesis. 
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The kinetic resolution of racemic starting material is possible with lipases and ω-transaminase and the 
ChiPros® process of BASF is able to supply enantiopure (R)- and (S)- amines on a ton scale 
(Scheme 6).2,3,46,58–61 Amongst others, the lipase from Burkholderia plantarii and Candida antarctica 
lipase B are employed for the acetylation of the (R)- amine, yielding the (S)- enantiomer in almost pure 
form.3,58 After separation by distillation or extraction, the (R)- amide is cleaved under basic conditions, 
giving also access to this product in enantiopure form.3 Alternatively, if only one of the enantiomers is 
required, the process can sometimes be transformed into a dynamic kinetic resolution to approach more 
than 50% yield, but the inclusion of such a racemization step typically requires harsh conditions 
(Scheme 6).59 
 
 
Scheme 6: Lipase catalyzed dynamic kinetic resolution by methoxyacetylation of racemic amines to produce enantiomerically 
enriched amines.58,59 By the racemization of the unreacted enantiomer the yields can be increased above 50%, but this typically 
requires harsh conditions.59 The bottom row shows some of the products that are accessible on a ton scale by the ChiPros® 
process of BASF.1,61  
 
By employing the deamination reaction, ω-TAs can also be used for a kinetic resolution, but the more 
interesting alternative is to use them for asymmetric synthesis by performing the amination reaction and 
approaching higher yields than 50% under suitable reaction conditions.62,63 Such a reaction formally 
represents a reductive amination as the prochiral starting ketone is transformed into an amine.62,64 
Difficulties for such a process are the unfavorable reaction equilibrium for reductive aminations, requiring 
the amine donor to be present in high excess and/or the removal of the formed co-product.65 The 
sitagliptin process for example uses isopropylamine as amine donor and the formed co-product acetone 
is removed at higher temperatures and low pressure.57 As ω-TAs are frequently inhibited by higher 
concentrations of these co-substrates and co-products also cascade reactions to recycle the amine 
donor and shift the equilibrium have been envisioned.59,64–70 These parameters still set a burden for 
large scale applications of ω-TAs and might require extensive protein engineering. In contrast, other 
problems that have encountered ω-TAs a couple of years ago are solved. Initially most of the described 
enzymes showed (S)- selectivity, but in a study by Höhne et al. 17 novel (R)- selective transaminases 
were identified.71 Additionally many mutants with a broadened substrate scope and high throughput 
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screening (HTS) methods for these enzymes have been reported.57,66,68,72 Their increased popularity 
also promoted the exploitation of ω-TAs for reaction cascades. The bioamination of alkenes after 
oxyfunctionalization73 and the amination of alcohols by combining alcohol dehydrogenases (ADHs) and 
ω-TAs was described.74 Additionally, these enzymes were employed for the production of 
aminoalcohols. In a work published by Sehl et al. the combination of thiamin diphosphate-dependent 
lyases and ω-TAs with different selectivities allowed to produce all different isomers of norephedrine 
(1R,2S and 1S,2R) and norpseudoephedrine (1R,2R and 1S,2S) (Scheme 7).75,76  
 
 
Scheme 7: Enzymatic cascade reaction to generate different ephedrine isomers, published by Sehl et al..75,76 By using two 
enantiocomplementary pyruvate decarboxylases first the carbon skeleton is assembled and the stereocenter of the hydroxyl group 
is set.75,76 By a combination with enantiocomplementary ω-TAs then the second stereocenter was introduced with the chiral 
amine.75,76 
 
In contrast to ω-TAs amino acid dehydrogenases and thereof derived amine dehydrogenases perform 
a “true” reductive amination (Scheme 8). Amino acid dehydrogenases are known for long time and the 
reductive amination of α-ketoacids with these enzymes is performed on an industrial scale to produce 
natural and unnatural amino acids.44,62,77 The power to assimilate free ammonia makes them potent 
enzymes for the generation of chiral amines distinguishing them also from most other enzymes in the 
above shown summary (Figure 2). In this way alanine dehydrogenase is also frequently used for the 
“real” reductive amination part in cascades that involve ω-TAs by recycling the generated pyruvate to 
alanine, which serves as the amine donor.64,65 Several crystal structures of these enzymes are available 
and the mechanism was investigated in detail.78–80 As most enzymes are specific for natural amino 
acids, the first D-amino acid dehydrogenase that has a broad substrate specificity was obtained by 
protein engineering81 and this technique was also used to expand the substrate scope to unnatural 
homo-amino acids82,83 or to β-keto acids for production of unnatural β-amino acids.84 An even more 
aspirational engineering approach was performed for the first time in the group of Bommarius. By 
saturation mutagenesis of amino acids in the carboxyl binding pocket of the active site, the enzymes 
were relieved from their dependency on α-ketoacids.85 These newly generated amine dehydrogenases 
were evolved from a leucine dehydrogenase85 and phenylalanine dehydrogenase scaffold86 and are 
able to perform the reductive amination of different ketone substrates with ammonia.85,86 Due to the 
great potential such “reductive aminases” have to produce chiral amines they were further evolved87 
and also other groups have generated such enzymes.88,89 During the writing of this thesis also two 
articles covering the amination of alcohols by the combined action of ADHs and an amine 
dehydrogenase in a cascade reaction were published.89,90 Yet, as these enzymes depend on the parent 
amino acid dehydrogenase scaffold, showing L-selectivity, it seems logical that they only allow access 
to one of the two enantiomers and still depend on ammonia as nitrogen source, leading to primary 
amines.  
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Scheme 8: Reductive aminaton of α-keto-acids (phenylpyruvate is shown here) with ammonia by phenylalanine dehydrogenase 
and NADH as reducing agent.79,80 Lys78 is an essential amino acid for activation of the α-keto group to facilitate the nucleophilic 
attack of ammonia.78–80 The imine intermediate is stabilized by an Asp residue and reduced by a hydride transfer from NADH.79,80 
Lys66 constitutes the carboxyl binding pocket and was the first amino acid to be mutated in the studies by Abrahamson et al. to 
generate amine dehydrogenases.78–80,85  
 
Next to amino acid dehydrogenases ammonia lyases are able to assimilate a source of free nitrogen 
and form novel carbon-nitrogen bonds. Under suitable conditions (high ammonia concentrations) the 
hydroamination reaction of these enzymes can be exploited for the asymmetric synthesis of various 
natural and unnatural amino acids and derivatives thereof.50,91–97 These enzymes also have been 
engineered and coupled with L-amino acid oxidases or D-amino acid oxidases in cascades to produce 
enantiomerically pure L- and D-phenylalanine derivatives by deracemizations, starting for both with 
cinnamic acids.95 
 
1.2.4 Enzymes and enzymatic cascade reactions for the preparation of secondary 
and tertiary α-chiral amines 
 
As it was described above in detail, most enzymatic methods only allow access to primary amines and 
the number of enzymes than can additionally be used for asymmetric synthesis of secondary and tertiary 
amines is rather small (Figure 3). 
 
Figure 3: Biocatalyst toolbox comprising an overview about enzymatic methods that were reported for the generation of secondary- 
and tertiary chiral amines. In addition to this application, amine oxidases and imine reductases can also be used to generate 
primary amines.  
1 INTRODUCTION 
27 
A noticeable engineering approach of ammonia lyases broadened the substrate scope of 
methylaspartate ammonia lyase.98 Next to ammonia now also a few other amine nucleophiles are 
accepted and the electrophile acceptor scope was enlarged to some fumarate derivatives.98 These 
mutations enabled methylaspartate ammonia lyase now also to be applied for the production of amino 
acid derivatives with secondary amines.98 Since amino acid lyases are considered as one of the most 
selective enzymes,50 despite these first improvements their substrate spectrum is still considered as 
very limited. Next to this enzyme also some more “exotic” enzymes catalyzing transformations that result 
in the selective establishment of carbon-nitrogen bonds for secondary and tertiary amines have recently 
been described or engineered (Figure 3). Derived from alkaloid biosynthesis the oxidative carbon-
carbon bond forming reaction of the berberine bridge enzyme also results in chiral amines99–101 as do 
the “Pictet-Spenglerases” norcoclaurine synthase and strictosidine synthase.102–105 The group of 
Frances Arnold has recently published their engineering of P450BM3 (better P411 as the most active 
variants had the Cys ligand of the heme replaced by Ser) for CH amination.55 Finally, Codexis Inc. has 
patented engineered opine dehydrogenase variants with up to 29 mutations, acquired over 11 rounds 
of directed evolution, that are able to perform reductive aminations and produce chiral secondary and 
tertiary amines under industrial relevant conditions (see also 4.5.2).106,107  
The above described enzymatic transformations are all excellent examples for the discovery and 
engineering of new enzymes and enzymatic activities that in the future might play important roles for 
chiral amine synthesis, however currently they lack general applicability. Hence, the most popular 
enzymatic methods published in literature that are applicable for secondary and tertiary amines are 
deracemizations employing monoamine oxidase from Aspergillus niger (MAO-N).2 In the initial discovery 
of this flavin containing enzyme from the fungi Aspergillus niger by Schilling and Lerch it showed mainly 
activity with a few primary aliphatic monoamines.108,109 Directed evolution performed in the group of 
Turner over about 15 years led to numerous enzyme variants with broadened substrate scope, activity 
and improved selectivity.110–115 The first mutants allowed the deracemization of primary amines (mainly 
α-methylbenzylamine and derivatives thereof, Scheme 9),110,111 but soon also variants with activity for 
secondary111,112,116 and tertiary amines113,115 were generated. By solving the crystal structures of several 
mutants also the effects for (some of) the mutations could be rationally assigned and more focused 
libraries were generated.115,117 For deracemizations the strict (S)- selectivity of MAO-N is used and 
combined with a nonselective reducing agent (Scheme 9).2,118 In such a procedure the unreacted (R)- 
enantiomer accumulates and the product can be obtained in (theoretically) 100% yield.2,118 
For the preparation of the other enantiomer, (R)- selective amine oxidases have been developed by 
protein engineering from a D-amino acid oxidase and a D-nicotine oxidase, enabling now access to (S)- 
amines.119,120 Next to the group of Turner also industry has evolved MAO-N121 for its application in 
deracemizations on production scale.38,121 Deracemizations with MAO-N are however not restricted to 
these one step transformations. The combination with ω-TAs was explored in several examples122,123 
and for non-chiral amines with ω-TAs also dealkylation reactions have been envisioned.123 Further, the 
combination with artificial metalloenzymes capable of imine reduction was investigated (see also 
below).124 
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Scheme 9: Deracemization of α-methylbenzylamine with the (S)- selective MAO-N.39 The unreacted (R)- enantiomer accumulates 
as the reduction of the imine is not selective.39,118  
 
1.2.5 Imine reductases – a novel class of enzymes with the ability to generate primary, 
secondary and tertiary amines 
 
Clearly, although much progress was made, there is still a lack of generally applicable enzymatic 
methods for the generation of secondary- and tertiary amines, especially regarding at the same time the 
formation of novel carbon-nitrogen bonds. Actually such a reaction would exactly represent an 
enzymatic counterpart for the reductive amination procedure in organic chemistry, the most widely 
applicable and popular chemical method for the generation of chiral amines.9,19 Unfortunately only 
limited numbers of imine reducing enzymes were described, although imines represent crucial 
intermediates in metabolic pathways.125–128 Especially their hydrolytic sensitive nature for long hindered 
a more detailed investigation of their potential as precursors for the generation of a broad range of chiral 
amines. Li et al. were the first ones to report the screening of a dynamic combinatorial library for the 
generation of various amines over imine intermediates, using caffeate induced whole cells of 
Acetobacterium woodii.129 The responsible enzyme however was not reported so far. Also other groups 
have reported the reduction of imines by different strains, including Saccharomyces cerevisiae,130 
Candida parapsilosis ATCC 7330,131 Saccharomyces bayanus132 and cell free extracts of Eisenia 
foetida.133 However in none of these reports the responsible enzyme was identified. The lack of enzymes 
suitable for the reduction of synthetically useful imines promoted the group of Thomas Ward to develop 
artificial metalloenzymes by the incorporation of biotinylated aminosulfonamide ligands with Rh, Ru and 
Ir in a protein (streptavidin) scaffold able to stereoselectively reduce imines.124,134–136  
The identification of the now designated class of imine reductases (IREDs) was then accomplished by 
Mitsukura et al..137–139 In their work, published 2010, imine reducing activity was detected after screening 
a large range of microorganisms (688 in total) for the reduction of the cyclic imine 2-methylpyrroline 1.137 
Bacterial strains of the genus Streptomyces that resulted in the formation of the (R)- and (S)- amine 
products (a secondary amine) were identified and for the first time the following identification of the 
enzymes was also successfully achieved.137,139–141 Shortly thereafter, in 2011 the identification and 
purification of the (R)- selective IRED was published138 and in 2013 also the cloning of the (S)- selective 
enzyme.139 Meanwhile also the first crystal structure of a third IRED (an (R)- selective enzyme from 
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Streptomyces kanamyceticus (R-IRED-Sk)) was solved and a mechanism proposed.142 An Asp residue 
in the assumed active site was suggested to be catalytically important for protonation of the imine 
substrate and its crucial role verified by site directed mutagenesis (Figure 4).142 
 
 
Figure 4: Left: Active site cleft of R-IRED-Sk with the NAPDH cofactor in black and the proposed catalytic Asp residue in red (pdb 
code R-IRED-Sk: 3zgy142). Subunit A of the IRED is shown in green and subunit B in blue. Right: Proposed mechanism for the 
enzymatic imine reduction by the Asp containing IRED.142 Protonation of the imine substrate by the active site amino acids to an 
iminium ion is followed by the hydride transfer from NADPH.142 This mechanism was suggested by Rodríguez-Mata et al. for an 
Asp containing IRED.142 Replacement of Asp by either Asn or Ala rendered the enzyme inactive (bottom right).142 
 
In the initial report on the newly discovered R-IRED a small set of imines, ketones and heterocyclic 
compounds (furanes, imidazoles, thiazoles, pyrimidines and pyrazines) was investigated for reduction, 
but activity was only found for imine 1.138 Also the substrate spectrum of the S-IRED was reported to be 
narrow and restricted to a few imines.139 The very restricted substrate spectrum of the (S)- selective 
enzyme described by Mitsukura et al.139 was in a following work published 2013 by Leipold et al. however 
revised143 and broad activities and very high selectivities demonstrated for this enzyme.139,143 The 
investigated substrates comprised many cyclic imines and iminiums (pyrrolidines, piperideines, 
isoquinolines and others) and led to the formation of chiral secondary and tertiary amines by using the 
wild type (wt) enzyme.143 The enormous potential for the preparation of chiral amines with IREDs that 
was suggested by the study of Leipold et al.143 led to a rapid increase of published new IREDs and 
applications of them since 2014.144–153 A new enzyme from Streptomyces aurantiacus was described by 
the group of Prof. Dr. Müller and its crystal structure solved in cooperation with the group of Prof. Dr. 
Einsle.144 In addition, the crystal structure of the (S)- selective IRED, which was initially described by 
Mitsukura et al.139 was solved and the potential of these IREDs investigated for the reductive amination 
of ketone substrates.144 The IREDs proved to be functional for this reaction, however the conversions 
were very low (from 0.1% to maximum 8.8% with 76% ee).144 A few weeks later our group published 
their investigations on the discovery of novel IREDs.145 By a database analysis it was for the first time 
shown, that the IRED family is much larger than assumed: hundreds of putative enzymes were identified 
and by characterization of three selected members, these enzymes were shown to encode for functional 
IREDs, with much higher activities than the previously described IREDs.145 In this study also catalytically 
important residues were identified and verified by site-directed mutagensis.145 To not anticipate these 
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findings, details about this discovery and the characterization of these enzymes, as well as the 
investigations on their substrate spectrum and the comparison with other IREDs that were published in 
the last two years during this work was ongoing will be presented and discussed in the following 
chapters.  
 
1.2.6 The integration of IREDs in cascade reactions to prepare chiral amines 
 
A first publication of a reaction cascade that included the use of an IRED to prepare chiral amines was 
published during the writing of this thesis.153 In this work, performed in the group of Turner, an IRED 
was combined with the (R)- selective amine oxidase 6-HDNO120 for deracemizations.153 As in contrast 
to the nonselective reduction with ammonia borane the reduction with the IRED is selective, higher 
enantiomeric excess values can be approached in fewer cycles of the deracemization procedure (see 
also Scheme 9 for the deracemization with a nonselective reducing agent).153 Likewise also the use of 
enantiocomplementary IREDs and the (S)- selective MAO-N might be envisioned.  
In addition one application of ω-TAs is described that led to chiral saturated heterocyclic amines over 
an imine intermediate. This noticeable exception, in which the use of a ω-TAs resulted in secondary 
amines was published by the group of Kroutil.154 In their work, the monoamination of a diketone triggered 
its spontaneous cyclization to a cyclic imine.154 The use of different ω-TAs in combination with a 
diastereoselective chemical reduction enabled the access to all possible diastereomers of the generated 
2,6-disubstituted piperidine, in this way representing a chemical/biological reaction cascade 
(Scheme 10).154–156 This reaction cascade was later extended by O’Reilly et al. and an enzymatic 
cascade combining ω-TAs and MAO-N for deracemization with a nonselective reducing agent set up,122 
however the reducing agent might now also be substituted by an IRED.  
 
 
Scheme 10: Chemical/biological reaction cascade to generate secondary amines with ω-TAs.154 The monoamination of a diketone 
triggers the spontaneous cyclization to the piperideine ring which is chemically reduced.154 Most ω-TAs showed high specificity 
for the sterically less demanding ketone and depending on their selectivity the (R)- or (S)- aminoketone was accessed.154 By the 
combination with different chemical reducing agents all diastereomers could be obtained.154,155 
 
1.2.7 The enzymatic generation of cyclic imines by polyamine oxidases and their 
combination with IREDs 
 
The use of the (S)- selective MAO-N and the engineering of (R)- selective amine oxidases to generate 
cyclic imines for deracemizations was already described above and another path to such compounds 
was shown with ω-TAs that were applied for the monoamination of diketones.2,118–120,122,154,155 In 
addition, the enzymatic generation of such imines might also be accomplished by polyamine oxidases 
with substrates that already contain the required number of carbon atoms and nitrogen. The selective 
oxidation of one of the amine moieties should then trigger their spontaneous cyclization as it was 
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described in the ω-TA procedure.122,154,155 With these compounds also a renewable resource of the 
substrates is accessible.157,158 Polyamine oxidases are yet in contrast to MAO-N not thoroughly 
investigated for biocatalytic purposes. In nature, these enzymes are involved in the degradation of 
polyamines and amino acids into intermediates of the tricarboxylic acid cycle159–161 and the described 
applications of them mainly include their use as biosensors for biogenic amines to monitor food and 
beverage freshness.162–164 The two best characterized members of this enzyme family are the putrescine 
oxidases from Kocuria rosea165–169 and Rhodococcus erythropolis.161,170–173 While the first enzyme was 
described already decades ago, the latter one was identified and characterized in 2008.161 It is well 
suited for heterologous expression in E. coli,161 shows high activity with its natural substrate 
1,4-diaminobutane and activity was also reported with a range of related natural polyamines.161 In further 
works also the nature of the flavin binding was investigated170,171 and the crystal structure of the enzyme 
solved.171 Due to this full characterization and its high activity with the natural substrate,161 the putrescine 
oxidase from Rhodococcus erythropolis (PuO-Re) represents a promising candidate for a combination 
with IREDs to allow the de novo production of (chiral) saturated heterocyclic amines from renewable 
resources (Scheme 11).  
 
 
Scheme 11: Enzymatic generation of cyclic imines by the regioselective oxidation of a polyamine with an amine oxidase. The 
products of these enzymatic reactions spontaneously cyclize to cyclic imines and in aqueous systems exist in an equilibrium of 
both forms, however compared to ω-TAs the amine oxidase performs a practically irreversible reaction to the aminoaldehyde. The 
reduction to the saturated heterocyclic compound could now be performed by an IRED.  
 
1.3 Aims of this work and experimental strategy 
 
Considering the current limitations with respect to the biocatalytic preparation of chiral secondary and 
tertiary amines, IREDs are regarded as a promising extension to the available methods. However as 
these enzymes were just recently described for the first time only very few enzymes are known and 
many of their properties remain to be discovered. This work will therefore focus on the identification and 
characterization of novel IREDs.  
For the identification of the novel IREDs a database analysis will be performed in cooperation with the 
bioinformatics group of the Institute of Technical Biochemistry. With the acquired data this novel protein 
family will have to be analyzed on a sequence level to establish guidelines for the definition and 
classification of IREDs. For the experimental confirmation of these analyses, three putative IREDs will 
be selected and characterized with respect to parameters that might enable their use as biocatalysts. 
The pH-activity profiles of these enzymes, their thermostabilities and the activities in presence of organic 
solvents were chosen for investigation. To be able to compare the new enzymes to the three (at this 
time) in literature described IREDs, kinetic constants with a set of model substrates will be determined. 
As such analyses require purified proteins, the expression and purification of these new enzymes will 
have to be established in advance.  
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Having the enzymes available and assessed their biochemical properties, potential applications to 
generate chiral amines by the use of IREDs will be approached. The substrate spectrum and the scope 
of reactions that can be catalyzed by the IREDs will be investigated in whole cell biotransformations and 
with purified enzymes using a panel of cyclic and exocyclic imines and carbonyl substrates. The targeted 
reactions include the reduction of the preformed imines to (chiral) amines and the direct reductive 
amination of the carbonyl compounds with a variety of different amines. 
Finally, the use of IREDs in multistep biocatalysis was envisioned. Such a reaction cascade could enable 
the de novo synthesis of N-heterocyclic compounds from renewable resources. The second enzyme 
required for the reaction cascade, a putrescine oxidase, was known from literature, but described to 
display a narrow substrate spectrum. To approach a broad applicability in terms of the generated 
N-heterocyclic compounds, protein engineering strategies by combining random methods (epPCR) and 
semi-rational strategies (site-saturation mutagenesis) were pursued to enhance the activity of the 
enzyme for unnatural polyamine substrates. The generated mutants were to be screened with previously 
established HTS systems and characterized to verify crucial positions that influence oxidation activity. 
Finally, this putrescine oxidase and the IREDs were to be combined and in vitro and an in vivo systems 
were investigated for their formation of N-heterocyclic compounds by the consecutive transformation of 
polyamines by both enzymes.  
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2 METHODS AND MATERIALS 
2.1 Materials 
2.1.1 Chemicals 
 
Except otherwise noted, all solvents, buffer components and chemicals were obtained from Sigma-
Aldrich and Fluka (Steinheim, Germany), Carl Roth GmbH (Karlsruhe, Germany), Acros Organics (Geel, 
Belgium), VWR (Darmstadt, Germany), Alfa Aesar (Karlsruhe, Germany), TCI Deutschland GmbH 
(Eschborn, Germany) and abcr GmbH (Karlsruhe, Germany).  
Polyamine substrates Bis(3-aminopropyl)amine 35, 3-(3-Aminopropoxy)propylamine 37 and 
2-(2-Aminoethoxy)ethylamine 38 were kindly provided by Orion Pharma (Espoo, Finland). 
Acetophenone was sourced from Riedel-de-Haën AG (Seelze, Germany) and acrylamide from Serva 
(Heidelberg, Germany). Nylon membranes for solid phase HTS were from GE Healthcare (Hybond-N; 
GE-Healthcare Europe GmbH; Freiburg, Germany) or Carl Roth GmbH (Roti®-Nylon 0.2; Karlsruhe, 
Germany) and BugBuster lysis reagent from MerckMillipore (Merck KGaA, Darmstadt, Germany). DNA 
and Protein Markers for agarose and SDS gel electrophoresis were from peqlab (peqlab Biotechnologie 
GmbH, Erlangen, Germany) or Fermentas (Thermo Fisher Scientific Germany, Braunschweig, 
Germany).  
 
2.1.2 Enzymes 
 
Horseradish Peroxidase was obtained from AppliChem (Darmstadt, Germany), Catalase, DNase I and 
lysozyme were sourced from Sigma Aldrich (Steinheim, Germany), glucose-6-phosphate 
dehydrogenase from Leuconostoc mesenteroides (NH4)2SO4 precipitated was purchased from Roche 
Diagnostics (Mannheim, Germany) and lyophilized from Alfa Aesar (Karlsruhe, Germany). Restriction 
enzymes, T4 DNA ligase and alkaline phosphatase were from Thermo Fisher Scientific (Braunschweig, 
Germany), Pfu polymerase from GeneOn (Ludwigshafen, Germany) and enzymes for Gibson Assembly 
from NEB (Frankfurt am Main, Germany).  
 
2.1.3 Kits 
 
Kits for purification of PCR products, gel extraction of DNA and minipreparations were from Zymo 
Research (Freiburg, Germany). The BCA Assay Kit for determination of protein concentrations was from 
Pierce (Thermo Fisher Scientific Germany, Braunschweig, Germany).  
 
2.1.4 DNA Sequences 
 
The genes for the IREDs contained an N-terminal His6 tag and a 3CV protease cleavage site, resulting 
in 21 additional amino acids. The synthesized DNA also contained additional homologous regions and 
a ribosome binding site (AGGAGG) for the plasmid pBAD33, allowing the DNA to be used for Gibson 
Assembly with this plasmid. In case of the putrescine oxidase the synthetic DNA also contained a 
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ribosome binding site (the same as above) and restriction enzyme recognition sites for cloning in 
pBAD18 plasmid DNA. Further the start codon was modified from Val (GTG) to Met (ATG) and an Ala 
as second amino acid inserted, resulting in an additional NcoI restriction endonuclease site (CCATGG).  
Gene synthesis was done by GeneArtTM (Life Technologies GmbH, Darmstadt, Germany) and DNA 
sequencing was performed by GATC Biotech (Konstanz, Germany).  
 
Table 1: Synthesized genes and their corresponding GenBank entries. Genes encoding for IREDs were synthesized in codon 
optimized form for expression in E. coli. The gene encoding for PuO-Re was not codon optimized.  
Name abbreviation GenBank entry codon optimized 
(R)- imine reductase Streptosporangium roseum DSM 43021 R-IRED-Sr YP_003336672.1 yes 
(R)- imine reductase Streptomyces turgidiscabies R-IRED-St WP_006374254.1 yes 
(S)- imine reductase Paenibacillus elgii S-IRED-Pe WP_010497949.1 yes 
Putrescine oxidase Rhodococcus erythropolis NCIMB 11540 PuO-Re EU240877.1 no 
 
The introduced amino acid sequence to encode for the His6-tag and the 3CV protease cleavage site in 
case of the IREDs was (new Met start codon in green and His6 tag in blue): 
“MGSSHHHHHHSSGLEVLFQGPA“ encoded by the following DNA sequence:  
“ATGGGTAGCAGCCATCATCACCACCATCATAGCAGCGGTCTGGAAGTTCTGTTTCAGGGTCCGG
CA” 
 
Sequence of the synthetic DNA for R-IRED-St (Met start codon in green, His6 tag in blue and stop 
codons in red):  
CTACTGTTTCTCCATACCCGTTTTTTTGGGCTAGCGAATTCGAGCTCTTTTTTGGTACCAGGAGGA
TTACATATGGGTAGCAGCCATCATCATCACCATCATAGCAGCGGTCTGGAAGTTCTGTTTCAGGG
TCCGGCAGGCGATAATCATACCAGCGTTAGCGTTATTGGTCTGGGTCTGATGGGTCAGGCACTG
GCAGCAGCATTTCTGAAAGCAGGTCATGCAACCACCGTTTGGAATCGTAGCGCAGATAAAGCAG
ATGGTGTTGTTGCAAATGGTGCAGTTCTGGCAGCCGCACCGGCAGATGCAGTTGCAGCAAGCGA
TCTGGTTGTTGTTTGTGTTAGCACCTATGATGTTGTGCATGATGTTATTGGTAGCCTGGGTGATGC
ACTGCGTGGTAAAACCGTTGTTAATCTGACCAGCGGTAGCAGCGAACAGGCACGTCAGACCGCA
GAATGGGCAGAAAAAAATGGTGCCCGTTATCTGGATGGTGCCATTATGATTACCCCTCCGGGTAT
TGGCACCGAAACCGCAGTGCTGTTTTATGCCGGTGATCAGGCAGTTTTTGATGCACATGAACCGG
TGCTGAAACTGCTGGGTGCAGGCACCACCTATCTGGGCACCGATCATGGTAAACCGGCACTGTT
TGATGTGAGCCTGCTGGGCCTGATGTGGGGTGCACTGAATAGCTTTCTGCATGGTGTTGCAATTG
TTGAAACCGGTGGTGTTAAAGCACAGGATTTTCTGCCGTGGGCTCATATGTGGCTGGATGCCATT
AAAATGTTTACCGCAGATTATGCAGCACAGATTGATGCGGGTGATGAAAAATTTCCGGCAAATGA
TGCAACCCTGGAAACCCATCTGGGTGCGCTGAAACATCTGGTTGAAGAAAGCGAAGCACTGGGT
GTTGATACCGAACTGCCGAAATATAGCGAAGCCCTGATGGAAGGTATTATTGCACAGGGTCATGC
CAAAAATTCATATGCCAGCGTTGTTAAAGCCTATCGTCGTCCGGCACGTTAATAATCTAGACTGCA
GAAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGA 
 
Native protein sequence of R-IRED-St 
MGDNHTSVSVIGLGLMGQALAAAFLKAGHATTVWNRSADKADGVVANGAVLAAAPADAVAASDLVV
VCVSTYDVVHDVIGSLGDALRGKTVVNLTSGSSEQARQTAEWAEKNGARYLDGAIMITPPGIGTETAV
LFYAGDQAVFDAHEPVLKLLGAGTTYLGTDHGKPALFDVSLLGLMWGALNSFLHGVAIVETGGVKAQ
DFLPWAHMWLDAIKMFTADYAAQIDAGDEKFPANDATLETHLGALKHLVEESEALGVDTELPKYSEAL
MEGIIAQGHAKNSYASVVKAYRRPAR 
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Sequence of the synthetic DNA for R-IRED-Sr (Met start codon in green, His6 tag in blue and stop 
codons in red):  
CTACTGTTTCTCCATACCCGTTTTTTTGGGCTAGCGAATTCGAGCTCTTTTTTGGTACCAGGAGGA
TTACATATGGGTAGCAGCCATCATCATCACCATCATAGCAGCGGTCTGGAAGTTCTGTTTCAGGG
TCCGGCACGTGATACCGATGTTACCGTTCTGGGTCTGGGCCTGATGGGTCAGGCACTGGCAGGC
GCATTTCTGAAAGATGGTCATGCAACCACCGTTTGGAATCGTAGCGAAGGTAAAGCAGGTCAGCT
GGCAGAACAGGGTGCAGTTCTGGCAAGCAGCGCACGTGATGCAGCAGAAGCAAGTCCGCTGGT
TGTTGTTTGTGTTAGCGATCATGCAGCAGTTCGTGCCGTTCTGGATCCGCTGGGTGATGTTCTGG
CAGGTCGTGTTCTGGTTAATCTGACCAGCGGCACCAGCGAACAGGCACGTGCAACCGCAGAATG
GGCAGCAGAACGTGGTATTACCTATCTGGATGGTGCAATTATGGCAATTCCGCAGGTTGTGGGC
ACCGCAGATGCATTTCTGCTGTATAGCGGTCCGGAAGCAGCATATGAAGCACATGAACCGACCC
TGCGTAGCCTGGGTGCAGGCACCACATATCTGGGTGCCGATCATGGTCTGAGCAGCCTGTATGA
TGTTGCACTGCTGGGTATTATGTGGGGCACCCTGAATAGCTTTCTGCATGGTGCAGCCCTGCTG
GGCACAGCAAAAGTTGAAGCCACCACCTTTGCACCGTTTGCAAATCGTTGGATTGAAGCAGTTAC
CGGTTTTGTTAGCGCATATGCCGGTCAGGTTGATCAGGGTGCATATCCGGCACTGGATGCAACC
ATTGATACCCATGTTGCAACCGTTGATCATCTGATTCATGAAAGCGAAGCAGCCGGTGTTAATAC
CGAACTGCCTCGTCTGGTTCGTACCCTGGCAGATCGTGCCCTGGCTGGCGGTCAGGGTGGTCT
GGGTTATGCAGCAATGATTGAACAGTTTCGTAGCCCGAGCGCATAATAATCTAGACTGCAGAAGC
TTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGA 
 
Native protein sequence of R-IRED-Sr:  
MRDTDVTVLGLGLMGQALAGAFLKDGHATTVWNRSEGKAGQLAEQGAVLASSARDAAEASPLVVVC
VSDHAAVRAVLDPLGDVLAGRVLVNLTSGTSEQARATAEWAAERGITYLDGAIMAIPQVVGTADAFLL
YSGPEAAYEAHEPTLRSLGAGTTYLGADHGLSSLYDVALLGIMWGTLNSFLHGAALLGTAKVEATTFA
PFANRWIEAVTGFVSAYAGQVDQGAYPALDATIDTHVATVDHLIHESEAAGVNTELPRLVRTLADRAL
AGGQGGLGYAAMIEQFRSPSA 
 
Sequence of the synthetic DNA for S-IRED-Pe (Met start codon in green, His6 tag in blue and stop 
codons in red):  
CTACTGTTTCTCCATACCCGTTTTTTTGGGCTAGCGAATTCGAGCTCTTTTTTGGTACCAGGAGGA
TTACATATGGGTAGCAGCCATCATCATCACCATCATAGCAGCGGTCTGGAAGTTCTGTTTCAGGG
TCCGGCAAATAGCAGCAATCCGAAAGATAACATTAGCGTTGGTAGCGCAAGCACCGCAACCAATC
GTAAAAGCGTTACCGTTATGGGTCTGGGTCCGATGGGTCAGGCAATGGCAGGCGTTTTTCTGGA
AAGCGGTTATGAAGTTACCGTTTGGAATCGTACCGCAAGCAAAGCAGATGAACTGGTTGCAAAAG
GTGCAATTCGTGCCAGCACCGTTGATGAAGCACTGGCAGCAAACGAACTGGTTATTCTGAGCCT
GACCGATTATGATGCAATGTATGCAATTCTGGAACCGAGCAGCGCAAATCTGAGCGGTAAAGTTC
TGGTGAATCTGAGCAGCGATACACCGGAAAAAGTTCGTGAAGCAGCAAAATGGCTGGCAGATCG
TGGTGCACGTCATGTTACCGGTGGTGTTCAGGTTCCGCCTAGCGGTATTGGTAAACCGGAAAGC
TATACCTATTATAGCGGTCCGCGTGAAGTTTTTGAAGCACATCGTGAAAGCCTGGAAATTCTGAC
CGGTACAGATTATCGTGGTGAAGATCCGGGTCTGGCAATGCTGTATTATCAGATTCAGATGGATA
TCTTCTGGACCAGTATGCTGAGCTATCTGCATGCACTGGCCGTTGCCAAAGCAAATGGTATTACC
GCAAAACAGTTTCTGCCGTATGCAAGCGCAACCCTGAGCAGCCTGCCGCAGTTTGTTGAATTCTA
TACACCGCGTCTGGATGAAGGTAAACATCCGGGTGATGTTGATCGTCTGGCCATGGGCCTGGCA
AGCGTTGAACATATTGTTCATACCACCGAAGATGCAGGTATTGATACCACCCTGCCTGCAGCAGT
TCTGGAAATCTTTAAACGTGGCATGGAAAATGGTCATGCCGGTGATAGCTTTACCAGCCTGATTG
AAATTTTCAAAAATCCGGTGCGCAGCTAATAATCTAGACTGCAGAAGCTTGGCTGTTTTGGCGGA
TGAGAGAAGATTTTCAGCCTGATACAGA 
 
Native protein sequence of S-IRED-Pe:  
MNSSNPKDNISVGSASTATNRKSVTVMGLGPMGQAMAGVFLESGYEVTVWNRTASKADELVAKGAI
RASTVDEALAANELVILSLTDYDAMYAILEPSSANLSGKVLVNLSSDTPEKVREAAKWLADRGARHVT
GGVQVPPSGIGKPESYTYYSGPREVFEAHRESLEILTGTDYRGEDPGLAMLYYQIQMDIFWTSMLSYL
HALAVAKANGITAKQFLPYASATLSSLPQFVEFYTPRLDEGKHPGDVDRLAMGLASVEHIVHTTEDAGI
DTTLPAAVLEIFKRGMENGHAGDSFTSLIEIFKNPVRS 
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Sequence of the synthetic DNA for PuO-Re (Met start codon in green, stop codons in red and introduced 
NcoI restriction site underlined):  
CACTATAGGGCGAATTGAAGGAAGGCCGTCAAGGCCGCATGAATTCTTTTTTGGGCTAGCAGGA
GGATTAACCATGGCCCCTACTCTCCAGAGAGATGTTGCAATCGTCGGCGCCGGCCCCTCTGGCC
TGGCAGCGGCAACCGCGCTGCGCAAGGCCGGCTTGTCCGTCGCCGTGATCGAAGCACGCGATC
GTGTCGGAGGCCGCACGTGGACCGACACCATCGACGGCGCAGTCCTGGAGATCGGCGGCCAGT
GGGTCTCCCCCGACCAGACTGCTCTGATCTCCTTGCTCGACGAACTCGGCCTGAAGACTTTCGA
GCGCTACCGCGAGGGCGAGTCCGTCTACATCTCGTCAGCAGGCGAGCGGACTCGATACACGGG
CGATTCCTTCCCCACGAACGAGACCACCAAGAAGGAGATGGACCGTCTCATCGACGAGATGGAC
GATCTCGCAGCGCAGATCGGCGCCGAGGAGCCGTGGGCACATCCCCTCGCCCGCGATCTCGAC
ACAGTCTCCTTCAAGCAGTGGCTGATCAATCAGTCCGACGACGCCGAGGCCCGTGACAACATCG
GCCTCTTCATCGCGGGTGGTATGCTCACCAAGCCCGCCCACTCGTTCTCCGCCCTACAGGCCGT
ACTCATGGCCGCTTCCGCAGGCTCGTTCTCCCACCTCGTGGACGAGGACTTCATCCTCGACAAG
CGAGTGATCGGCGGAATGCAGCAGGTATCTATCCGCATGGCGGAGGCCCTCGGTGACGACGTC
TTCCTCAACGCACCCGTGCGTACGGTGAAGTGGAACGAATCCGGTGCAACGGTGTTGGCGGAC
GGCGACATTCGCGTCGAGGCAAGCCGAGTGATCCTGGCCGTACCACCCAACCTCTACTCCCGGA
TCTCCTACGATCCCCCGCTGCCGCGTCGTCAGCACCAGATGCATCAGCATCAGTCTCTCGGCCT
CGTCATCAAGGTGCACGCCGTGTACGAGACGCCTTTCTGGCGCGAAGACGGCCTCTCCGGCAC
CGGCTTCGGCGCGTCCGAGGTAGTGCAGGAGGTGTACGACAACACCAACCACGAGGACGATCG
CGGCACCCTGGTCGCTTTTGTCTCCGACGAGAAGGCCGACGCGATGTTCGAGCTTTCCGCCGAG
GAGCGTAAGGCCACGATTCTGGCCTCACTCGCCCGCTACCTGGGCCCGAAGGCCGAAGAGCCG
GTTGTGTACTACGAATCCGACTGGGGCTCGGAGGAATGGACCCGCGGTGCGTACGCGGCGAGC
TTCGATCTCGGCGGCCTGCACCGCTACGGCGCGGATTCCCGCACGCCCGTCGGACCGATCCAC
TTCTCGTGCTCCGACATCGCAGCCGAGGGATACCAGCACGTGGACGGTGCCGTTCGGATGGGT
CAGCGCACCGCCGCCGACATCATCGCCCGCAGCAAGGCCTGATAACCCGGGTCTAGAGTCGAC
AAGCTTCTGGGCCTCATGGGCCTTCCTTTCACTGCCCGCTTTCCAG 
 
Native protein sequence of PuO-Re:  
VPTLQRDVAIVGAGPSGLAAATALRKAGLSVAVIEARDRVGGRTWTDTIDGAVLEIGGQWVSPDQTAL
ISLLDELGLKTFERYREGESVYISSAGERTRYTGDSFPTNETTKKEMDRLIDEMDDLAAQIGAEEPWAH
PLARDLDTVSFKQWLINQSDDAEARDNIGLFIAGGMLTKPAHSFSALQAVLMAASAGSFSHLVDEDFIL
DKRVIGGMQQVSIRMAEALGDDVFLNAPVRTVKWNESGATVLADGDIRVEASRVILAVPPNLYSRISY
DPPLPRRQHQMHQHQSLGLVIKVHAVYETPFWREDGLSGTGFGASEVVQEVYDNTNHEDDRGTLVA
FVSDEKADAMFELSAEERKATILASLARYLGPKAEEPVVYYESDWGSEEWTRGAYAASFDLGGLHRY
GADSRTPVGPIHFSCSDIAAEGYQHVDGAVRMGQRTAADIIARSKA 
 
2.1.5 Primers 
 
The following primers were used in this work to amplify DNA, generate mutants and for sequencing 
purposes. All primers were synthesized by metabion International AG (Martinsried, Germany) 
 
Table 2: Summary of primers used in this study. Primers were used for PCR to generate fragments for Gibson Assembly (GA), 
for (site directed) mutagenesis and for sequencing. The numbering for the mutations corresponds not to the native protein 
sequence, but starts with the Met start codon of the corresponding expression construct. For example R-IRED-Sr D191A refers 
to amino acid number 170 of the native protein sequence. 
Primer name direction sequence 
pBAD_GA 
forward 5‘-CTACTGTTTCTCCATACCCG-3‘ 
reverse 5‘-CTGTATCAGGCTGAAAATCTTCTC-3‘ 
R-IRED-Sr_D191A 
forward 5‘-GCAGCCTGTATGCTGTTGCACTGCTG-3‘ 
reverse 5‘-CTGTATCAGGCTGAAAATCTTCTC-3‘ 
R-IRED-St_D193A 
forward 5‘-CGGCACTGTTTGCTGTGAGCCTGCTG-3‘ 
reverse 5‘-CAGCAGGCTCACAGCAAACAGTGCCG-3‘ 
S-IRED-Pe_Y208D 
forward 5‘-CTGGCAATGCTGTATGATCAGATTCAGATGG-3‘ 
reverse 5‘-CCATCTGAATCTGATCATACAGCATTGCCAG-3‘ 
pBAD 
forward 5‘-CCATAAGATTAGCGGATCCTACCTG-3‘ 
reverse 5‘-CACTTCTGAGTTCGGCATGGGG-3‘ 
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Table 2: continued.  
Primer name direction sequence 
PuO-Re_E324D 
forward 5‘-GTCCGAGGTAGTGCAGGACGTGTACGACAACACCAACC-3‘ 
reverse 5‘-GGTTGGTGTTGTCGTACACGTCCTGCACTACCTCGGAC-3‘ 
PuO-Re_L168F169 
forward 5‘-GAGGCCCGTGACAACATCGGCNNKNNKATCGCGGGTGGTATGCTCACC-3‘ 
reverse 5‘-GGTGAGCATACCACCCGCGATMNNMNNGCCGATGTTGTCACGGGCCTC-3‘ 
PuO-Re_V201E203 
forward 5‘-GGCTCGTTCTCCCACCTCDNKGACNNKGACTTCATCCTCGACAAG-3‘ 
reverse 5‘-CTTGTCGAGGATGAAGTCMNNGTCMNHGAGGTGGGAGAACGAGCC-3‘ 
PuO-Re_M174 
forward 5‘-CTCTTCATCGCGGGTGGTNHKCTCACCAAGCCCGCCCAC-3‘ 
reverse 5‘-GTGGGCGGGCTTGGTGAGMDNACCACCCGCGATGAAGAG-3‘ 
PuO-Re_L207 
forward 5‘-GTGGACGAGGACTTCATCNNYGACAAGCGAGTGATCGGC-3‘ 
reverse 5‘-GCCGATCACTCGCTTGTCRNNGATGAAGTCCTCGTCCAC-3‘ 
PuO-Re_D104 
forward 5‘-CGGACTCGATACACGGGCNNKTCCTTCCCCACGAACGAG-3‘ 
reverse 5‘-CTCGTTCGTGGGGAAGGAMNNGCCCGTGTATCGAGTCCG-3‘ 
PuO-Re_SE_ 
libraryA[a] 
forward 5‘-GCAGGCTCGTTCTCCCACNDTGTGGACNHKGACTTCNDTCTCGACAAGCGAGTGATC-3‘ 
reverse 5‘-GATCACTCGCTTGTCGAGAHNGAAGTCMDNGTCCACAHNGTGGGAGAACGAGCCTGC-3‘ 
PuO-Re_SE_ 
libraryB[a] 
forward 5‘-GGCTCGTTCTCCCACCTCNDTGACGAGNDTTTCATCCTCGACAAGCGA-3‘ 
reverse 5‘-TCGCTTGTCGAGGATGAAAHNCTCGTCAHNGAGGTGGGAGAACGAGCC-3‘ 
PuO-Re_SE_ 
libraryC[a] 
forward 5‘-CTCGTTCTCCCACCTCGTGNDTGAGGACNDTATCCTCGACAAGCGAGTG-3‘ 
reverse 5‘-CACTCGCTTGTCGAGGATAHNGTCCTCAHNCACGAGGTGGGAGAACGAG-3‘ 
[a]: The libraries were generated and screened by solid phase assay but no further analysis was done during this project. The lysate 
screening, purification and characterization of these mutants is ongoing work of another PhD project at the Institute of Technical 
Biochemistry. 
 
2.1.6 Plasmids 
 
Plasmids used in this study were pBAD18 (pBR322 ori, ampicillin resistance, arabinose inducible 
expression) and pBAD33 (pACYC184 ori, chloramphenicol resistance, arabinose inducible 
expression).174 Maps for pBAD33 and pBAD18 are shown in Figure 5 and Figure 6.  
 
Table 3: Plasmids used and generated in this study. The numbering for the mutations corresponds not to the native protein 
sequence, but starts with the Met start codon of the corresponding expression construct. For example R-IRED-Sr D191A refers 
to amino acid number 170 of the native protein sequence.  
plasmid  insert ITB # source/generated by  
pBAD33 -  Dr. Sandra Facey, ITB Stuttgart 
pBAD18 -  Dr. Sandra Facey, ITB Stuttgart 
pBAD33 R-IRED-Sr pITB1236 this work 
pBAD33 R-IRED-St pITB1237 this work 
pBAD33 S-IRED-Pe pITB1238 this work 
pBAD33 R-IRED-Sr D191A pITB1239 this work 
pBAD33 R-IRED-St D193A pITB1240 this work 
pBAD33 S-IRED-Pe Y208A pITB1241 this work 
pBAD18 PuO-Re pITB1242 this work 
pBAD18 PuO-Re E324D pITB1243 this work 
pBAD18 PuO-Re E203G pITB1244 epPCR 
pBAD18 PuO-Re I154V E203V - epPCR 
pBAD18 PuO-Re E203S pITB1245 saturation mutagenesis 
pBAD18 PuO-Re V201S E203G pITB1246 saturation mutagenesis 
pBAD18 PuO-Re L207V pITB1247 saturation mutagenesis 
pBAD18 PuO-Re V201A E203P pITB1248 saturation mutagenesis 
pBAD18 PuO-Re D104L pITB1249 saturation mutagenesis 
pBAD18 PuO-Re L168S F169Q pITB1250 saturation mutagenesis 
pBAD18 PuO-Re V201A E203G pITB1251 saturation mutagenesis 
pBAD18 PuO-Re A24T V201A E203M pITB1252 saturation mutagenesis 
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Figure 5: Vector map of pBAD33. The map was generated with Snapgene.  
 
 
Figure 6: Vector map of pBAD18. The map was generated with Snapgene.  
 
2.1.7 E. coli strains 
 
The following E. coli strains were used in this work:  
E. coli XL1-Blue for cloning and molecular biological applications (plasmid production, etc.) and E. coli 
JW5510175 for protein expression and biotransformations.  
 
Genotype E. coli XL1-Blue:  
endA1 gyrA96(nalR) thi-1 recA1 glnV44 relA1 hsdR17(rK- mK+) lac [F' proAB+ lacIq Δ(lacZ)M15::Tn10]  
 
Genotype E. coli JW5510:  
F- Δ(araD-araB)567 ΔlacZ4787(::rrnB-3) λ- ΔygjG763::kan rph-1 Δ(rhaD-rhaB)568 hsdR514 
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2.2 Cultivation media and growth of bacterial cells 
 
For growth of bacteria lysogeny broth (LB) medium (yeast extract 5 g/l, tryptone 10 g/l and NaCl 10 g/l) 
or terrific broth (TB) medium (tryptone 12 g/l, yeast extract 24 g/l, glycerol 4 ml/l and 1 x TB buffer: 
72 mM K2HPO4 and 17 mM KH2PO4) was used.  
To prepare competent cells and after transformations cells were cultivated in SOC medium (yeast 
extract 5 g/l, tryptone 20 g/l, NaCl 0.584 g/l, KCl 0.186 g/l, MgSO4 20 mM, glucose 20 mM) at 37 °C 
and 180 rpm.  
 
LB agar plates contained 1.5% agar and the respective antibiotics.  
 
Cells were generally grown at 37 °C and 180 rpm. 
Protein expression was always performed in TB medium and for protein expression the temperature 
was lowered to 25 °C. Cells were grown in Infors HT Multitron Shakers (Infors AG, Bottmingen, 
Switzerland).  
 
For long term storage of E. coli cultures glycerol stocks were prepared and stored at - 80 °C. Glycerol 
stocks were generated by the addition of final 15% sterile glycerol to LB grown overnight cultures.  
 
The following antibiotics and inducers were used:  
Ampicillin at a final concentration of 100 µg/ml and chloramphenicol (dissolved in EtOH) at a final 
concentration of 34 µg/ml. L-arabinose was used at a final concentration of 0.02% for induction of protein 
expression  
 
2.3 Preparation of competent cells and transformation of E. coli 
 
Chemically competent cells of E. coli for transformations were prepared according to the RbCl method 
as described in literature.176 
For screening of PuO-Re libraries electrocompetent cells were used. Preparation of them was done as 
described in literature.177 
E. coli cells that were used for the preparation of competent cells were grown in SOC media as described 
above. 
 
Transformation of chemically competent cells was done by heat shock at 42 °C for 30 s after incubating 
cells and DNA for 30 min on ice. Afterwards cells were incubated with SOC media for 1 h at 37 °C 
and 180 rpm.  
 
For the transformation of mutant libraries in electrocompetent cells they were mixed with the salt free 
DNA in a previously chilled electroporation cuvette with 0.2 cm electrode gap (Bio-Rad Laboratories 
GmbH, Munich, Germany). Electroporation was then done with 2 kV in a GenePulser from Bio-Rad 
(Bio-Rad Laboratories GmbH, Munich, Germany). After the transformation the cells were immediately 
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recovered in 1 ml pre-warmed SOC medium and grown for 20 min at 37 °C and 180 rpm. After this time 
cells were plated on nylon membranes for screening. Nylon membranes were previously placed on 
LB-Amp-Ara plates and pre-warmed to 25 °C. In preliminary tests the transformation efficiency and 
plating volume was estimated to obtain ~ 1500 colonies per membrane. 
 
2.4 PCR for amplification of DNA 
 
Standard PCR protocols were used for the amplification of the DNA obtained from GeneArtTM with the 
synthetic DNA encoding for the IREDs. Due to its high GC content (~ 65%) touchdown PCR was used 
for the amplification of the putrescine oxidase gene.178 
Successful amplification of the targets was verified by illumination of the peqGREEN (peqlab 
Biotechnologie GmbH, Erlangen, Germany) stained DNA with UV light after agarose gel electrophoresis.  
After PCR the amplification products were purified with the PCR purification kit from ZymoResearch 
(Freiburg, Germany).  
 
2.5 Restriction enzyme based gene cloning 
 
The synthetic gene encoding for PuO-Re was amplified by PCR, purified and afterwards digested with 
EcoRI and HindIII for 2 h. pBAD18 plasmid DNA was obtained by minipreparation from XL1-Blue cells 
and also digested with EcoRI and HindIII for 4 h. The digested plasmid DNA was dephosphorylated with 
FastAP (alkaline phosphatase) for 1 h and purified by agarose gel electrophoresis.  
The PuO-Re insert DNA and the digested plasmid DNA were mixed in a ratio of 5:1 and ligated with T4 
DNA ligase overnight at 18 °C. Next day, the ligase was heat inactivated and 2.5 µl of the ligation mixture 
transformed in chemically competent E. coli XL1-Blue cells. Cells that grew overnight were used to 
inoculate fresh cultures for minipreparations to confirm the correct ligation by DNA sequencing.  
 
Cloning of the epPCR PuO-Re libraries was done as for the wild type gene, but the libraries directly 
transformed in electrocompetent E. coli JW5510 cells for screening.  
 
2.6 Gibson assembly for molecular cloning 
 
Gibson Assembly was used for generation of IRED expression constructs. Therefore the synthetic DNA 
with the IRED genes (already containing homology regions to the pBAD33 plasmid) was amplified by 
PCR. The PCR products were purified and mixed with digested and purified pBAD33 plasmid DNA. 
Isothermal Gibson assembly was performed with an equimolar ratio of the DNA fragments according to 
literature for 1 h in a PCR machine at 50 °C.179–181 After cooling down to 8 °C, assembly products were 
transformed in chemically competent E. coli XL1-Blue cells. Cells were plated on LB-Cm agar plates 
and grown overnight at 37 °C. Some of these colonies were picked and grown for a minipreparation. 
DNA Sequencing of the plasmid then confirmed the correct assembly.  
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2.7 Methods to generate mutants and mutant libraries 
2.7.1 Site directed mutagenesis – QuikChange® method 
 
Site directed mutagenesis was performed according to the QuikChange® procedure of the commercial 
available kit from Agilent.182 
 
2.7.2 Random mutagenesis by epPCR 
 
epPCR was performed to generate random mutant libraries of PuO-Re. epPCR was done as described 
by Cirino et al..183 
Conditions for an epPCR were modified compared to usual PCR in a way that an epPCR dNTP mix 
consisting of final 0.2 mM dGTP, 0.2 mM dATP, 1 mM dCTP and 1 mM dTTP was used. Further, MgCl2 
was increased and MnCl2 was included (1-10 µM). The DNA template was reduced to 10 ng and the 
amplification performed with Taq polymerase. The setup and the amplification program for the epPCR 
are shown in Table 4 and Table 5.  
 
Table 4: Setup for the epPCR. 
component volume [µl] final concentration 
Taq Buffer with KCl 10 X 5 1x 
ep-dNTP mix 10 X 5 see above 
forward Primer 5 µM 3 0.3 µM 
revers Primer 5 µM 3 0.3 µM 
MgCl2 25 mM 14 7 mM 
MnCl2 (x µM) 5 variable (1-10 µM) 
template DNA 1 0.2 ng/µl 
Taq 1 U/µl 5 0.1 U/µl 
H2O 9 - 
final volume 50  
 
Table 5: PCR program for the epPCR. 
temperature time cycles 
95 °C 2 min 1 
95 °C 15 s 
30 57 °C 15 s 
72 °C 2 min  
72 °C 10 min 1 
8 °C ∞ 1 
 
After the epPCR the template DNA was digested with DpnI and the individual libraries (variations in the 
MnCl2 concentration) cloned into a TOPO-TA cloning vector (Life Technologies, Darmstadt, Germany) 
according to the manufacturer’s instructions for estimation of the library diversity. After transformation 
in E. coli XL1-Blue, the cells were grown on LB-Kan-XGal (50 µg/ml kanamycin and 20 µg/ml XGal) 
plates and white colonies picked for sequencing. To estimate the mutation load from each library 10 
randomly picked colonies were sequenced.  
Libraries having an average mutation load of about 4 changed nucleotides corresponding to 1-2 amino 
acid exchanges were used for screening.  
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For screening, epPCR mutant libraries of PuO-Re were cloned with EcoRI and HindIII into pBAD18 and 
then transformed in electrocompetent cells of E. coli JW5510 (see 2.3) for screening. Library screening 
was done as described in 2.11. 
 
2.7.3 Site saturation mutagenesis with degenerated codons 
 
Saturation mutagenesis of PuO-Re was done with QuikChange style primers containing degenerated 
codons, but to achieve adequate efficiencies during amplification and transformation a modified Gibson 
Assembly protocol was used.179–181 
PCR was therefore performed with the pBAD sequencing primers and one QuikChange primer, resulting 
in an exponential amplification of the DNA and incorporation of the degenerated codon. Afterwards the 
upstream and downstream fragments containing the mutations were assembled with the plasmid 
backbone (3 fragments, ratio 1:1:1) and the libraries transformed in E. coli JW5510 for screening. From 
one of the grown plates a whole plate resuspension and minipreparation thereof was done for 
sequencing as library quality control.184 
 
2.8 Gene expression in shake flasks and deep well plates 
 
Expression of IRED and PuO-Re genes was done in the same way, but the antibiotic was different. For 
cells with PuO-Re in pBAD18 ampicillin (100 µg/ml) was used and for pBAD33 with the IRED genes 
chloramphenicol (34 µg/ml) was used. For the cells with both plasmids that were tested in the reaction 
cascade, Amp and Cm as antibiotics were used.  
 
Protein production was performed in the arabinose deficient E. coli host JW5510. Expression was 
performed in TB media with antibiotics and the cells were grown after inoculation with the overnight 
culture at 37 °C and 180 rpm. After about 2.5 h the cells reached and OD600 of ~ 0.7 and gene expression 
was induced with 0.02% L-Arabinose. The cells were shifted to 25 °C and 180 rpm and expression 
performed overnight.  
Next day the cells were harvested by centrifugation at 4 °C and 9000 g for 30 min (centrifuge 
Avanti J 26S XP, Beckman Coulter, Krefeld, Germany; rotor JLA 8.1). 
The cells were then used for biotransformations (see 2.13) or for purification of the expressed protein 
(see 2.9). 
 
Generation of small amounts of cell lysate for screening of PuO-Re mutant libraries was done by 
expression in 96 well plates.  
Therefore a preculture was grown over night in 800 µl LB media in a 96 deep well plate 
(MASTERBLOCK®, Greiner Bio-One, Frickenhausen, Germany). Each well was inoculated with a single 
colony from an agar plate of the mutant libraries using a sterile tooth pick.  
The plates were sealed with BREATHSealTM (Greiner Bio-One, Frickenhausen, Germany) and 
incubated over night at 37 °C and 180 rpm. On the next day, the plate was replicated to a new plate 
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using a 96 well plate replicator stamp and afterwards 200 µl sterile 60% glycerol added to store the plate 
at - 80 °C.  
The new deep well plates contained 800 µl TB media with Amp (100 µg/ml) and 0.02% L-Ara for 
expression. The plates were incubated at 25 °C overnight for growth and expression of the mutant 
libraries.  
After expression, the cells were centrifuged at 4 °C in the plate for 1 h at 4000 rpm (Eppendorf centrifuge 
5810R, swing out rotor A-4-62). For cell lysis the pellet was resuspended in 200 µl BugBuster solution 
(1 x Bug Buster from a 10 x stock, DTT 1 mM, EDTA 0.5 mM, DNase 0.1 µg/ml, PMSF 1 mM, Tris buffer 
final 50 mM pH 8.0 and glycerol 5 % final) per well. Lysis was performed for 15 min at 25 °C and 
subsequently the lysate cleared by centrifugation at 4 °C (90 min, 4000 rpm). The cleared lysate was 
then transferred to a new 96 well plate and stored at - 80 °C until further screening.  
 
2.9 Cell lysis and purification of proteins 
2.9.1 Immobilized Metal Affinity Chromatography (IMAC) for purification of 
His6-tagged IREDs 
 
For His6-tag purification of IREDs the cell pellets from the expression were resuspended in 1.5 ml/g 
buffer A (sodium phosphate 50 mM pH 7.0 with 300 mM KCl, 5 % glycerol, 1 mM β-mercaptoethanol 
and 5 mM imidazole), combined and frozen at - 80 °C. After thawing of the cell suspension, DNase I (1 
µl/ml from a 5 mg/ml stock) and lysozyme (1 µl/ml from a 5 mg/ml stock) were added. Cell disruption 
was performed by high-pressure homogenization (3 cycles, 750-1000 bar) with an EmulsiFlex C-5 
(Avestin, Canada).  
The cell lysate was cleared by centrifugation for 45 min at 4 °C and 38800 g (centrifuge RC 6 Plus, 
Sorvall) and afterwards filtered using 0.2 µm filters (PES membrane, VWR, Darmstadt, Germany).  
The lysate could be stored at - 80 °C or was used immediately for purification.  
Protein purification was done at 8 °C using an ÄktaExplorer (GE Healthcare Europe, Freiburg, Germany) 
equipped with up to three serial 5 ml HiTrap Chelating Sepharose HP columns charged with Ni2+ (GE 
Healthcare Europe, Freiburg, Germany). Unbound and weakly bound proteins were washed off from the 
column with 5 column volumes (cv) of a 4% mixture of buffer A and B (buffer A + 500 mM imidazole). 
For elution of His6-tagged IREDs the concentration of buffer B was raised to 40% for 8 cv, followed by 
a cleaning step for 5 cv with 100% buffer B. Fractions with highly purified IREDs were pooled and 
concentrated by ultrafiltration using a Vivaspin ultrafiltration spin column (10 kDa Mw cut off, PES 
membrane, Sartorius, Goettingen, Germany). Desalting was done with PD10-columns (Sephadex G 25 
Medium, 85-260 µm, GE Healthcare, Freiburg, Germany). For storage, NADPH was added and the 
IREDs frozen in small aliquots at - 80 °C. Analysis of IRED purity was done by SDS-PAGE using 15% 
gels and size exclusion chromatography on HPLC (see 2.20). 
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2.9.2 Ion exchange chromatography with a MonoQ column as second IRED 
purification step 
 
For further purification of R-IRED-Sr by ion exchange chromatography using a MonoQ column, the 
buffer was exchanged to MonoQ Buffer A (20 mM BisTris pH 7.0, 5% glycerol). The column was then 
washed with two steps (6% and 15%) MonoQ Buffer B (20 mM BisTris pH 7.0, 5 % glycerol, 1 M KCl) 
and the IRED eluted with 45% buffer B.  
Fractions containing R-IRED-Sr were individually concentrated and the buffer exchanged to 20 mM 
BisTris with 5 % glycerol by washing them in Vivaspin ultrafiltration spin column. Prior to storage at 
– 80 °C NADPH was added.  
 
2.9.3 Ion exchange chromatography with a Q-sepharose HP column for purification 
of PuO-Re wt and mutants 
 
Lysis of cells expressing PuO-Re was done as described above for cells expressing IREDs. Purification 
of PuO-Re or the respective mutant was then done by ion exchange chromatography with a 
Q-Sepharose HP column as described by van Hellemond et al..161 Purified proteins were analyzed by 
SDS-PAGE (Figure S67). 
 
2.10 Protein quantification by BCA assay 
 
Quantification of purified proteins was done with the BCA kit from Pierce (Thermo Fisher Scientific 
Germany, Braunschweig, Germany) according to the manufacturer’s instruction.  
 
2.11 Solid phase assay and activity assays with cell lysate for HTS of PuO-Re 
mutant libraries 
2.11.1 Solid phase assay 
 
Solid phase assay screening for amine oxidase activity was done as described in literature with slight 
modifications.  
After transformation a sufficient amount of cells was plated on the nylon membrane. The volume was 
estimated that about 1500 cells were growing on one plate. Cells were then grown over night at 25 °C 
on LB-Amp-Ara plates for expression of the PuO-Re mutants. 
Next day, the membranes were frozen at - 20 °C for at least 1 h. After thawing of the membranes they 
were placed on a 90 mm diameter filter paper in a glass petri dish (SCHOTT AG, Mainz, Germany) 
soaked with 1.8 ml Tris buffer 50 mM pH 8.0 with 0.1 mg/ml HRP for background reduction.  
After 1 h background reduction the membranes were transformed into a new petri dish with a filter paper 
soaked with the assay solution (Tris buffer 50 mM pH 8.0, 0.01 mg/ml HRP, 0.5 mg/ml diaminobenzidine 
and 10 mM substrate). The membranes were incubated at room temperature until the active colonies 
developed an intense dark brown color (Scheme 12 and Figure 27). These colonies were transformed 
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with a sterile tooth pick to a new membrane and subjected a second screening round after overnight 
grow to eliminate false positives and refine the screening procedure. Active colonies in the second 
screening round were transferred to LB-Amp plates and then grown in 96 well plates as described 
above (2.8).  
From the epPCR library about 60000 - 70000 colonies were screened.  
For saturation mutagenesis, the library size was calculated and screened to a completeness of > 95% 
to > 99% (depending on the library size, calculated with GLUE).185 
 
 
Scheme 12: Polymerization of 3,3-diaminobenzidine to a complex brown dye precipitate with HRP and H2O2.
186 
 
2.11.2 Activity assays with cell lysates 
 
Expression of mutant libraries in 96 well plates and generation of cell lysates was done as described 
above. Lysates were used for activity assays with 4-aminoantipyrine and vanillic acid as described in 
paragraph 2.12.2.187 Depending on the activity with the screened substrate 5-25 µl of the lysate were 
used.  
Active mutants were then reassessed in triplicates with 5-20 µg total protein from individual small scale 
(50 ml) expressions.  
 
2.12 Liquid phase assays to determine the specific activities of purified proteins 
2.12.1 Spectrophotometric detection of NADPH consumption to determine the IRED 
activity 
 
To determine the pH profile of IREDs, the thermostability, the activity in presence of organic solvents 
and record kinetic parameters the specific activities of the IREDs were determined by monitoring the 
consumption of the co-substrate NADPH photometrically in a PolarStar Omega 96 well plate reader 
(BMG Labtech GmbH, Ortenberg, Germany) at 340 nm or 370 nm. One unit of IRED activity was defined 
as the amount of protein that oxidizes 1 µmol NADPH per minute. 
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Typically reactions were performed in 96 well plates (Greiner Bio-One GmbH, Frickenhausen, Germany) 
at 30 °C with an appropriate amount of enzyme in a final volume of 300 µl sodium phosphate 
buffer 50 mM pH 7.0. 0.3 µM of NADPH were used for recordings with substrates 2-methylpyrroline 1 
and 2-methylpiperideine 3a performed at 340 nm and 0.3 - 0.6 µM NADPH were used for recordings at 
370 nm, done for substrates possessing an aromatic ring (2-phenylpiperideine 3b, 2-p-fluorophenyl-
piperideine 3c, 3,4-dihydroisoquinoline 5a and 1-methyl-3,4-dihydroisoquinoline 5b). The extinction 
coefficients were for each experiment determined experimentally as some of the substrates exhibited 
slightly brown color or overlapped partially with the NADPH spectrum.  
For 340 nm a typical ε of 5.136 mM-1 cm-1 was determined and for 370 nm ε was 2.066 mM-1 cm-1.  
 
To determine the pH profile of the IREDs the following buffers were used: sodium citrate buffer 
(pH 4.0 - 6.5; prepared according to McIlvaine),188 sodium phosphate buffer (pH 6.0 - 8.0), Tris HCl 
buffer (pH 7.5 - 9.0) and glycine NaOH buffer (pH 8.5 - 10.0). In these assays 5 mM of substrate 1 was 
used.  
 
The activity in presence of organic solvents was determined in sodium phosphate buffer pH 7.0 with 5% 
to 25% organic solvent and 5 mM of substrate 1.  
 
To determine the half life time of the IREDs at 30 °C and 50 °C samples were incubated at the respective 
temperature and regularly samples taken. The residual specific activity with 10 mM of substrate 1 was 
then plotted against the time and a nonlinear regression with the Solver plugin of Microsoft Excel 
performed to an exponential decay function of the form: A=A0*e-λ*t with A0 representing the specific 
activity at t = 0 h to calculate the half-life times.  
 
Determination of the T50
  15
 [°C] was done as described in literature with slight modifications.189 Small 
samples of the enzymes were incubated in a PCR machine for 15 min at the respective temperatures 
following a relaxation time of 15 min at 8 °C. The residual specific activity with 10 mM of substrate 1 was 
then determined and plotted against the temperature. The curve was fitted by nonlinear regression with 
the Solver plugin of Microsoft Excel to a sigmoidal dose response curve of the following form: 
A = Amin+
(Amax-Amin)
1+(
X
C
)
B  (with Amax and Amin as the maximum and minimum specific activity, B being the slope 
of the middle part (Hill Slope) and C representing the inflection point (X50))190 to calculate the T50
  15
 [°C] 
with the reference value for maximum (100%) activity after incubation on ice.  
 
For investigation of the temperature dependency of the reaction rate of S-IRED-Pe the specific activity 
with 10 mM of substrate 1 was determined at different temperatures. Therefore an Ultrospec 3000 
photometer (Pharmacia Biotech, now part of GE HealthCare) with a temperature controlled cuvette 
holder (Fisons B3 Heating Circulator Bath, Haake) was used. The temperature of the buffer in the 
cuvette was extra controlled in a reference cuvette with a thermometer and after staying constant for at 
least 2 min, the reactions were started by the addition of IRED, NADPH and substrate. The total volume 
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added was less than 5%. To avoid substrate evaporation at increased temperatures the cuvettes were 
sealed (Figure 7).  
 
 
Figure 7: Experimental setup to determine the temperature dependence of the reaction rate of S-IRED-Pe.  
 
Kinetic constants of the IREDs were calculated by determining the specific activity of the enzymes with 
varying concentrations of the different substrates (see x-axis of Figure S1 to Figure S5 and Figure S34 
to Figure S48). Substrates were either dissolved in H2O or DMSO, with the organic solvent being present 
from 1-5% maximum, depending on the solubility of the respective substrate. Nonlinear regression of 
the measured activities to the Michaelis-Menten equation was then performed with the Solver plugin of 
Microsoft Excel using “XL_Kinetics” or self-written spreadsheets.191,192 With some substrates, the IREDs 
showed lower activities at higher concentrations. In these cases the Michaelis-Menten equation was 
adapted to substrate inhibition kinetics using the following formula: "v=(vmax×[S])/(KM+[S]×(1+([S]/KI)))". 
 
To determine the kinetics for the reductive amination reaction, the same setup was used as described 
above. The substrate solution consisted of varying concentrations of aldehyde 11 premixed with the 
respective excess amount (equimolar, 10-fold and 50-fold) of amine 22 adjusted to pH 8.0 or pH 9.0 in 
buffer. 
 
2.12.2 Detection of H2O2 formation by PuO-Re 
 
Amine oxidase activity was determined by monitoring the formation of the co-product H2O2 in a coupled 
spectrophotometric assay with HRP and 4-aminoantipyrine plus vanillic acid as dye according to 
Holt et al..187 In combination with HRP and H2O2 they are converted into a red quinoneimine dye 
(Scheme 13).  
 
 
Scheme 13: Formation of a red quinoneimine dye by HRP from 4-aminoantipyrine and vanillic acid with H2O2.
187 
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This assay was also used to determine the activity with lysates from the PuO-Re mutant libraries and to 
determine the kinetic constants for purified PuO-Re by measuring the specific activities of the enzyme 
at different substrate concentrations. Calculation was done as described above for the IREDs.  
The absorbance coefficient of the dye was determined with a H2O2 calibration curve to be 
6.212 mM-1 cm-1 (literature 6.234 mM-1 cm-1).187 
 
2.13 Whole cell biotransformations with IREDs 
 
Whole cell biotransformations with IREDs were performed with fresh cells directly after an overnight 
expression. After cell harvest, the pellet was washed once with 50 ml sodium phosphate buffer 50 mM 
pH 7.0. Biotransformation samples consisted of OD=30 cells (~ 50 mg/ml cww), 10 mM of the imine 
substrates (dissolved either in H2O or DMSO) and 50 mM glucose for cofactor recycling. Reactions were 
performed in 50 mM sodium phosphate buffer pH 7.0 with a final DMSO concentration of maximum 5%. 
Biotransformations were done in screwed capped glass vials at 25 °C and 180 rpm. Regularly 
(usually 0 h, 0.5 h, 1 h, 3 h, 5 h, 8 h, and 24 h) samples were taken, mixed with internal standard, the 
cells centrifuged and the supernatant analyzed by GC or HPLC as described below (2.18 and 2.19). As 
negative control cells harboring an empty pBAD33 plasmid were used. 
 
2.14 Biotransformations with purified proteins 
2.14.1 IRED biotransformations with cyclic imine substrates 
 
Biotransformation using purified IREDs were done according to literature142 with slight modifications. 
The IRED concentration in the reactions was 250 µg/ml and 10 mM of the imine substrate from a H2O, 
DMSO or MeOH stock were used. The maximum concentration of organic solvent was 5%. For cofactor 
recycling 5 mM NADPH, 20 mM glucose-6-phosphate and 5 U/ml glucose-6-phosphate dehydrogenase 
were used. In a later stage of the project the NADPH was scaled down to 2.5 mM and 25 mM 
glucose-6-phosphate was used. This change did not result in alterations of the conversions and 
conversion rates.  
Reactions were performed in 50 mM sodium phosphate buffer pH 7.0. Samples were incubated in 
screwed capped glass vials at 25 °C and 180 rpm. As negative control the IREDs were heat inactivated 
at 95 °C for 10 min.  
For GC analytics, regularly samples were taken and mixed with an internal standard. Preparation of the 
sample for GC or HPLC analytics was done as described below (2.18 and 2.19).  
 
2.14.2 IRED biotransformations with exocyclic imine substrates 
 
Biotransformations with exocyclic imine substrates were done as with cyclic imines but Tris buffer 
(50 mM) with a pH of 8.0 was used and the IRED scaled up to 2.5 mg/ml. In addition 
glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides was used in its lyophilized 
powder form. Reconstitution of the lyophilized powder was done in small aliquots at 1 kU/ml with the 
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following buffer: 5 mM glycine buffer pH 8.0 with 0.1% bovine serum albumin (BSA). Each aliquot was 
used maximum twice as advised by the manufacturer.  
The substrate was added from a DMSO or MeOH stock and the final concentration of the organic solvent 
was maximum 5%.  
 
2.14.3 Reductive amination reactions with R-IRED-Sr 
 
Reductive amination reactions with IREDs were performed with a final protein concentration of 
2.5 mg/ml or 10 mg/ml. As negative controls reactions were done in which the IRED was substituted by 
heat inactivated enzyme (10 min at 95 °C) or by BSA. The other components of the control 
biotransformations were identical to the ones with active IRED.  
Reactions for reductive aminations consisted of 10 mM carbonyl substrate (benzaldehyde 11 or 
acetophenone 20, dissolved in DMSO) and the amine substrate (ammonia 21, methylamine 22 and 
aniline 12 dissolved either in H2O or DMSO) at equimolar, 10-fold and 50-fold excess of the amine to 
the carbonyl substrate. For recycling of the NAPDH cofactor (2.5 mM in reactions) 25 mM glucose-6-
phosphate and 5 U/ml of the reconstituted lyophilized glucose-6-phosphate dehydrogenase were used. 
Reactions were performed in Tris-HCl buffer at a pH of 8.0, 8.5 and 9.0 with a final DMSO concentration 
of 5% in all samples. The reactions were incubated in 5 ml screwed capped glass vials at 25 °C and 
180 rpm and regularly samples were taken.  
Preparation of samples for GC or HPLC analysis was done as described below.  
 
2.15 Reaction cascade with purified IREDs and PuO-Re 
 
For the reaction cascade with purified proteins IREDs and PuO-Re were used in equimolar ratio (10 µM 
each enzyme). Samples were incubated in 100 mM Tris buffer pH 8.0 with 2.5 mM NADPH, 20 mM 
glucose-6-phosphate, 5 U/ml glucose-6-phosphate dehydrogenase, catalase (2000 U/ml) and 10 mM 
amine substrate (dissolved in H2O). Samples were incubated for 3 h at 25 °C and 180 rpm and 
afterwards quenched by the addition of 50 µl 5 M NaOH, followed by derivatization as described in 2.17.  
 
2.16 Reaction cascade with whole cells expressing IREDs and PuO-Re 
 
For coexpression of IREDs and PuO-Re wt chemically competent cells of E. coli strain JW5510 were 
transformed with both plasmids simultaneously. Cells were plated on LB-Amp-Cm and a single colony 
of the grown transformants used for overnight expression of both proteins as described above for strains 
having only one plasmid.  
Biotransformations were then set up as described in 2.13 for IRED biotransformations, but Tris buffer 
pH 8.0 was used. Biotransformations were performed at 25 °C and 180 rpm in screwed capped glass 
vials and regularly samples were taken.  
For analysis, cells were centrifuged down and the supernatant used for extraction and derivatization as 
described below (2.17).  
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2.17 Preparation of samples for GC and HPLC analytics and derivatizations 
 
Samples of IRED biotransformations with substrates 1 and 3a were derivatized and extracted with acetic 
anhydride and dichloromethane as solvent as described by Dobos et al..193 
 
IRED biotransformations with the residual substrates (3b, 3c, 5a to 5c, benzylidenemethylamine 7, 
benzylideneaniline 9, benzophenoneimine 15 and phenylethylideneaniline 18) and reductive amination 
reactions were extracted twice with MTBE after the addition of 50 µl 5 M NaOH to the supernatant. 
Extractions of reactions with substrate cinnamaldehyde 45 were done twice with MTBE without the 
addition of NaOH.  
 
Derivatization of 2-phenylpiperidine 4b, α-methylbenzylamine 26 and N-α-dimethylbenzylamine 27 for 
chiral GC was done with acetic anhydride. 200 µl of the extracted sample were used and mixed with 
20 µl acetic anhydride and 20 µl pyridine, incubated for 1 h at 70 °C followed by quenching with 200 µl 
2% aqueous methylamine solution. The organic phase was then analyzed by GC-FID. 
 
Derivatization of polyamines and biotransformation products from polyamines in the reaction cascade 
with purified proteins and whole cells was done with isobutylchloroformate (IBCF) as described by 
Cunha et al..194 
 
2.18 GC-FID and GC-MS analytics 
 
Results of the biotransformations with substrates 1, 3a to 3c and their corresponding products were 
analyzed by GC. Reductive amination reactions with amine nucleophiles ammonia 21 and methylamine 
22 were also analyzed by GC, as well as reactions with polyamine substrates 1,4-diaminobutane 28, 
1,5-diaminopentane 29 and 1,5-diamino-2-methylpentane 31. GC-FID analyses were carried out on a 
Shimadzu GC-2010 equipped with an AOC-20i auto injector. Identification of compounds was done by 
detection via flame ionization detector (FID) and comparison of the retention times to commercial 
available reference materials. For quantification of biotransformations, calibration curves with the 
authentic standards were prepared. GC conditions and programs are given in Table 6. The GC-FID was 
operated with H2 as carrier gas (linear velocity 30 cm/s) and samples were injected in split mode. In 
addition product analyses were done by GC-MS on a Shimadzu GCMS-QP2010 system equipped with 
an AOC-5000 auto injector and He as carrier gas. Mass spectra were determined by electron impact 
(EI) ionization with 70 eV, an ion source temperature of 200 °C and an interface temperature of 250 °C. 
Mass detection was performed in scan mode from 35 m/z to 500 m/z. Columns and oven temperature 
programs were the same as for GC-FID analysis.  
For GC-MS headspace the CombiPal sampler was operated in headspace mode with a 2.5 ml heated 
headspace syringe. Biotransformation samples were filled in 20 ml headspace vials and heated 
to 150 °C. 250 µl of the gas phase were injected for analysis.  
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Table 6: GC-FID and GC-MS conditions used for analysis and quantification. The column “compounds” lists only the substrates 
of the biotransformations in case of the achiral methods. Products and byproducts could be detected with the same method. For 
the chiral methods only the detected products are listed in this column. The basis for the assignment of the enantiomers and 
comments are given in the last column.  
compounds column chiral 
injector 
temperature 
[°C] 
detector 
temperature 
[°C] 
column oven 
temperature program 
comment/ 
assignments of 
enantiomers 
1-acetylated DB5 no 250 330 
100 °C hold 2 min, 
30 °C/min to 130 °C, 
5 °C/min to 150 °C hold 1 min, 
50 °C/min to 310 °C hold 3 min 
 
2-acetylated β-Dex 225 yes 250 255 
100 °C hold for 2 min, 
50 °C/min to 130 °C,  
1.5 °C/min to 150 °C,  
50 °C/min to 210 hold 1 min 
authentic reference 
material of (R)- and 
(S)- enantiomers; 
(R)- before (S)-; 
Figure S6. 
3a-acetylated DB5 no 250 330 
100 °C hold for 2 min,  
35 °C/min to 140 °C,  
5 °C/min to 170 °C,  
75 °C/min to 310 hold 3 min 
 
4a-acetylated β-Dex 225 yes 250 255 
100 °C hold for 2 min,  
50 °C/min to 130 °C,  
1.5 °C/min to 150 °C,  
75 °C/min to 230 hold 3 min 
authentic reference 
material of (S)- 
enantiomer; 
analogy to 2;  
(R)- before (S)-;  
Figure S7. 
3b and 3c  ZB-5 no 250 330 
100 °C hold for 2 min,  
30 °C/min to 150 °C,  
5 °C/min to 185 °C,  
75 °C/min to 320 °C hold 3 min  
 
4b-acetylated 
CP-Chirasil 
Dex-CB 
yes 210 250 
90 °C,  
4 °C/min to 200 °C hold 3 min  
Figure S7;  
(S)- before (R)-.147 
7, 11, 20 ZB-5 no 250  330  
65 °C hold for 3 min,  
30 °C/min to 109 °C,  
1 °C/min to 117 °C,  
50 °C/min to 325 °C hold 3 min 
given are the 
imines and 
carbonyl substrates 
for the reductive 
amination reaction. 
26-acetylated 
and  
27-acetylated 
CP-Chirasil 
Dex-CB 
yes 225  225  
90 °C,  
10 °C/min to 140 °C,  
1.5 °C/min to 158 °C,  
75 °C/min to 220 °C hold 3 min  
authentic reference 
material of (R)- and 
(S)- enantiomers; 
(S)- before (R)-;  
Figure S55 and 
Figure S57. 
45 DB5 no 250 330 
70 °C hold for 2 min,  
30 °C/min to 130 °C,  
2 °C/min to 145 °C,  
50 °C/min to 300 hold 2 min 
 
28, 29 and 31 DB-5 no 250 200 / 250  
50 °C hold for 2 min,  
15 °C/min to 90 °C,  
20 °C/min to 220 °C hold 1 min, 
25 °C/min to 320 °C hold 4 min  
reaction cascade 
with purified 
proteins and whole 
cells. 
28 and 29 DB-5 no  200 / 250  
80 °C hold for 3 min, 
8 °C/min to 120 °C,  
50 °C/min to 310 °C hold 2 min  
GC-MS 
headspace. 
columns:  
ZB-5 (Phenomenex, Aschaffenburg, Germany): length; 30 m x 0.25 mm x 0.25 µm 
CP-Chirasil Dex-CB (Agilent, Waldbronn, Germany): length: 25 m x 0.25 mm x 0.25 µm 
Supelco β-Dex 225 (Sigma Aldrich, Steinheim, Germany): length 30 m × 0.25 mm × 0.25 µm 
DB5 (Agilent, Waldbronn, Germany): length 30 m × 0.25 mm × 0.25 µm 
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2.19 HPLC analytics 
 
Substrate conversions and product formations in biotransformations with 5a to 5c, 9, 15, 18 and 11 
with 12 were analyzed by reversed-phase HPLC on an Agilent 1200 series system equipped with a 
diode array detector (G1315D), degasser (G1322A), quaternary pump (G1311A), temperature 
controlled column compartment (G1316A) and a standard autosampler unit (G1329A) from Agilent 
Technologies (Waldbronn, Germany). Chiral analysis of biotransformations products was done with 
chiral stationary phases by normal phase HPLC using an identical HPLC device. Detection of analytes 
was done by monitoring their UV signals. Identification of compounds was performed by comparison 
with reference materials and by comparing their absorbance spectra from 200-310 nm. Quantification 
of compounds was done using calibration curves with the authentic standards at their maximum specific 
absorbance wavelengths. The applied methods and parameters for detection are summarized in 
Table 7.  
 
Table 7: HPLC methods and settings used for analysis and quantification. The column “compounds” lists only the substrates of 
the biotransformations in case of the achiral methods. Products and byproducts could be detected with the same method. For the 
chiral methods only the detected products are listed in this column. The basis for the assignment of the enantiomers and comments 
are given in the last column. Mobile phases: ABC = ammonium bicarbonate buffer, ACN = acetonitrile, iProp = isopropyl alcohol, 
DEA = diethylamine.  
compounds  column chiral mobile phase 
flow 
rate 
[ml/min] 
injection 
volume 
[µl] 
temperature 
[°C] 
DAD settings 
(wavelength/ 
bandwidth 
and reference) 
comment/ 
assignments 
of 
enantiomers  
5a and 5b XBridge C8 no 
isocratic 
10 mM ABC  
pH 9.0 / 
ACN 
67.5/32.5 
0.6 0.5 25 
216/4;  
248/4;  
264/4  
Ref: 360/100 
 
6b Chiralpak IC yes 
isocratic  
heptane/iProp/DEA 
98:2:0.1 
1 5 20 
248/4;  
264/4  
Ref: 360/100 
Figure S11; 
(S)- before 
(R)-.143 
5c XBridge C8 no 
isocratic 
10 mM ABC  
pH 9.0 / 
ACN 
67.5/32.5 
0.6 1 25 
226/8;  
248/4;  
276/4;  
284/4 
Ref 360/100 
 
4c Chiralpak IC yes 
isocratic 
hexane/ 
iProp:DEA 
(99.5/0.5) 
98/2 
1 5 25 
220/4;  
248/4;  
264/4 
Ref 360/100 
Figure S8;  
(R)- before 
(S)-.147 
9, 15 and 
18 
XBridge C8 no 
isocratic 
10 mM ABC  
pH 9.0 / 
ACN 
55/45 
0.6 0.5 30 
22/10;  
240/4;  
256/4;  
284/4 
Ref 360/100 
 
18 Chiralpak IB yes 
isocratic 
hexane/iProp 
95/5 
0.4 2.5 20 
220/10;  
244/10;  
292/10 
Ref 360/10 
Figure S19; 
(S)- before 
(R)-.195–197 
columns: 
XBridge C8 3 x 100 mm, 3.5 µm particle size (Waters, Eschborn, Germany) 
Chiralpak IC 250 x 4.6 mm ID (Chiral Technologies Europe, Illkirch, France) 
Chiralpak IB 150 x 4.6 mm ID (Chiral Technologies Europe, Illkirch, France) 
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2.20 SEC analysis on HPLC to determine the protein purity 
 
Analysis of His6-tagged IRED purity by size exclusion chromatography on HPLC was performed as 
described in literature.151 A Phenomenex Yarra 3µ SEC-2000 column (Aschaffenburg, Germany) was 
used with an Agilent 1200 HPLC system equipped with a diode array detector (G1315D), degasser 
(G1322A), quaternary pump (G1311A), temperature controlled column compartment (G1316A) and a 
temperature controlled high performance autosampler unit (G1367B). Analytes were separated in runs 
performed for 25 min using a mobile phase of 50 mM sodium phosphate buffer pH 6.5 with 100 mM 
NaCl at a flow rate of 0.2 ml/min and 30 °C. Until injection, the samples in the autosampler unit were 
kept at 8 °C. 5 µl of the purified protein solution diluted to a concentration of 2 µg/µl in the mobile phase 
were injected and the UV signal at 280 nm recorded. Estimation of the IRED purity was then done by 
calculating the fraction of the A280 signal corresponding to the IRED compared to the total UV280 signal. 
For calibration of the size exclusion column a gel filtration standard from BioRad was used (#151-1901, 
Bio-Rad Laboratories GmbH, Munich, Germany). 
 
2.21 Synthesis of substrates and products and NMR analysis 
 
The following compounds were not commercially available and hence synthesized to be used as 
substrates for IREDs, PuO-Re or as product standards for identification and quantification of 
biotransformation results.  
Synthesized compounds were characterized by 1H- and 13C- nuclear magnetic resonance (NMR) 
spectroscopy on a Bruker Avance 500 spectrometer operating at 125.76 MHz or 500.15 MHz at 23 °C 
in deuterated solvents with tetramethylsilane as internal standard. Chemical shifts are expressed in ppm 
relative to tetramethylsilane. 
 
2.21.1 Synthesis of 2-methylpiperideine (imine 3a) 
 
Synthesis of imine substrate 3a was done as described in literature.144,198 
 
 
Scheme 14: Synthesis of imine 3a from amine 4a with NCS and DBU.  
 
7.5 g (56 mmol) N-Chlorosuccinimide (NCS) were dissolved in 250 ml dry diethyl ether and under N2 
atmosphere on ice slowly 6 ml (51 mmol) 4a were added over 30 min. The reaction was then stirred 
overnight at room temperature. The complete conversion of the amine was confirmed by TLC staining 
and by GC-MS. The organic phase was washed with water (3 x 50 ml), dried over MgSO4 and the solvent 
completely removed by rotary evaporation until a slightly yellow oily liquid was obtained (6.64 g, 
49.7 mmol, 97.4%). The oil was dissolved in 50 ml dry DCM and over 25 min slowly 9.8 ml 
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diazobicyclo-[5.4.0]-undec-7-ene (DBU, 65.7 mmol, 1.3 equivalents) were added. The solution was 
stirred for 6 h at room temperature. During this time the color changed from pale yellow to dark brown 
and by GC the conversion to the imine was confirmed.  
Purification of the imine was done by distillation at reduced pressure (800 to 400 mbar) and precipitation 
of the product as its hydrochloride salt by the addition of 2 M HCl in diethyl ether afforded imine 3a as 
slightly yellow ionic liquid (0.7 g, 7.1 mmol, 14% yield). NMR spectra (Figure S92 and Figure S93) were 
in accordance with literature results.144,147,199 
 
1H-NMR (500 MHz, CD3OD) δ (ppm): 1.80 – 1.95 (m, 4 H), 2.40 (s, 3 H), 2.77 – 2.85 (m, 2 H), 
3.60 – 3.68 (m, 2 H). 
13C-NMR (500 MHz, CD3OD) δ (ppm): 18.0, 20.2, 24.8, 32.1, 45.8, 191.9. 
 
2.21.2 Synthesis of 2-phenylpiperideine (imine 3b) 
 
Synthesis of imine substrate 3b was performed during the supervision of a chemist internship according 
to literature.34,143,147 Imine 3b hydrochloride was obtained as brown crystals with about 50% yield 
(4.7 mmol, 0.92 g). NMR spectra (Figure S94 and Figure S95) were in accordance with literature 
results.147 
 
1H-NMR (500 MHz, CD3OD) δ (ppm): 2.06 – 2.02 (m, 4 H), 3.31 – 3.35 (m, 2 H), 3.81 – 3.89 (m, 2 H), 
7.61 – 7.70 (m, 2 H), 7.75 – 7.82 (m, 1 H), 7.86 - 7.94 (m, 2 H). 
13C-NMR (500 MHz, CD3OD) δ (ppm): 18.4, 20.4, 29.9, 46.5, 129.0, 130.8, 133.2, 136.2, 185.3. 
 
2.21.3 Synthesis of 2-p-fluorophenylpiperideine (imine 3c) 
 
Synthesis of imine substrate 3c was performed during the supervision of a chemist internship 
analogously to the synthesis route for 3a with NCS and DBU as described above. The imine was 
obtained as a mixture of a green-yellow oil and yellow needles of DBU after evaporation of the solvent.  
Purification of the crude product was done by flash column chromatography during this work.  
For flash column chromatography the silica was deactivated with 1% trimethylamine. Purification with 
cyclohexane:ethyl acetate (70:30) with 0.5% trimethylamine afforded the product as clear yellow liquid 
in 46% yield (0.36 g, 2 mmol) with > 95% purity after evaporation of the solvent. NMR spectra 
(Figure S96 and Figure S97) were in accordance with literature results.147 
 
1H-NMR (500 MHz, CDCl3) δ (ppm): 1.63 – 1.71 (m, 2H), 1.79 – 1.87 (m, 2 H), 2.57 – 2.63 (m, 2 H), 
3.78 – 3.85 (m, 2 H), 7.0 – 7.10 (m, 2 H), 7.73 – 7.79 (m, 2 H). 
13C-NMR (500 MHz, CDCl3) δ (ppm): 19.7, 21.8, 27.0, 49.8, 115.0 (d, J = 21.8 Hz), 127.8 (d, J = 8.2 Hz), 
136.3 (d, J = 3.0 Hz), 163.7 (d, J = 248.8 Hz), 164.5. 
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2.21.4 Synthesis of 1-methyl-1,2,3,4-tetrahydroisoquinoline (amine 6b) 
 
Amine 6b was synthesized by reduction with NaBH4 from imine 5b as described in literature by 
Huber et al..144 
 
1 mmol (0.182 g) imine hydrochloride were dissolved in 5 ml ice cold MeOH. 2 mmol NaBH4 (75.7 mg) 
were dissolved in dry ice cold MeOH and added under N2 atmosphere to the imine.  
After stirring for 2 h on ice the imine was fully reduced as indicated by HPLC analysis and TLC staining 
with Ninhydrin solution (1.5 g Ninhydrin dissolved in 100 ml n-butanol with 3 ml acetic acid). The reaction 
was stopped by the addition of 5 ml 5 M NaOH. The amine product was extracted twice with 20 ml DCM, 
washed with H2O and the organic phase dried by the addition of MgSO4. The organic phase was filtered 
and concentrated by rotary evaporation. 0.126 g of amine 6b was obtained as slightly yellow oil in 
about 87% yield. NMR spectra (Figure S98 and Figure S99) were in accordance with literature 
results.143,144 
 
1H-NMR (500 MHz, D2O) δ (ppm): 1.52 (d, J = 6.8 Hz, 3 H), 2.84 – 2.92 (m, 1 H), 2.94 – 3.02 (m, 1 H), 
3.06 – 3.14 (m, 1 H), 3.34 (dt, J = 12.5, 5.5 Hz, 1 H), 4.28 (q, J = 6.7 Hz, 1 H), 7.20 – 7.30 (m, 4 H). 
13C-NMR (500 MHz, D2O) δ (ppm): 20.1, 26. 9, 39.8, 50.8, 126.1, 126.5, 127.0, 129.1, 133.3, 137.2. 
 
2.21.5 Synthesis of 1,4-diaminopentane and 1,5-diaminohexane (polyamines 32 
and 33) 
 
Polyamine substrates no. 32 and 33 were synthesized at the Institute of Technical Biochemistry during 
the supervision of a chemist internship according to literature.200 
 
NMR spectrum 1,4-diaminopentane (polyamine 32) (Figure S100): 
1H-NMR (125 MHz, CDCl3) δ (ppm): 1.28 (d, J = 6.3 Hz, 3 H), 1.41 – 2.17 (m, 8 H), 2.82 – 3.11 (m, 2 H), 
3.40 – 3.59 (m, 1 H). 
 
NMR spectrum 1,5-diaminohexane (polyamine 33) (Figure S101): 
1H-NMR (125 MHz, CDCl3) δ (ppm): 1.06 (d, J = 6.3 Hz, 3 H), 1.26 – 1.37 (m, 4 H), 1.38 – 1.49 (m, 6 H), 
2.64 – 2.74 (m, 2 H), 2.83 – 2.96 (m, 1 H). 
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3.1 Imine reductases – novel biocatalysts 
3.1.1 Identification and selection of novel IREDs 
 
IREDs were just recently described and have emerged as promising biocatalysts for chiral amine 
synthesis.107,201 These enzymes can be applied either for the asymmetric reduction of imines, in 
reductive amination reactions or as part of enzymatic cascade reactions. This work will deal with 
examples for all of these different applications. At the time this work started, only three IREDs were 
described in total in the public available literature137–142 and an additional one in a Japanese patent.202 
These first IREDs were discovered by Mitsukura et al. using traditional screening of microorganisms, 
purification of the responsible proteins and the identification of the genes.139–141 With the availability of 
the sequences by BLAST203 homologous genes can be found in GenBank,204 which stores an increasing 
number of genetic information obtained from whole genome sequencing projects and thereby provides 
sequences for a wealth of uncharacterized biocatalysts. After a BLAST search with the sequences of 
the two initially by Mitsukura et al. described IREDs (the (R)- selective IRED from Streptomyces sp. 
GF3587 (R-IRED-Ss) and the (S)- selective IRED from Streptomyces sp. GF3546 (S-IRED-Ss))127-129 
indeed about 350 putative novel IREDs were identified. Interestingly, at the time of the first BLAST 
search many of the obtained entries were designated as new sequences. They were often stored for 
less than three months in GenBank, again underlining the novelty of the IRED superfamily and the 
importance of expanding the known sequence space for the discovery of novel enzymes. 
In cooperation with Silvia FademrechtI the identified sequences were used to set up a database for 
identification and selection of novel IREDs. The bioinformatic works including the establishment of the 
database and the analysis of the sequences were done by Silvia Fademrecht. 
All sequences that were selected for storage in the in house established database system205 had an 
expectation threshold (E value) of 10-30 to ensure a high global sequence identity to already confirmed 
IRED sequences. This stringent threshold was chosen as due to the limited information available about 
characterized IREDs no further criteria could be applied to refine and reduce the number of sequences. 
The average sequence identity of all database members was 36%. The final version of this database 
was named “Imine Reductase Engineering Database” and made publically available online under: 
https://ired.biocatnet.de/.145 
A network analysis of the sequences stored in the database, that was based on sequence similarity 
revealed a clear separation into two superfamilies above a sequence identity threshold of 49% 
(Figure 8).145 They can be traced back to the (R)- selective IRED (R-IRED-Ss) and the (S)- selective 
IRED (S-IRED-Ss) that were used as seed sequences.139–141 Therefore, the superfamilies were further 
dedicated as an (R)- type IRED and an (S)- type IRED superfamily. The assignment into these two 
superfamilies and the thereof derived classification at the very early stage of IRED discovery is 
inherently restricted to the limited number and information available for the few characterized enzymes. 
During the ongoing work on this project, many more novel IREDs were characterized and information 
about them published in literature.142–150 To include the growing information available about IREDs, the 
                                                                
I: Bioinformatics group, Institute of Technical Biochemistry, University of Stuttgart. 
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database was updated and contains at the current version > 1400 entries encoding for more than 1100 
proteins, divided into 14 superfamilies.152 Nevertheless for most of the superfamilies no enzymes are 
characterized. Hence, it is difficult to make general predictions about novel IREDs stored in the database 
with respect to their activity and selectivity. In contrast, for the characterized members of the (R)- type 
IRED and (S)- type IRED superfamilies (in the actual database, version 3, they were renamed as 
superfamily 1 and superfamily 2)152 a few exceptions from the suggested selectivity pattern are now 
described.148,149 Nevertheless as the overall majority of the IRED superfamily members tend to show 
the dedicated selectivity pattern, the initially suggested predictions based on global sequence identity 
greatly facilitate the selection and the characterization of novel IREDs. With further clarifications about 
the mechanism of the enzymatic imine reduction, as well as the resolution of more structures it is 
expected that a refinement of the IRED classification will allow more precise predictions. 
 
 
Figure 8: Assignment of the (R)- type IRED superfamily (circled in green) and the (S)- type IRED superfamily (circled in blue) in 
the first version of the “Imine Reductase Engineering Database”.145 The (R)- type superfamily contains 282 proteins whereas the 
(S)- type superfamily is considerably smaller with only 74 members. Superfamilies were further divided into three homologous 
families for the (R)- type IREDs and two homologous families for the (S)- type IREDs. IREDs that were at the time of publication 
described in literature (R-IRED-Ss, R-IRED-Sk and S-IRED-Ss) are colored as green diamonds. Novel IREDs that were selected 
for characterization in this work are colored as red ellipses. This figure was provided by Silvia Fademrecht.145  
 
To prove that the putative IRED sequences, stored in the database indeed encode for functional 
enzymes, capable of imine reduction some of the database members were selected for biochemical 
characterization. For the selection of these enzymes the bioinformatic database analyses and the 
information about the biochemical properties of the published IREDs were combined to estimate the 
importance of conserved residues that might be responsible for the imine reducing activity.  
In the initial characterization performed by Mitsukura et al. several potential enzyme inhibiting 
compounds were tested and the results indicated a hydroxy- and thiol- sensitive nature of R-IRED-Ss.138 
In contrast, chelating agents like EDTA did not result in decreased activity, making metal assisted 
catalysis unlikely.138 During this time a third IRED was published in the public literature.142 An (R)- 
selective enzyme from Streptomyces kanamyceticus (R-IRED-Sk) was cloned, its crystal structure 
resolved and a mechanism proposed (see also 1.2.5).142 Based on its sequence similarity, the enzyme 
clustered in the (R)- type IRED superfamily, thereby also further indicating the established selectivity 
pattern. The sequence of this enzyme was therefore used as an additional seed sequence for the 
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database.145 By combining the biochemical- and the new mechanistic information with the conservation 
analysis, novel IREDs were now selected. An alignment of these three characterized enzymes with their 
closest related homologous was performed (Figure 9). As highlighted in this alignment (Figure 9), IREDs 
possess many overall conserved residues (yellow), superfamily specific conserved residues (blue and 
green), but also major deviations in the conserved positions could be identified from the consensus 
sequence (red). The selection of the novel IREDs for characterization was done based on the highest 
sequence identity, but disregarding the sequences that showed major deviations in the conserved 
residues (colored in red in Figure 9). The selected enzymes for characterization were derived from 
Streptosporangium roseum DSM 43021 (highest sequence identity to R-IRED-Sk142), Streptomyces 
turgidiscabies (highest sequence identity to R-IRED-Ss138,141) and Paenibacillus elgii (highest sequence 
identity to S-IRED-Ss139,140; see also Table 8).  
 
Table 8: Novel IREDs that were selected for characterization and their relation to the three already characterized IREDs. 
origin of novel IRED abbreviation homology to sequence identity superfamily 
Streptosporangium roseum DSM 43021 R-IRED-Sr R-IRED-Sk 60.8% 1 ((R)- type) 
Streptomyces turgidiscabies R-IRED-St R-IRED-Ss 80.7% 1 ((R)- type) 
Paenibacillus elgii S-IRED-Pe S-IRED-Ss 60.5% 2 ((S)- type) 
 
 
Figure 9: Excerpt of an alignment of the closest homologous sequences (next to others, they include R-IRED-Sr, R-IRED-St and 
S-IRED-Pe) to the three characterized IREDs from Streptomyces kanamyceticus (R-IRED-Sk),142 Streptomyces sp. GF3587 
(R-IRED-Ss)140 and Streptomyces sp. GF3546 (S-IRED-Ss).139 Residues colored in yellow are conserved in both IRED 
superfamilies, green/blue colored residues are superfamily specific conserved and red residues indicate a deviation from the 
consensus sequence. The details about the selection of R-IRED-Sr, R-IRED-St and S-IRED-Pe for characterization are given in 
the main text.  
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For production of the three IREDs, the corresponding genes were ordered from GeneArtTM in codon-
optimized form for expression in E. coli. As expression system the arabinose inducible pBAD33 plasmid 
(Figure 5) was chosen as the pET/IPTG based expression system was meanwhile described to result 
in large amounts of insoluble protein.143 Furthermore plasmids of the pBAD series can be combined as 
they possess compatible origins of replication and different selection markers.174 This might facilitate the 
combinatorial use of different expression plasmids and the establishment of enzymatic cascade 
reactions. Plasmids from the pBAD33 series, however do not have a ribosome binding site, hence in 
the ordered DNA a synthetic one (AGGAGG) was included seven bases in front of the ATG start codon. 
Design of this ribosome binding site was done considering criteria published in literature for high level 
expression.206–209 In addition an N-terminal His6-tag for purification and a 3CV protease cleavage site 
for tag removal was included.210–212 The detailed sequence of the synthetic DNA ordered for each IRED 
is given in section 2.1.4.  
The expression of the three IREDs was tested and optimized during the supervision of the diploma 
thesis of Sebastian Hofelzer.213 Of the tested conditions, the highest levels of protein were obtained 
after expression over night at 25 °C in TB media. At higher temperatures IREDs tend to form insoluble 
inclusion bodies. The purification of the IREDs was established by Ni2+ affinity chromatography on an 
Äkta Explorer system. The result of a typical IRED purification and the purity estimated by size exclusion 
chromatography (SEC) in HPLC is shown in Figure 10 and Table 9.  
In literature IREDs are often described to be well expressed, but insoluble. During these investigations 
it seemed however that the solubility of the IREDs was mainly affected by the lysis method, something 
that was also described for other proteins.214,215 By using high pressure homogenization the yields of 
purified protein were usually > 250 mg per liter of E. coli culture for each IRED. In contrast, in the 
beginning cell disruption was performed by ultrasonication and in these cases for the purified proteins 
often less than 50 mg per liter culture were obtained. However next to an influence on solubility, with 
high pressure homogenization also a more effective lysis might contribute to the higher yields. On the 
denaturing SDS gel, IREDs migrated according to their molecular weight around 33 kDa (Figure 10). To 
visualize also minor contaminants 20 µg total protein were loaded on the gel. According to the SDS gel 
and based on the SEC analysis in HPLC (Table 9), the purity of the IREDs reached after optimization 
~ 90% (the calculation is based on the fraction of the total UV280 signal in the HPLC SEC analysis).  
 
Table 9: Purity of IREDs determined by SEC analysis in HPLC.  
IRED 
purity [%] based on A280 
in HPLC SEC analysis 
HPLC run 
R-IRED-Sr 90.3 Figure S26 
R-IRED-St 87.0 Figure S27 
S-IRED-Pe 91.6 Figure S28 
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Figure 10: 15% SDS-PAGE of a typical Ni2+ affinity chromatography purification of R-IRED-Sr, R-IRED-St and S-IRED-Pe. To 
compare the purity of the IREDs and visualize minor contaminants 20 µg total protein were loaded.  
 
After purification of the IREDs, the buffer was exchanged and the proteins concentrated. IREDs were 
found to be very soluble proteins and concentration of them to > 70 mg/ml did not result in precipitation. 
Interestingly the (R)- selective IREDs displayed a bright yellow color after purification, whereas the (S)- 
selective IRED was colorless (Figure 11). This color was also stable during dialysis, but lost after heat 
denaturation of the enzyme. A spectral analysis of the two proteins indicated a maximum of the 
absorbance around 340 nm.  
 
 
Figure 11: Color of purified IREDs. R-IRED-Sr: 86 mg/ml; R-IRED-St: 81 mg/ml; S-IRED-Pe: 74 mg/ml. 
 
3.1.2 Imine reducing activity of the novel IREDs 
 
To verify and determine the activity of these newly selected putative IREDs the reduction of the 
previously described substrate 2-methylpyrroline 1 was tested with whole cells having the IREDs 
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expressed as well as with purified proteins. As controls in whole cell biotransformations, cells with an 
empty pBAD33 plasmid were used, whereas for the reduction with purified proteins, the enzymes were 
heat inactivated (95 °C, 10 min).  
Biotransformations employing whole cells with this substrate resulted in a rapid conversion of the 
substrate, in contrast to the cells with an empty vector that did not show any conversion. Both of the 
R-IREDs fully converted the substrate within 3 hours to the amine product 2-methylpyrrolidine 2, 
whereas the (S)- selective IRED showed conversions of around 95% in 24 h (Table 10, Figure 12 and 
Table S1). By chiral GC-FID also the expected selectivity could be confirmed. The R-IREDs performed 
the transformations with an excellent enantiomeric excess of 98.3% and 99.0% for R-IRED-Sr and 
R-IRED-St, respectively, whereas the product of the S-IRED-Pe catalyzed biotransformation was 
obtained in 94.9% ee (Table 10, Figure S6).  
Also in biotransformations with purified proteins excellent conversion rates could be obtained 
(summarized in detail in section 3.5).  
 
 
Figure 12: Time course of the reduction of 10 mM 2-methylpyrroline 1 to 2-methylpyrrolidine 2 by whole cells expressing the gene 
encoding for S-IRED-Pe. The measured points are the average of a triplicate and the error bars show the standard deviation.  
 
To compare these three novel IREDs to the ones that were at that time described in literature, the kinetic 
constants were determined for the imine substrate 1. In a spectrophotometric assay the initial decrease 
of the NADPH absorbance at 340 nm was monitored and the specific activities plotted versus the 
different employed substrate concentrations. As all three IREDs showed decreased activities at higher 
substrate loadings, the Michaelis-Menten equation was adapted to substrate inhibition kinetics. For all 
three enzymes the affinities for 1 were in the low mM range, but the turnover numbers showed greater 
variations. R-IRED-Sr is one of the most active IREDs for the turnover of this substrate, having a kcat of 
approximately 1 s-1. In contrast, the (S)- selective IRED showed comparably lower turnover numbers of 
only about 0.03 s-1. The kinetic constants for this substrate for the three IREDs are summarized in 
Table 11.  
After solving the first crystal structure of an IRED (the (R)- selective IRED from Streptomyces 
kanamyceticus (R-IRED-Sk)) a catalytic mechanism was proposed for this enzyme based on analogy 
with the structurally closely related enzyme family of the β-hydroxyacid dehydrogenases 
(β-HADs).142,216,217 It involves the protonation of the imine substrate by an Asp (position 187) in the active 
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site of the enzyme, followed by the reduction via the hydride transfer from NADPH.142 This Asp residue 
represents one of the highest conserved residues of IREDs and almost all of the (R)- type IREDs 
possess this amino acid (86% Asp and 11% Glu) at standard position 187.145 However, it is a superfamily 
specific conserved amino acid (see also Figure 9) and with one exception all of the members of the (S)- 
type IREDs have a Tyr residue at this position.145 These residues are located in the assumed active site 
cleft of the enzymes within a distance of 5-7 Å from the NAPDH. To underline the importance of the Asp 
residue, the group of Prof. Dr. Gideon Grogan at University of York has performed mutagenesis at this 
position and the substitution with either Ala or Asn rendered R-IRED-Sk inactive (see also Figure 4).142 
In order to confirm the crucial role of this residue and at the same time investigate whether the Tyr at 
the same position in the (S)- type superfamily could adopt the role of the proposed catalytic Asp, site 
directed mutagenesis with these three novel IREDs was performed. By mutating the respective residues 
to Ala, the proposed catalytic function of the enzymes should be abolished or at least diminished. The 
mutants were generated by QuikChange® PCR and indeed in biotransformations an effect was 
observed. The expression level of all three mutants (R-IRED-Sr D191A, R-IRED-St D193A and 
S-IRED-Pe Y208A) was about equal compared to the wt enzymes, based on SDS-PAGE analysis with 
the lysate of the soluble protein fraction. Yet, the (R)- selective IREDs showed decreased conversion 
rates to about 15% and 5%, for R-IRED-Sr and R-IRED-St, respectively, but not a complete inactivation 
(Table 10). Due to the full conversion of substrate 1 with the wild type enzymes, the comparison of the 
conversion rates was done with the initial measuring points 0.5 h and 1 h (Table 10). In contrast, the 
(S)- selective IRED hardly showed any conversion in 24 h (total product formation < 1%; Table 10). In 
addition to the decreased conversion rates, also the enantioselectivities for the enzymatic reduction 
decreased. Again the effect was more pronounced for S-IRED-Pe, for which a drop from about 95% ee 
to about 65% ee was observed (Table 10).  
 
Table 10: Product formations and enantiomeric excess values in [%] for the reduction of 10 mM 1 with whole cells expressing 
IREDs and mutants thereof. All biotransformations were done in triplicates and the error represents the standard deviation. -: not 
detected.   
 
IRED 
product formation [%] 
ee [%] 
0.5 h 1 h 8 h 24 h 
R-IRED-Sr 46.29 ± 0.42 89.79 ± 2.89 > 99 > 99 98.3 ± 0.0 (R) 
R-IRED-St 29.58 ± 1.49 64.59 ± 4.19 > 99 > 99 99.0 ± 0.0 (R) 
S-IRED-Pe 18.66 ± 0.12 38.07 ± 0.38 94.54 ± 1.33 96.84 ± 1.01 94.9 ± 0.0 (S) 
R-IRED-Sr D191A 7.22 ± 0.14 14.89 ± 0.32 58.32 ± 4.21 63.73 ± 3.81 91.4 ± 0.1 (R) 
R-IRED-St D193A 1.11 ± 0.23 2.17 ± 0.06 13.40 ± 0.35 17.42 ± 2.40 94.1 ± 0.0 (R) 
S-IRED-Pe Y208A - - 0.37 ± 0.18 0.88 ± 0.21 65.7 ± 0.3 (S) 
 
After purification of the R-IRED mutants, also their catalytic constants were determined, analogously to 
the wt enzymes. Both mutant enzymes showed decreased affinities and turnover numbers for imine 
substrate 1. Overall the catalytic efficiency (kcat/KM) decreased by a factor of about 100 for R-IRED-Sr 
D191A and 400-fold for R-IRED-St D193A, respectively. In addition, both mutant enzymes showed 
enhanced substrate inhibition. The kinetic constants for the mutant enzymes are also summarized in 
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Table 11. Due to the low activity in whole cell biotransformations with S-IRED-Pe Y208A this enzyme 
was not purified for further analysis.  
 
Table 11: Kinetic constants for the reduction of 1 with purified IREDs and mutants. All specific activities were determined in 
triplicates for varying concentrations of the substrate. To calculate kcat, KM and KI the data was then fitted by nonlinear regression 
to the Michaelis-Menten equation.  
enzyme 
KM 
[mM] 
kcat 
[s-1] 
kcat /KM 
[s-1 mM-1] 
KI 
[mM] 
Michaelis-
Menten plot 
R-IRED-Sr 1.08 ± 0.13 0.96 ± 0.02 0.89 ± 0.11 28.40 ± 3.01 Figure S1 
R-IRED-St 1.81 ± 0.07 0.45 ± 0.02 0.25 ± 0.02 21.07 ± 1.48 Figure S2 
S-IRED-Pe 1.29 ± 0.15 26.32 x 10-3 ± 1.53 x 10-3 20.40 x 10-3 ± 2.61 x 10-3 33.28 ± 8.02 Figure S3 
R-IRED-Sr D191A 11.19 ± 1.34 0.10 ± 0.01 8.98 x 10-3 ± 1.29 x 10-3 4.69 ± 0.41 Figure S4 
R-IRED-St D193A 5.41 ± 0.80 3.04 x 10-3 ± 0.06 x 10-3 0.56 x 10-3 ± 0.08 x 10-3 17.16 ± 1.50 Figure S5 
 
3.2 Biochemical characterization of the novel IREDs 
 
As the available literature for characterized IREDs is still rather poor and many properties of these 
enzymes are unknown, in the following a biochemical characterization of the three newly selected 
enzymes was performed. This included the determination of the pH optima, the thermal stability of the 
enzymes and their activity in the presence of different organic solvents. As IREDs were described to 
form dimers in solution and the resolved crystal structures also indicate that this might be required for 
activity, the oligomerization state of these enzymes was determined by SEC in HPLC. The substrate 
profile and selectivity of R-IRED-Sr, R-IRED-St and S-IRED-Pe as well as the reactions they can 
catalyze will be discussed in the following chapters (3.3, 3.4, 3.5 and 3.6).  
 
3.2.1 pH Profile of the IREDs 
 
To optimize the use of IREDs in in vitro systems, the pH profile of the three novel IREDs was elucidated. 
To determine the optimal pH for the enzymatic reduction, the specific activity of the purified enzymes 
was recorded with substrate 1 using different buffer conditions. The stock solutions of the enzymes were 
prepared in highly concentrated form (30-50 mg/ml) and for the activity assays the IREDs had to be 
diluted by a factor of 50-1000. Hence, residual buffer components from the storage and purification 
could be neglected. The tested buffers involved a pH range from pH 4.0 to pH 10.0, always with two 
overlapping data points after switching to the next buffer systems. The overlapping data points allowed 
to check for effects provoked by the different buffer ions. For the pH range from 4.0 to 6.5 sodium citrate 
buffer according to McIlvaine188 was used, from pH 6.0 to pH 8.0 sodium phosphate buffer was used, 
from pH 7.5 to pH 9.0 Tris HCl buffer was used and from pH 8.5 to pH 10.0 glycine/NaOH buffer was 
employed.  
All three IREDs displayed a relatively broad pH profile, with their maximal specific activity determined at 
a neutral pH of 7.0 in sodium phosphate buffer. Above pH 9.0 and below pH 5.5 the activity rapidly 
decreased (Figure 13, Figure 14 and Figure 15). In contrast to a recent report in literature,148 the pH 
profile of the Tyr containing S-IRED-Pe is comparable to the pH profiles of the (R)- selective IREDs that 
possess Asp in their active sites (see also 4.2).  
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Figure 13: pH profile of R-IRED-Sr for the reduction of 1 in sodium citrate buffer (pH 4.0 - 6.5), sodium phosphate buffer 
(pH 6.0 - 8.0), Tris HCl buffer (pH 7.5 - 9.0) and glycine/NaOH buffer (pH 8.5 - 10.0). Specific activities were determined in 
triplicates with 5 mM of 1 at 30 °C and the error bars show the standard deviation.  
 
 
Figure 14: pH profile of R-IRED-St for the reduction of 1 in sodium citrate buffer (pH 4.0 - 6.5), sodium phosphate buffer 
(pH 6.0 - 8.0), Tris HCl buffer (pH 7.5 - 9.0) and glycine/NaOH buffer (pH 8.5 - 10.0). Specific activities were determined in 
triplicates with 5 mM of 1 at 30 °C and the error bars show the standard deviation.  
 
 
Figure 15: pH profile of S-IRED-Pe for the reduction of 1 in sodium citrate buffer (pH 4.0 - 6.5), sodium phosphate buffer 
(pH 6.0 - 8.0), Tris HCl buffer (pH 7.5 - 9.0) and glycine/NaOH buffer (pH 8.5 - 10.0). Specific activities were determined in 
triplicates with 5 mM of 1 at 30 °C and the error bars show the standard deviation.  
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3.2.2 Thermostability of the IREDs 
 
Next to their pH dependency, the thermal stabilities of the three IREDs were investigated. In initial 
thermostability tests S-IRED-Pe showed enhanced resistance against inactivation at 30 °C and 40 °C, 
but the (R)- selective IREDs rapidly lost their activity at the higher temperature. For the determination of 
the half-life times the (R)- selective IREDs were therefore incubated at 30 °C and S-IRED-Pe at 50 °C. 
Regularly samples were taken and an activity assay with 1 as substrate performed. The declining 
residual specific activity was then fitted to an exponential decay function and the half-life time calculated.  
At 30 °C, the (R)- selective IREDs lost most of their activity within one day, resulting in half-life times of 
about 9 h and about 18 h for R-IRED-Sr and R-IRED-St, respectively (Figure 16 and Table 12). In 
contrast S-IRED-Pe was much more stable and after 7 days at 50 °C more than 70% of the residual 
activity could be detected. Based on this data, the calculated half-life time is > 400 h (Table 12). 
 
 
Figure 16: Residual specific activities in [%] for the reduction of 10 mM 1 to determine the half-life time of R-IRED-St after 
incubation at 30 °C. The decreasing activities were fitted to an exponential decay function of the formula A=A0*e
-λ*t with A0 
representing the specific activity at t = 0 h (set as 100%). All activities were determined in triplicates and the error bars give the 
standard deviation.  
 
Table 12: Half-life times of R-IRED-Sr and R-IRED-St at 30 °C and half-life time of S-IRED-Pe at 50 °C.  
IRED temperature [°C] half-life time [h] plot 
R-IRED-Sr 30 9.2 Figure S21 
R-IRED-St 30 17.8 Figure 16 
S-IRED-Pe 50 > 400 Figure S22 
 
In addition for all three IREDs temperatures were determined at which the enzymes retain 50% residual 
activity after incubation for a certain time (T50). In literature, these T50 values are frequently used to 
quantify and compare thermostability.49,189 The time frame set in these experiments was 15 min and the 
resulting T50
  15
 [°C] values are summarized in Table 13. To determine the data, small samples of the 
IREDs were incubated for 15 min in a PCR cycler spanning a gradient from 25 °C to 70 °C. To ensure 
comparability of all samples the PCR cycler started at 8 °C, heated then for 15 min to the desired 
temperatures, followed again by a cooling step to 8 °C for 15 min. After that relaxation time, the residual 
specific activity with substrate 1 was determined and the data fitted to a four parameter dose-response 
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curve using nonlinear regression. From the fitting function the T50
  15 [°C] was calculated. Close to 40 °C, 
the (R)- selective IREDs rapidly lost activity and the calculated T50
  15
 were about 39 °C and 38 °C for 
R-IRED-Sr and R-IRED-St, respectively (Table 13). As expected from the greater half-life time 
S-IRED-Pe had to be incubated at around 65 °C to reach the T50
  15
 (Table 13). 
 
Table 13: Calculated temperatures at that the IREDs retain 50% activity after a 15 min incubation time (T50
  15
 [°C]).  
IRED T50
  15
 [°C] plot 
R-IRED-Sr 38.8 Figure S23 
R-IRED-St 38.2 Figure S24 
S-IRED-Pe 65.0 Figure 17 
 
 
Figure 17: Specific activities for the reduction of 10 mM 1 in [U/mg] with S-IRED-Pe after incubation at different temperatures for 
15 min. Activities were fitted to a sigmoidal dose-response curve to determine the T50
  15
. Using the above shown data S-IRED-Pe 
displayed 50% residual activity when incubated at 65.0 °C for a period of 15 min. All activities were determined in triplicates and 
the error bars give the standard deviation. 
 
Due to the higher thermal stability for S-IRED-Pe also the temperature-activity profile was recorded. The 
holder for the cuvette with the buffer was heated with a temperature-controlled water bath and in a 
second reference cuvette the temperature in the cuvette measured (see also Figure 7 for the 
experimental setup). After the desired reaction temperature stayed constant for some time, the reaction 
was started by the addition of S-IRED-Pe, substrate and NADPH. The specific activities were then 
calculated and plotted against the temperature. As it is generally agreed a temperature increase of 
about 10 °C resulted in the doubling of the reaction rates. The maximum activity was reported at ~ 65 °C, 
followed by a strong drop, due to the rapid inactivation of the enzyme (Figure S25).  
 
3.2.3 Oligomerization of the IREDs 
 
Dimerization was described for IREDs138,139 and most IRED crystal structures were also resolved as 
dimers (or dimers of dimers).142,144,148 Considering the three dimensional structure of IREDs, in which 
both subunits arrange by a so called reciprocal domain swapping,142 dimerization seems to be essential 
for the proper function of the enzyme. To check the oligomerization state of these three novel IREDs, 
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the purified proteins were analyzed by SEC in HPLC. Thereby also the degree of purity from the 
purification could be estimated more quantitatively than by SDS-PAGE. The calibration of the SEC 
column was performed with a gel filtration standard containing proteins and vitamins of known molecular 
weight. All IREDs eluted after around 13.8 min, a retention time that indicates that these proteins form 
dimers in solution (Figure 18).  
 
 
Figure 18: Calibration of the Yarra 3µ SEC-2000 column with a gel filtration standard from BioRad (blue diamonds) 
TG: thyroglobulin (670 kDa), γG: γ-globulin (158 kDa), OA: ovalbumin (44 kDa), MG: myoglobin (17 kDa), VB: vitamin B12 
(1.35 kDa). SEC analysis in HPLC was used for purity analysis of the IREDs and to examine their oligomerization state. According 
to the retention time of around 13.8 min, all three IREDs form dimers in solution. 
 
3.2.4 Effect of organic solvents on the activity of the IREDs 
 
In general amines are regarded as rather polar compounds, however some of the higher molecular 
weight imine substrates and amine products that were chosen for investigation display only limited 
solubility in aqueous buffer systems. In addition the preparation of sufficiently concentrated substrate 
stock solutions facilitates the experimental setup and enhances reproducibility. By the addition of small 
amounts of co-solvents also insufficient mixing might be avoided and the stability of hydrolytically 
unstable exocyclic imines enhanced. To avoid damaging the enzyme, the effect of different water 
miscible solvents on the IRED activity was investigated. The solvents selected for investigation were 
methanol (MeOH), ethanol (EtOH), dimethyl sulfoxide (DMSO), acetonitrile (ACN), glycerol, tert-butyl 
alcohol (t-BuOH), isopropyl alcohol (iProp) and acetone. All solvents were tested in concentrations from 
5% to 25% (% v/v) and the specific activities of the IREDs with substrate 1 determined.  
All three IREDs showed a similar trend with MeOH, glycerol and DMSO being well tolerated solvents 
(60% to 80% residual activity), whereas the other solvents often led in already low concentrations to 
strongly decreased activities (Figure 19, Figure 20 and Figure 21). Again, as already observed for the 
pH and the temperature profile, the (S)- selective IRED from Paenibacillus elgii showed the broadest 
tolerance versus non physiological conditions. Even in the presence of 25% MeOH around 60% of the 
initial activity is left. In addition to Figure 19, Figure 20 and Figure 21, all specific activities for the three 
IREDs at all concentrations of the eight solvents are summarized in Table S9.  
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Figure 19: Effect of different water miscible organic solvents on the activity of R-IRED-Sr. All solvents were tested in concentrations 
from 5%-25%. The specific activity was recorded in triplicates with 5 mM of 1 as substrate. The reference value for 100% activity 
was determined for a solvent free system (sodium phosphate buffer 50 mM pH 7.0). Activities < 1% are not shown in Figure 19.  
 
 
Figure 20: Effect of different water miscible organic solvents on the activity of R-IRED-St. All solvents were tested in concentrations 
from 5%-25%. The specific activity was recorded in triplicates with 5 mM of 1 as substrate. The reference value for 100% activity 
was determined for a solvent free system (sodium phosphate buffer 50 mM pH 7.0). Activities < 1% are not shown in Figure 20. 
 
 
Figure 21 Effect of different water miscible organic solvents on the activity of S-IRED-Pe. All solvents were tested in concentrations 
from 5%-25%. The specific activity was recorded in triplicates with 5 mM of 1 as substrate. The reference value for 100% activity 
was determined for a solvent free system (sodium phosphate buffer 50 mM pH 7.0).  
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3.3 Whole cell biotransformations to investigate the substrate spectrum and the 
selectivity of the IREDs 
 
The natural role of IREDs and the substrates that are converted by them in the host organisms are 
unknown, instead they were discovered by screening for microorganisms that were able to catalyze the 
stereoselective reduction of imine 1.137 To further explore the substrate scope and the selectivity of these 
three novel IREDs, whole cell biotransformations were performed with a panel of cyclic imine substrates, 
bearing different substituents next to the C=N double bond. In addition several isoquinoline derivatives 
were investigated for their activity and selectivity. As negative controls, cells with an empty pBAD33 
plasmid were employed. For whole cell biotransformations always fresh cells had to be used, as after 
storage and freezing the cells lost considerable amounts of activity. Cells for biotransformations were 
used after expression over night at 25 °C. Prior to use cells were washed once with buffer.  
To investigate the influence different ring sizes and other substituents next to the C=N double bond 
display on the activity and selectivity of the IREDs several cyclic piperideine substrates, analogously to 
the already tested five-membered cyclic imine substrate 2-methylpyrroline 1, were selected for 
reduction. The chosen substrates 2-methylpiperideine 3a, 2-phenylpiperideine 3b and 
2-p-fluorophenylpiperideine 3c were not commercially available and had to be synthesized. Details 
about the synthesis of them, their purification and the NMR spectra are summarized in 2.21 and 7.12. 
The selected isoquinoline substrates included 3,4-dihydroisoquinoline 5a, 1-methyl-3,4-
dihydroisoquinoline 5b and 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 5c.  
Biotransformations were done with a final OD600 of 30 (~ 50 mg/ml cell wet weight) of IRED expressing 
cells and glucose for in situ cofactor regeneration. Regularly samples of the biotransformation were 
taken and the conversions for all of these substrates determined by GC or HPLC analysis using 
calibration curves with authentic standards of the substrates and products. The selectivities of the 
products were determined by chiral GC or chiral HPLC analysis. Assignment of the produced 
enantiomers was done by comparison with authentic enantiopure standards or by comparison with the 
available literature. Details therefore are given in the sections 2.18 and 2.19 and in Figure S6, Figure S7, 
Figure S8 and Figure S11.  
Except for substrate 5c all three IREDs converted this panel of model compounds. Often conversion 
rates were high and led to full substrate consumption in 24 h (Table 14). By increasing the ring size from 
a pyrroline to a piperideine scaffold, conversion rates strongly increased. Substrate 3a was fully 
converted in less than 1 h with cells expressing an R-IRED. Also for cells with S-IRED-Pe full conversion 
was obtained and within < 5 h this required considerably less time than for imine 1. However, although 
the substrate was completely converted with all three IREDs, only about 65% of the product could be 
recovered in all of these biotransformations (Table 14). In contrast, cells with an empty pBAD33 plasmid 
did not show any conversion. By chiral GC the enantiomeric excess for product 4a was determined and 
found to be > 99% for all three IREDs, with no traces from the opposite enantiomer detectable 
(Figure S7). In contrast, with the phenyl substituted substrate 3b conversion rates strongly dropped and 
for S-IRED-Pe after 24 h only 14% of the product was detected. Using cells expressing an R-IRED within 
8 h about 50% of the product could be obtained (Table 14), although the substrate was fully consumed 
by the cells (exemplarily shown in Figure S9 for R-IRED-St). Along with the decreased conversion rates 
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also the selectivity for product 4b, that was obtained in these biotransformations, decreased. The highest 
enantiomeric excess of about 68% ee for (R)-4b was obtained with S-IRED-Pe (Table 14 and 
Figure S7)II. Interestingly with a p-fluorophenyl modification, substrate 3c was converted much better by 
all three IREDs. In already 1 h reaction time cells with R-IRED-St produced > 80% of the product and 
the use of cells with R-IRED-Sr resulted in > 90% conversion to the amine in 24 h (Figure S10). 
Transformation by S-IRED-Pe was slightly lower, but still led to 63% product formation in 24 h 
(Table 14). The selectivities for this product (4c) were determined by chiral HPLC and in the 
biotransformations excellent enantiomeric excess values of up to 90% were obtained for all three IREDs 
(Table 14 and Figure S8). The full dataset containing all samples and the ee values measured at 
different times is given in Table S2. 
 
Table 14: Product formations and enantiomeric excess values in [%] obtained in whole cell biotransformations with 10 mM of 
piperideine substrates 3a, 3b and 3c performed with E. coli JW5510 expressing R-IRED-Sr, R-IRED-St or S-IRED-Pe. The values 
in Table 14 are the average of a triplicate and the error gives the standard deviation. The change in the selectivity from the (R)- 
to the (S)- product for R-IRED-Sr and R-IRED-St and vice versa in the case of S-IRED-Pe is caused by a change in the priority of 
the substituents for the Cahn-Ingold-Prelog assignment. 
 
substrate IRED 
product formation [%] 
ee [%] 
1 h 8 h 24 h 
3a 
R-IRED-Sr 64.38 ± 1.48 64.22 ± 2.21 64.35 ± 8.15 > 99 (R) 
R-IRED-St 66.99 ± 2.72 69.86 ± 7.11 64.81 ± 2.02 > 99 (R) 
S-IRED-Pe 58.95 ± 4.00 74.18 ± 6.89 69.00 ± 1.04 > 99 (S) 
3b 
R-IRED-Sr 20.88 ± 0.31 43.62 ± 1.26 48.02 ± 1.83 23.2 ± 0.4 (S) 
R-IRED-St 26.69 ± 0.84 50.05 ± 2.09 47.79 ± 1.20 56.0 ± 0.3 (S) 
S-IRED-Pe 1.06 ± 0.11 9.54 ± 0.30 14.22 ± 0.19 67.9 ± 0.5 (R) 
3c 
R-IRED-Sr 46.67 ± 2.34 89.79 ± 8.17 94.06 ± 4.37 86.5 ± 0.0 (S) 
R-IRED-St 82.26 ± 4.96 96.11 ± 3.42 94.39 ± 5.22 90.0 ± 0.0 (S) 
S-IRED-Pe 8.17 ± 1.05 49.95 ± 1.39 63.00 ± 0.41 87.0 ± 0.0 (R) 
 
Except from substrate 5c, isoquinolines were well accepted by all three IREDs. The simplest member 
of them 5a, was fully converted with all three IREDs in less than 8 h (Table 15 and complete dataset in 
Table S3). Using the methyl substituted analog 5b it was shown that these transformations also proceed 
selectively (Figure S11). Conversions for substrate 5b reached > 95% using the (R)- selective IREDs, 
with the better enantioselectivity for the (R)- product displayed by R-IRED-Sr (93% ee). Although 
R-IRED-Sr and R-IRED-St are closely related (> 54% sequence identityIII), the selectivity for the product 
in this biotransformation differed considerably and with R-IRED-St it was obtained with an ee of only 
around 50%. S-IRED-Pe produced the opposite enantiomer in about 95% ee with 80% conversion 
in 24 h (Table 15). In contrast, the bulkier substrate 5c was only accepted by S-IRED-Pe. In 24 h 
                                                                
II: The opposite stereoselectivity for products 4b and 4c, compared to 4a is not caused by a different optical orientation, but is due 
to the change in the priority numbering of the substituents for the Cahn-Ingold-Prelog assignment.291 
III: Pairwise sequence alignments were performed using the European Molecular Biology Open Software Suite (EMBOSS) applying 
the Needleman-Wunsch algorithm to the native IRED sequence.292–294 
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around 15% of the product was formed and this increased to about 30% in 48 h (Table S3). By chiral 
HPLC the formation of the (S)- enantiomer of the product could be confirmed, but no sufficient resolution 
from the residual substrate was obtained to be able to calculate an ee valueIV. Both (R)- selective 
enzymes did not lead to any product formed (Table 15). These results were meanwhile also confirmed 
by data published in literature, indicating a broader range of substrates accepted by S-IREDs.143,147 
Interestingly for this substrate also cells with an empty pBAD33 plasmid showed some substrate 
consumption (~ 20% in 24 h, Figure S12), but no product formation could be detected. The full dataset 
for the whole cell biotransformations with isoquinolines 5a to 5c with all values is given in Table S3. A 
summary of the conversions and selectivities for all of the whole cell biotransformation after 24 h is also 
given in Figure 37.  
 
Table 15: Product formations and enantiomeric excess values in [%] obtained in whole cell biotransformations with 10 mM of 
isoquinoline substrates 5a, 5b and 5c performed with E. coli JW5510 expressing R-IRED-Sr, R-IRED-St or S-IRED-Pe. The values 
in Table 15 are the average of a triplicate and the error gives the standard deviation. -: not detected; n.a.: not available; n.d.: not 
determined. 
 
substrate IRED 
product formation [%] 
ee [%] 
1 h 8 h 24 h 
5a 
R-IRED-Sr 75.52 ± 4.18 > 99 > 99 n.a. 
R-IRED-St 83.75 ± 2.91 > 99 > 99 n.a. 
S-IRED-Pe 67.14 ± 0.91 > 99 > 99 n.a. 
5b 
R-IRED-Sr 51.59 ± 3.32 99.32 ± 6.35 91.51 ± 6.71 93.0 ± 0.2 (R) 
R-IRED-St 37.14 ± 0.93 98.06 ± 3.63 94.18 ± 4.14 50.7 ± 0.1 (R) 
S-IRED-Pe 9.25 ± 0.31 54.75 ± 2.45 79.42 ± 4.75 94.9 ± 0.1 (S) 
5c 
R-IRED-Sr - - - - 
R-IRED-St - - - - 
S-IRED-Pe - 9.62 ± 0.85 14.82 ± 0.75 n.d. (S) 
 
  
                                                                
IV: The separation of the enantiomers of product 6c was described with different chiral HPLC methods by Leipold et al.143 and 
Heath et al.120 using a Chiralcel OD-H column and by Quinto et al.,295 Dürrenberger et al.134 and Muñoz Robles et al.136 with a 
Chiralpak IC column. The columns Chiralpak IB (equivalent to Chiralcel OD-H)296 and Chiralpak IC were available and all of the 
described methods tested, however none of them resulted in a sufficient separation of the reaction products. In all cases one of 
the enantiomers co-eluted with the residual substrate and method optimization also did not lead to a satisfactory separation. With 
Chiralpak IB the (R)- enantiomer of the product eluted first but overlapped with the peak of substrate 5c. In these runs the formed 
product (S)-6c could be detected. With Chiralpak IC the (S)- enantiomer of the product eluted first but no separation of the residual 
imine substrate was possible. With this method nothing of (R)-6c could be detected and therefore it was concluded that the 
enzyme is (S)- selective. 
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3.4 Determination of IRED kinetic parameters to investigate the substrate 
preference 
 
To determine not only the conversions and the selectivities for whole cell biotransformations, but also 
get insights into the substrate preference of the three novel IREDs, kinetic constants were determined 
for the set of cyclic imine model substrates (substrates 1, 3a to 3c and 5a to 5b).  
Kinetic constants were determined by spectrophotometrically monitoring the decrease of the NADPH 
absorbance and calculation of the initial specific activities with different substrate concentrations. The 
kinetics of the three enzymes with substrate 3a were determined as described above for 1, using a 
wavelength of 340 nm. Due to their strong absorbance at 340 nm for substrates 3b, 3c, 5a and 5b a 
wavelength of 370 nm was used.  
In general the kinetic constants reflect the conversion rates from the biotransformation employing whole 
cells expressing the IREDs (see 3.3). For the substrates 1, 3a and 5a higher turnover numbers were 
measured compared to their substituted analogs 3b to 3c and 5b (Table 17 for R-IRED-Sr, Table 18 for 
R-IRED-St and Table 19 for S-IRED-Pe). In the biotransformations this is reflected by higher conversion 
rates. For isoquinoline substrates 5a and 5b higher affinities were measured for all IREDs, compared to 
the pyrroline and piperideine substrates. The determined KM values for 5a and 5b are in the low µM 
range, compared to affinities in the mid µM to the mM range for substrates 1 and 3a to 3c (Table 17, 
Table 18 and Table 19). By directly comparing substrates 1 and 3a it becomes obvious that all IREDs 
prefer six-membered rings as substrates, compared to pyrrolines. The Michaelis-Menten plots for these 
two substrates recorded with S-IRED-Pe are shown in Figure 22. The catalytic efficiency (kcat/KM) of this 
enzyme for substrate 3a is approximately four times higher than for 1 (Table 16), meaning that if both 
substrates would be present to the enzyme at the same time, it would discriminate them in favor of 3a. 
The same tendency was much more pronounced, for the R-IREDs that showed about 60- and 160-times 
higher catalytic efficiency (R-IRED-Sr and R-IRED-St, respectively) comparing these two substrates 
(Table 16). Indeed, the use of substrate 3a with R-IRED-Sr resulted in one of the highest observed 
kcat/KM value for all IRED substrates.107,147,148,150 As observed for substrates 1 and 3a (see for example 
in Figure 22), IREDs tend to be inhibited by some of the substrates at higher concentrations. The 
inhibition was however less pronounced for S-IRED-Pe and often inhibition constants were in the range 
of 100 mM.  
 
Table 16: Comparison of the catalytic efficiency (kcat/KM) of R-IRED-Sr, R-IRED-St and S-IRED-Pe with substrates 1 and 3a. All 
three enzymes prefer the piperideine substrate 3a.  
kcat/KM 
[s-1 mM-1]  
1 
 
3a 
R-IRED-Sr 0.89 ± 0.11 54.81 ± 4.28 
R-IRED-St 0.25 ± 0.02 35.65 ± 2.65 
S-IRED-Pe 20.40 x 10-3 ± 2.61 x 10-3 84.36 x 10-3± 4.91 x 10-3 
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Figure 22: Michaelis-Menten plots for S-IRED-Pe with substrates 1 and 3a. The six-membered piperideine substrate is reduced 
with an about four times higher catalytic efficiency. The enzyme was inhibited by both substrates at higher concentrations.  
 
Table 17: Summary of the kinetic constants recorded for R-IRED-Sr with the panel of cyclic imine model substrates 1, 3a - 3c and 
5a - 5b. All specific activities were determined in triplicates for varying concentrations of the substrate. To calculate kcat, KM and 
KI the data was then fitted by nonlinear regression to the Michaelis-Menten equation. 
imine 
KM 
[µM] 
kcat 
[s-1] 
kcat/KM 
[s-1 mM-1] 
KI 
[mM] 
Michaelis- 
Menten plot 
1 1.08 x 103 ± 0.13 x 103 0.96 ± 0.02 0.89 ± 0.11 28.40 ± 3.01 Figure S1 
3a 195.84 ± 15.09 10.74 ± 0.14 54.81 ± 4.28 10.78 ± 1.60 Figure S34 
3b 450.25 ± 10.27 43.13 x 10-3 ± 0.64 x 10-3 98.78 x 10-3 ± 2.60 x 10-3 16.27 ± 1.64 Figure S37 
3c 376.37 ± 38.42 44.41 x 10-3 ± 1.21 x 10-3 0.12 ± 0.01 - Figure S40 
5a 50.43 ± 5.80 0.42 ± 0.01 8.36 ± 0.98 5.95 ± 1.41 Figure S43 
5b 78.17 ± 16.21 0.22 ± 0.01 2.84 ± 0.61 23.89 ± 0.78 Figure S46 
 
Table 18: Summary of the kinetic constants recorded for R-IRED-St with the panel of cyclic imine model substrates 1, 3a - 3c and 
5a - 5b. All specific activities were determined in triplicates for varying concentrations of the substrate. To calculate kcat, KM and 
KI the data was then fitted by nonlinear regression to the Michaelis-Menten equation. 
imine 
KM 
[µM] 
kcat 
[s-1] 
kcat/KM 
[s-1 mM-1] 
KI 
[mM] 
Michaelis- 
Menten plot 
1 1.81 x 103 ± 0.07 x 103 0.45 ± 0.02 0.25 ± 0.02 21.07 ± 1.48 Figure S2 
3a 229.59 ± 16.24 8.18 ± 0.19 35.65 ± 2.65 31.22 ± 3.66 Figure S35 
3b 265.67 ± 15.01 119.41 x 10-3 ± 4.04 x 10-3 0.45 ± 0.03 6.55 ± 0.83 Figure S38 
3c 319.00 ± 14.46 0.20 ± 0.00 0.61 ± 0.03 10.68 ± 0.39 Figure S41 
5a 57.67 ± 9.88 0.33 ± 0.02 5.79 ± 1.08 3.62 ± 0.74 Figure S44 
5b 26.41 ± 3.38 101.03 x 10-3 ± 1.78 x 10-3 3.83 ± 0.49 14.52 ± 2.02 Figure S47 
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Table 19: Summary of the kinetic constants recorded for S-IRED-Pe with the panel of cyclic imine model substrates 1, 3a - 3c and 
5a - 5b. All specific activities were determined in triplicates for varying concentrations of the substrate. To calculate kcat, KM and 
KI the data was then fitted by nonlinear regression to the Michaelis-Menten equation. 
imine 
KM 
[µM] 
kcat 
[s-1] 
kcat/KM 
[s-1 mM-1] 
KI 
[mM] 
Michaelis- 
Menten plot 
1 1.29 x 103 ± 0.15 x 103 26.32 x 10-3 ± 1.53 x 10-3 20.40 x 10-3 ± 2.61 x 10-3 33.28 ± 8.02 Figure S3 
3a 1.95 x 103 ± 0.43 x 103 117.78 x 10-3 ± 3.27 x 10-3 84.36 x 10-3± 4.91 x 10-3 140.38 ± 20.54 Figure S36 
3b 1.42 x 103 ± 0.05 x 103  2.74 x 10-3 ± 0.09 x 10-3 1.93 x 10-3 ± 0.10 x 10-3 7.72 ± 0.23 Figure S39 
3c 2.82 x 103 ± 0.08 x 103 10.31 x 10-3 ± 0.05 x 10-3 3.66 x 10-3 ± 0.11 x 10-3 - Figure S42 
5a 126.21 ± 4.33 109.40 x 10-3 ± 2.23 x 10-3 0.87 ± 0.04 91.26 ± 9.74 Figure S45 
5b 137.79 ± 9.83 11.16 x 10-3 ± 0.37 x 10-3 81.03 x 10-3 ± 6.38 x 10-3 - Figure S48 
 
3.5 Biotransformations with purified IREDs 
3.5.1 Establishing biotransformations with purified IREDs and 2-methylpyrroline 1 
 
Next to their application as whole cell biocatalysts, the use of IREDs was also tested in purified form. 
Although the required purification of the enzymes and the need for a cofactor regeneration system, 
initially represents an increased effort, it could become of advantage for an overall process as the use 
of isolated enzymes might facilitate product recovery and downstream processing or might eliminate 
competing side reactions.38,45,46,62 Ketoreductases (KREDs) for examples are nowadays usually 
employed in purified form.45 
To establish a setup for biotransformations with isolated IREDs, the reduction of 1 was investigated. For 
regeneration of the NADPH cofactor glucose-6-phosphate and glucose-6-phosphate dehydrogenase 
were chosen. Using 250 µg/ml of the enzyme, with R-IRED-Sr and R-IRED-St the substrate could be 
fully converted within 1 h as shown in Table 20 and Figure 23. As already observed in whole cell 
biotransformations and confirmed by determining the kinetic constants, the use of S-IRED-Pe resulted 
in a slower conversion rate but after 24 h > 99% of substrate 1 were reduced to the amine by the enzyme 
(Table 20). As control for these biotransformations and all of the following that were performed with 
purified proteins, the respective IREDs were heat inactivated (95 °C for 10 min) and in none of these 
control reactions any product formation could be observed. 
 
Table 20: Conversion of 10 mM substrate 1 to product 2 in [%] with purified IREDs. The biotransformations were performed in 
triplicates and the errors give the standard deviation.  
 
substrate IRED 
product formation [%] 
0.5 h 1 h 8 h 24 h 
1 
R-IRED-Sr 97.45 ± 3.69 > 99 > 99 > 99 
R-IRED-St 68.53 ± 0.82 99.11 ± 0.65 > 99 > 99 
S-IRED-Pe 6.07 ± 0.00 14.49 ± 0.06 81.91 ± 1.64 > 99 
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Figure 23: Time course for the reduction of 10 mM imine 1 to amine 2 with purified R-IRED-Sr. All measured points are the average 
of a triplicate and the error bars show the standard deviation.  
 
3.5.2 The reduction of exocyclic imine substrates and the optimization of 
biotransformations with purified IREDs 
 
To explore the substrate scope and the reactions that can be catalyzed by IREDs, their activity was 
tested with some more challenging exocyclic imines, representing a new class of substrates for these 
enzymes. Due to the hydrolytic sensitive nature of the C=N double bond these substrates are generally 
expected to be less stable.218,219 The use of isolated enzymes might therefore be preferable compared 
to whole cell biocatalysts as in such a system no transport barrier across the cell membrane exists.  
In a first test the conversions of two exocyclic imine substrates were tested with the IREDs. The selected 
substrates were benzylidenemethylamine 7 and benzylideneaniline 9. By GC analysis low activity for all 
three IREDS with 7 could be detected and 9 was converted in low amounts with the (R)- selective IREDs. 
As an initial optimizing step, the enzyme amount used for the biotransformation was increased to 
2.5 mg/ml and the reaction examined at different pH values. Whereas at pH 7.0 and below mainly the 
hydrolysis products of the imines (benzaldehyde 11 and aniline 12) were detected, at pH 8.0 using the 
increased amount of enzymes for all three IREDs with substrate 7 conversions to the amine product 8 
well above the background could be obtained (14% with S-IRED-Pe and > 50% with R-IRED-St; 
Table 21, full dataset shown in Table S4). In addition for imine substrate 9 increased formation of the 
amine product could be detected. The best conversions were observed by the use of R-IRED-St (about 
67%), whereas it remained low for R-IRED-Sr (< 10% product formation, Table 22, full dataset shown 
in Table S5) and with S-IRED-Pe only traces of the product could be detected. Next to the amine 
products, in both biotransformations (7 and 9 as substrate) two byproducts could be detected in relatively 
high quantities (depending on the enzyme and substrate from 3% to > 50%). These two byproducts 
were identified as benzylalcohol 13 and benzylamine 14.  
The further optimization of the setup for the reduction of exocyclic imines aimed for a deeper 
understanding of the formation of the two reaction byproducts benzylalcohol 13 and benzylamine 14. 
The formation of imines by the condensation of carbonyls and amines, as well as their hydrolysis is a 
spontaneous process. In an aqueous buffer system however it is expected not to be on the side of the 
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imine. The reactions leading to these two byproducts are therefore assumed to be due to the rapid 
hydrolysis of the imine substrate in the aqueous buffer system.  
The reduction to the alcohol could theoretically be due to several issues. As neither the natural substrate 
nor the mechanisms of the IREDs is fully understood, yet, it should be taken into account that these 
enzymes might also be able to reduce carbonyl compounds nevertheless, in literature all attempts to 
catalyze the reduction of others than C=N double bonds failed.138,146,147 Another possibility for the 
reduction of the C=O double bond could be the contamination of the enzyme preparation with co-purified 
KREDs. In the initial purifications of the IREDs it was attempted to maximize the yields of the enzymes 
and therefore the enzymes used in the biotransformations described above had purities of less than 
85% as determined by SEC in HPLC (Table 23, Figure 24 and Figure S31).  
As described above the formation of imines is in an equilibrium with their hydrolysis. Although their 
formation in the aqueous system is assumed to be unfavored, small amounts of the imine are present. 
Thus, the second byproduct benzylamine was formed by a reductive amination reaction of 
benzaldehyde 11 with ammonia. This means, that IREDs represent very effective catalysts in 
withdrawing already small amounts of imines from this equilibrium. A possible source for the ammonia 
that led to the reductive amination reaction might be provided by the cofactor regeneration system. The 
employed glucose-6-phosphate dehydrogenase was supplied as ammonium sulfate precipitation and 
by its application considerable amounts of ammonia (final concentration ~ 30 mM) are transferred to the 
reaction system. 
 
Table 21: Formation of product 8 in [%] by reduction of 10 mM of the exocyclic imine substrate 7 with all three IREDs. Experiments 
were done in triplicates and errors give the standard deviation. Due to the instability of the imine bond in the aqueous buffer 
system, substrate 7 hydrolyzed to benzaldehyde 11 and methylamine. The formation of two new byproducts by the further 
conversion of 11 is also given in [%]. Reduction of 11 is assumed to be caused by contaminating KREDs in the purified enzyme 
preparation. The reductive amination of 11 is assumed to be catalyzed by the IREDs with the cofactor regeneration system 
(supplied as ammonium sulphate precipitation) as the nitrogen source. -: not detected. 
 
 product formation [%] 
time [h] 
R-IRED-Sr R-IRED-St S-IRED-Pe 
8 13 14 8 13 14 8 13 14 
1 
9.81 ± 
0.26 
4.44 ± 
0.16 
- 
8.26 ± 
0.29 
- - - - - 
3 
22.77 ± 
0.84 
12.73 ± 
0.86 
- 
15.26 ± 
0.09 
2.43 ± 
0.39 
- 
4.22 ± 
0.37 
- - 
24 
42.01 ± 
0.92 
46.22 ± 
1.95 
11.77 ± 
0.15 
56.67 ± 
0.36 
4.35 ± 
0.23 
- 
13.92 ± 
0.51 
3.83 ± 
0.55 
- 
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Table 22: Formation of product 10 in [%] by reduction of 10 mM of the exocyclic imine substrate 9 with the (R)- selective IREDs. 
Experiments were done in triplicates and errors give the standard deviation. Due to the instability of the imine bond in the aqueous 
buffer system, substrate 9 hydrolyzed to benzaldehyde 11 and aniline 12. The formation of two new byproducts by the further 
conversion of 11 is also given in [%]. Reduction of 11 is assumed to be caused by contaminating KREDs in the purified enzyme 
preparation. The reductive amination of 11 is assumed to be catalyzed by the IREDs with the cofactor regeneration system 
(supplied as ammonium sulphate precipitation) as the nitrogen source.  
 
 product formation [%] 
time [h] 
R-IRED-Sr R-IRED-St 
10 13 14 10 13 14 
1 
0.91 ± 
0.11 
9.07 ± 
0.60 
2.61 ± 
0.20 
11.89 ± 
0.42 
1.68 ± 
0.04 
1.96 ± 
0.07 
3 
3.58 ± 
0.64 
19.93 ± 
1.08 
3.21 ± 
0.19 
33.90 ± 
1.63 
2.73 ± 
0.10 
1.83 ± 
0.05 
24 
6.49 ± 
2.65 
64.14 ± 
2.77 
7.59 ± 
0.46 
67.00 ± 
13.99 
10.49 ± 
0.82 
4.30 ± 
0.39 
 
To proof the above mentioned considerations for byproduct formation and further optimize the setup to 
suppress their formation, biotransformations with imine 7 were repeated under modified conditions. First, 
to confirm that the cofactor regeneration system supplied the ammonia for the reductive amination 
reaction, this glucose-6-phosphate dehydrogenase preparation was substituted by a lyophilized 
formulation from a different vendor. The use of this salt free version should prevent the amination 
reaction (formation of benzylamine 14).  
To check for contaminating KREDs in the enzyme preparation, one of the applied IREDs (R-IRED-Sr, 
approx. 84% purity, Table 23, Figure 24 and Figure S31) was subjected to a further purification step by 
ion exchange chromatography with a MonoQ column. After the ion exchange chromatography an 
increase in purity could be observed by SDS-PAGE and in HPLC analysis (Table 23, Figure 24 and 
Figure S32). The purity of the peak fractions from the MonoQ purification was determined to be > 95% 
(Table 23). The fractions B12 and B11 of this enzyme preparation (Figure 24) were now combined and 
used for the biotransformation with modified conditions (lyophilized glucose-6-phosphate 
dehydrogenase) and 7 as substrate. Another control experiment to check for alcohol 13 formation, was 
performed by using the R-IRED-Sr mutant D191A in a biotransformation. As described in the first 
chapters (Table 11 in 3.1.2) this enzyme exhibits ~ 100-fold decreased activity (kcat/KM) for the reduction 
of the cyclic imine substrate 1. With about 89% purity after Ni2+ affinity chromatography (Table 23, 
Figure S29), the IRED mutant R-IRED-Sr D191A displayed slightly higher purity than the wt enzyme 
(approx. 84%, Table 23). 
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Figure 24: SDS-PAGE to compare the purity of R-IRED-Sr purified by Ni2+ affinity chromatography with the fractions of the 
R-IRED-Sr preparation of the further purification by ion exchange chromatography. To compare the purity and to visualize also 
minor contaminants, 20 µg total protein were loaded for all samples.  
 
Table 23: HPLC SEC analysis to determine the purity of Ni2+ affinity chromatography and MonoQ purified R-IRED-Sr. In addition 
the purity of the IRED mutant R-IRED-Sr D191A is given. This protein was purified only by Ni2+ affinity chromatography. As in this 
purification only the fractions containing the highest IRED content were taken and combined, the yields decreased but the protein 
reached a higher degree of purity than the wt enzyme that was purified by the same technique.  
IRED and purification step purity [%] HPLC run 
R-IRED-Sr wt Ni2+-NTA column 84.0% Figure S31 
R-IRED-Sr wt MonoQ fraction B12 > 95% Figure S32 
R-IRED-Sr wt MonoQ fraction B11 > 95% data not shown 
R-IRED-Sr wt MonoQ fraction B10 > 95% data not shown 
R-IRED-Sr wt MonoQ fraction B9+B8 94.9% data not shown 
R-IRED-Sr D191A Ni2+-NTA column 89.0% Figure S29 
 
By increasing the enzyme purity from about 84% to > 95% (Table 23) the fraction of the amine product 8 
raised from about 40% to ~ 80% in 24 h (Table 21, Table 24 and Figure 25). At the same time, the 
formation of alcohol 13 was reduced from > 45% to only ~ 6% (Table 21, Table 24 and Figure 25). In 
addition by the substitution of the glucose-6-phosphate dehydrogenase with its lyophilized version no 
formation of benzylamine 14 could be detected. This indicates that the ammonia for the reductive 
amination was indeed supplied by the cofactor regeneration system.  
In reactions catalyzed by the IRED mutant R-IRED-Sr D191A after 24 h, no amine product 8 was 
detected and although the purity was also higher than in case of the wt enzyme still about 3% 
benzylalcohol 13 were formed (Table 24). This underlines that IREDs definitively prefer the reduction of 
C=N double bonds and it seems likely that the majority of the carbonyl reduction of benzaldehyde 11 is 
caused by contaminations with co-purified KREDs. A weak promiscuous activity of IREDs towards 
carbonyls can at the moment however also not fully be excluded. As the purity of about 89% obtained 
with the mutant R-IRED-Sr D191A seemed to be sufficient to have tolerable levels of carbonyl reduction 
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activity, care was taken that this level of purity was obtained in all further purification by IMAC by 
combining only the peak fractions of the eluting IRED. 
 
 
Figure 25: Time course showing the substrate conversion and product formation in [%] for the reduction of 10 mM imine 
substrate 7 to the amine product 8 with MonoQ purified R-IRED-Sr (fractions B12+B11 were combined, > 95% purity, see 
Table 23). The biotransformation was done in triplicates and the error bars give the standard deviation. By increasing the purity 
of the IRED, the formation of the alcohol byproduct was reduced. The use of lyophilized glucose-6-phosphate dehydrogenase for 
cofactor regeneration suppressed the reductive amination reaction that resulted in the formation of benzylamine 14 in the 
biotransformations above, as no ammonia is present in this enzyme preparation.  
 
Table 24: Formation of product 8 in [%] by reduction of 10 mM of the exocyclic imine substrate 7 with MonoQ purified R-IRED-Sr 
(fractions B12+B11 were combined, > 95% purity, see Table 23) and the IRED mutant R-IRED-Sr D191A (~ 89% purity, see 
Table 23). The biotransformations were done in triplicates and the errors give the standard deviation. The increase in IRED purity 
decreased the formation of the alcohol 13 byproduct. As intended, the formation of the amination product 14 was prevented by 
the use of lyophilized glucose-6-phosphate dehydrogenase, thus confirming the ammonium sulphate precipitated version of it as 
the ammonia source for the reductive amination reaction. In biotransformations with the mutant R-IRED-Sr D191A no amine 
product was formed, but the alcohol byproduct. -: not detected.  
 
 product formation [%] 
time [h] 
R-IRED-Sr MonoQ purification (> 95% purity) R-IRED-Sr D191A 
7 8 11 13 14 7 8 11 13 14 
0 
59.43 ± 
0.92 
- 
40.57 ± 
1.20 
- - 
59.01 ± 
2.31 
- 
40.99 ± 
2.81 
- - 
1 
47.11 ± 
2.02 
19.62 ± 
0.51 
33.27 ± 
0.65 
- - 
60.94 ± 
1.75 
- 
39.06 ± 
1.79 
- - 
3 
36.16 ± 
1.62 
34.62 ± 
0.38 
27.76 ± 
0.16 
1.46 ± 
0.22 
- 
60.96 ± 
2.04 
- 
39.04 ± 
1.86 
- - 
5 
28.61 ± 
1.99 
44.98 ± 
1.38 
24.79 ± 
0.88 
1.63 ± 
0.09 
- 
60.81 ± 
2.75 
- 
39.19 ± 
1.86 
- - 
8 
23.84 ± 
1.65 
54.81 ± 
1.87 
19.12 ± 
0.74 
2.23 ± 
0.31 
- 
62.91 ± 
3.33 
- 
37.09 ± 
1.54 
- - 
24 
8.71 ± 
0.27 
75.88 ± 
1.37 
9.58 ± 
1.64 
5.83 ± 
0.51 
- 
53.18 ± 
2.58 
- 
44.29 ± 
1.24 
2.53 ± 
0.44 
- 
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3.5.3 Biotransformations of further exocyclic imine substrates 
 
With this optimized reaction setup two more exocyclic imine substrates were investigated for their 
reduction by IREDs. Benzophenoneimine 15 with an electron rich di-arylic structure and 
phenylethylideneaniline 18 were tested as additional substrates. The latter one is structurally closely 
related to 9, but due to the additional methyl group allows determining the selectivity for the reduction 
of exocyclic imine substrates, as during the reduction a stereocenter is formed.  
In the negative control for the biotransformation with imine 15, performed with heat inactivated enzyme, 
the hydrolysis of the substrate could be followed for about 5-8 h and after this time only the hydrolyzed 
byproduct (ketone 17) could be detected (Figure S17). This indicates a slightly higher hydrolytic stability 
in direct comparison with imine 7, which instantly after the reaction setup hydrolyzed and resulted in a 
detectable ratio of approximately 40/60 benzaldehyde 11 and benzylidenemethylamine 7 by GC 
analysis (t = 0 h in Figure 25 in 3.5.2). With the active enzyme (R-IRED-Sr) the reduction of imine 15 to 
the amine product benzhydrylamine 16 could be detected and after about 3 h close to 50% of it was 
formed (Table 25). At this time in the biotransformations also most of the residual imine substrate was 
hydrolyzed, thus further product formation was also limited (Figure S16). The other two IREDs, 
R-IRED-St and S-IRED-Pe, showed in preliminary tests only very low conversion of 15 and were 
therefore not further investigated. The HPLC peak areas in these initial investigation were only ~ 1.3% 
and about 10% for R-IRED-St and S-IRED-Pe compared to the area of R-IRED-Sr. 
 
Table 25: Formation of benzhydrylamine 16 and the hydrolytic byproduct benzophenone 17 in [%] in a biotransformation with 
purified R-IRED-Sr and 10 mM of imine 15 as substrate. For the negative control, the IRED was heat inactivated by treatment at 
95 °C for 10 min. Both reactions were done in triplicates and the errors give the standard deviation. Further reduction of 17 to the 
alcohol was not observed in all cases. The full dataset with all measured points is given in Table S6 and Figure S16. -: not 
detected.  
 
 product formation [%] 
time [h] 
R-IRED-Sr negative control 
16 17 16 17 
1 34.22 ± 0.98 30.91 ± 0.42 - 45.32 ± 0.19 
3 47.56 ± 0.37 40.75 ± 1.78 - 76.90 ± 2.35 
24 52.55 ± 2.94 45.84 ± 1.55 - 88.48 ± 2.64 
 
To determine the stereoselectivity of the R-IREDs for the reduction of exocyclic substrates, imine 18 
was selected. As S-IRED-Pe showed only low activity with 9 (see 3.5.2), it was not tested with imine 18. 
Analogously to imine 9 R-IRED-St was more active with substrate 18 and the amine product 19 was 
obtained with about 80% conversion in 24 h. In contrast, R-IRED-Sr only produced about 10% of 19 
(Table 26). By chiral HPLC the selectivity was determined and both enzymes found to be (R)- selective, 
producing 19 with a very high ee of 88% and 94%, respectively (Table 26 and Figure S19). Again, as 
also seen in the case of imine 15, the hydrolysis of this electron rich substrate took slightly longer than 
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for substrates like 7. In the negative controls with the heat inactivated enzymes it took about 5-8 h until 
a potential equilibrium of the ketone/amine (acetophenone 20 and aniline 12) and imine 
(phenylethylideneaniline 18) was reached.  
 
Table 26: Product formations and stereoselectivities in [%] for the reduction of 10 mM 18 by (R)- selective IREDs. Both 
biotransformations were performed in triplicates and the errors give the standard deviation. For a better overview in Table 26 only 
the desired product 19 is shown. Quantification of the hydrolytic products 12 and 20 is shown in the full dataset in Table S7. 
Reduction of the ketone 20 to 1-phenylethanol 25 was not observed or is below the detection limit. -: not detected; n.d.: not 
determined. 
 
 product formation [%] 
time [h] 
R-IRED-Sr R-IRED-St 
19 ee [%] 19 ee [%] 
1 - n.d. 21.32 ± 1.08 n.d. 
3 1.48 ± 0.23 n.d. 47.71 ± 2.57 n.d. 
24 10.18 ± 5.65 94.2 ± 0.5 (R) 83.85 ± 20.47 87.8 ± 0.3 (R) 
 
3.6 The reductive amination of aldehydes and ketones with IREDs 
 
The hydrolytically sensitive nature of the imine bond for long term has hindered the discovery of broadly 
applicable imine reducing enzymes and the existence of imines in nature was believed to be restricted 
to transient intermediates in specialized metabolic pathways or during enzyme 
catalysis.39,53,58,113-117,176-178 The full exploitation of this reversible imine formation for the subsequent 
reduction by an IRED to result in novel C-N bonds therefore represents a synthetically highly desirable 
goal. First indications for such a reductive amination were already observed as a formed byproduct with 
ammonia 21 and benzaldehyde 11 during the reduction of exocyclic imines (Table 21 and Table 22). In 
these experiments already very low levels of the imine intermediate (they were below the detection limit) 
led to considerable amounts of the reductive amination product (approximately 5-10%, see Table 21 
and Table 22). As this bimolecular reaction represent a very attractive extension for potential 
applications of IREDs, an efficient process for this reductive amination was to be developed. The 
parameters affecting the individual steps of the reaction were taken into account and their influence 
investigated. As R-IRED-Sr showed for most substrates the highest activities (Table 14, Table 15, 
Table 17 and Table 21) and proved in initial tests superior to the other two IREDs, this enzyme was 
selected for the optimization process. During the purification process care was taken to reach a level of 
about 90% purity (determined by SEC analysis in HPLC, see also Figure 10) to avoid too high byproduct 
formations (as discussed in 3.5.2).  
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3.6.1 The reductive amination of aldehydes 
 
First the reductive amination of aldehydes was investigated. Benzaldehyde 11 served as the model 
carbonyl acceptor and three different amine nucleophiles were used (ammonia 21, methylamine 22 and 
aniline 12). These three amine nucleophiles differ in their nucleophilicity with 21 being the weakest 
one.223 In an attempt to shift the equilibrium from the carbonyl/amine to the condensation (imine) side 
also the use of different excess amounts of the amine donors were investigated. Amines were used in 
equimolar concentrations, as well as in 10-fold and 50-fold molar excess amounts (except for 12, which 
was not used at this concentration due to solubility limitations). To be able to compare the conversion 
rates and judge byproduct formation, all reactions were done with the same batch of purified protein and 
each IRED aliquot was used only once. As negative controls, reactions were performed under identical 
conditions with heat inactivated R-IRED-Sr (95 °C for 10 min) and with BSA substituting the IRED. In 
none of these control reactions however any product formation was observed.  
In general in these biotransformations, the conversion rates increased along with the excess amount of 
the amine nucleophile and also led to higher overall product formations. By using 21 as nucleophile the 
concentration of the product (benzylamine 14) after 24 h raised from 7% to 51% and final 61% with the 
increasing amount of the nucleophile (equimolar, 10-fold and 50-fold, Table 27). With the more potent 
nucleophile 22 also the conversion rates increased and after 1 h at equimolar concentration 6% of the 
amination product 8 were formed, whereas at the higher excess amounts (10-fold and 50-fold) 33% and 
58% of 8, respectively, were formed in 1 h (Table 27). Amine 12 was also an effective nucleophile and 
a final conversion to the amination product 10 of 25% after 24 h was obtained (Table 27). In contrast, 
the use of higher excess amounts of 12 (10-fold molar excess) was not advisable and the final 
conversions in 24 h dropped to less than 5%. It might be possible that the use of this nucleophile at the 
high concentrations caused inhibitory effects on the applied IRED.  
Next to the amination product the reduction of the carbonyl compound to benzylalcohol 13 was 
observed. With about 7% alcohol formation this side reaction was most pronounced for the reaction 
conditions with the lowest amounts of amine nucleophile and decreased at higher excess amounts or 
when stronger nucleophiles like 22 were used (Table S10, Table S11 and Table S12). Another potential 
byproduct arises when performing reductive aminations with ammonia as nucleophile. The product that 
is generated in this case, benzylamine 14, is also a potent nucleophile. Indeed the low levels of this 
product that are initially formed are deceptive as 14 instantly reacted with 11, forming a new imine 
intermediate 23. During the proceeding reaction, this intermediate vanished again completely 
(Figure S49 and Table S10) as 11 was completely converted to 14 and in addition small amounts of the 
dialkylation product dibenzylamine 24 were found. A full reaction scheme for the formation of the 
dialkylation product is shown in Scheme S1 and the full dataset can be found in Table S10. Such a 
highly selective monoamination with only tiny amounts of dialkylation product formed represents a 
significant advancement over chemical reductive amination methodologies.224 In these procedures, 
often two-step processes are required to avoid the formation of extensive amounts of dialkylation 
products.224 In addition, at the moment this dialkylation represents an undesired side product, but on the 
other hand it also highlights the versatility of enzymatic reductive aminations that could be further 
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developed into reaction cascades to assemble more complex molecules by the repeated (selective) 
reductive amination of simple precursors.  
 
Table 27: Conversion of 10 mM benzaldehyde 11 into the amination products 14, 8 and 10 by purified R-IRED-Sr using three 
different amine nucleophiles (21, 22 and 12) at varying molar excess amounts. As negative controls reactions with heat inactivated 
R-IRED-Sr and reactions with BSA substituting the IRED were performed. In none of these control reactions any product formation 
was observed. All biotransformations were performed in triplicates and the errors give the standard deviation. The full dataset with 
all measured points is shown in detail in Table S10, Table S11 and Table S12. -: not detected. 
 
carbonyl 
acceptor 
amine 
nucleophile 
equivalents 
of nucleophile 
product formation [%] 
1 h 8 h 24 h 
11 21 1[a] 
< 1 (14)| 
- (24)[a] 
1.25 ± 0.13 (14)| 
< 1 (24)[a] 
6.60 ± 0.25 (14)| 
2.18 ± 0.06 (24)[a] 
11 21 10[a] 
< 1 (14)| 
- (24)[a] 
21.43 ± 0.28 (14)| 
< 1 (24)[a] 
51.22 ± 2.13 (14)| 
3.15 ± 0.03 (24)[a] 
11 21 50[a] 
< 1 (14)| 
- (24)[a] 
48.03 ± 0.76 (14)| 
< 1 (24)[a] 
60.66 ± 1.12 (14)| 
< 1 (24)[a] 
11 22 1 5.54 ± 0.22 34.64 ± 1.29 51.18 ± 2.75 
11 22 10 32.82 ± 0.56 71.56 ± 3.31 66.19 ± 0.48 
11 22 50 57.95 ± 3.28 73.33 ± 3.80 68.98 ± 4.08 
11 12 1 4.06 ± 0.16 13.44 ± 1.30 24.97 ± 5.28 
[a]: given are the equivalents of nucleophile 21. As detailed above, product 14 that was formed during the reaction acted as 
an additional nucleophile. Higher amounts of product 14 were obtained as given in the table, but they are trapped in the new 
imine intermediate 23 formed by the reaction of 11 with 14. Reduction of this second imine by the IRED led to the dialkylation 
product 24. The amounts of 24 formed are given as the second values in Table 27. 
 
3.6.2 The reductive amination of ketones to generate chiral amines 
 
The reductive amination methodology was then extended and the use of ketones as carbonyl substrates 
investigated as thereby directly chiral amines can be generated. However, compared to an aldehyde, 
ketones are far less reactive and especially aromatic unsaturated ketones like acetophenone 20 were 
described to be challenging substrates.224 
By employing the reductive amination conditions developed for aldehydes with ketone 20 as carbonyl 
compound, only in the case of the 50-fold molar excess amount of the amine nucleophiles considerable 
levels of the amination products could be detected. Using nucleophile 21 after 24 h ~ 5% of 
α-methylbenzylamine 26 was found to be formed, whereas the use of 22 resulted in about 9% of 
N-α-dimethylbenzylamine 27 (top row in Table 28). To further optimize the conversion rates, the 
equilibrium was again shifted towards to condensation product by changing the pH of the reaction. At 
higher pH values, the fraction of the reactive amine species capable of the nucleophilic attack on the Cα 
carbon can be enhanced. Indeed, increasing the pH of the reaction from 8.0 to 8.5 and 9.0 boosted the 
conversion rates. With 21 and 22 as nucleophiles the conversions after 24 h could be doubled to 10% 
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and 19%, respectively (Table 28). Due to the lower conversions observed in the combination of 11 
and 12, this nucleophile was not tested here.  
As R-IRED-Sr displays decreased activities at increased pH values (Figure 13) the reactions were also 
performed with higher enzyme loadings. Using a fourfold increased amount of the enzyme (10 mg/ml), 
the overall conversions could again be raised to finally 16% with nucleophile 21 and about 40% for 
nucleophile 22. Remarkably, the transformations of the enzyme to form the novel C-N bonds proceeded 
for both nucleophiles with very high to excellent selectivities. The products 26 and 27 were obtained 
with an ee > 97% for 26 and > 86% in the case of 27 as determined by chiral GC analysis (Table 28, 
Figure S55 and Figure S57). 
 
Table 28: Conversion of 10 mM acetophenone 20 into the amination products 26 and 27 by purified R-IRED-Sr using the two 
amine nucleophiles 21 and 22 at different pH values after 24 h. Nucleophiles 21 and 22 were in all reactions used at 50-fold molar 
excess. As negative controls reactions with heat inactivated R-IRED-Sr and reactions with BSA substituting the IRED were 
performed. In none of these control reactions any product formation was observed. Reduction of ketone 20 to the alcohol 25 was 
in all cases detected only in traces (< 1%). All biotransformations were performed in triplicates and the errors give the standard 
deviation. The full dataset with all measured points is shown in detail in Table S13 and Table S14. 
 
amine 
nucleophile 
pH 
product 
formation after 
24 h [%] 
ee [%] 
amine 
nucleophile 
pH 
product 
formation after 
24 h [%] 
ee [%] 
21 8.0 5.45 ± 0.03 96.6 ± 0.2 (R) 22 8.0 8.57 ± 0.08 86.7 ± 0.4 (R) 
21 8.5 7.09 ± 0.07 97.6 ± 0.4 (R) 22 8.5 15.19 ± 0.22 86.3 ± 0.3 (R) 
21 9.0 10.12 ± 0.06 97.7 ± 0.2 (R) 22 9.0 18.95 ± 1.02 86.3 ± 0.1 (R) 
21 9.0 15.82 ± 0.66[a] 97.1 ± 0.1 (R) 22 9.0 39.18 ± 1.38[a] 86.6 ± 0.0 (R) 
[a]: these reactions were performed with the enzyme concentration 4-fold increased to 10 mg/ml. 
 
3.6.3 Kinetic characterization of the reductive amination reaction 
 
To obtain further information about the reductive amination reaction, kinetic measurements were 
performed for the reaction of R-IRED-Sr with 11 and 22 at pH 8.0 and pH 9.0 (the reaction is shown in 
the heading of Table 27). Assuming steady state conditions, the initial reaction rates with a pre-
equilibrated substrate solution (11 with different molar excess amounts of 22 in buffer at the respective 
pH) were determined. The data was then fitted to the Michaelis-Menten equation, implying that imine 7 
is the single substrate for R-IRED-Sr. Both parameters, the increasing pH value of the reaction or the 
increase of the amine nucleophile excess amount, had an effect on the determined apparent KM (KM app) 
value. Conditions that are assumed to favor imine formation (higher pH, higher nucleophile excess 
amount, see Table 27 and Table 28) directly go along with a decrease in KM app. The apparent affinity 
dropped from > 20 mM at pH 8.0 using equimolar concentrations of 22 to less than 2 mM (50-fold excess 
of 22 at pH 9.0, Figure 26, Table 29 and Figure S59). It is concluded, that in these measurements the 
increased imine availability directly reflects the relative amount of substrate the enzyme is exposed to. 
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These results therefore also confirm the above mentioned intention, to shift the equilibrium towards the 
imine for the optimization of the biotransformations (3.6.1 and 3.6.2). The concentration of the imine is 
initially assumed to be in a steady-steady equilibrium and as it re-forms after withdrawal by the IRED it 
is expected to stay constant. In such a situation the higher imine availability directly leads to a higher 
saturation of the enzyme with its substrate and hereby enhances the reaction rates. The maximal 
turnover numbers were detected at the 50-fold excess amount of 22 at a pH of 8.0 and are around 
0.5 min-1. Although imine availability at pH 8.0 is suspected to be lower than at pH 9.0 (Table 29 and 
above), it seems possible that the reactions rates might be higher as the enzyme loses activity at the 
higher pH (Figure 13). The strong increase in the determined turnover numbers at the 50-fold excess 
amount of 22, both at pH 8.0 and 9.0 (Table 29), might also indicate that under the conditions with the 
lower excess amounts of 22, the imine formation could become the rate limiting step of the reaction. 
Thus, the determined turnover numbers should in this cases be designated as apparent kcat (kcat app). 
 
Table 29: Steady state kinetic parameters for R-IRED-Sr catalyzed reductive amination of 11 with different molar excess amounts 
of 22 at pH 8.0 and 9.0. All specific activities were determined in triplicates for varying concentrations of the substrate. To calculate 
kcat, KM and KI the data was then fitted by nonlinear regression to the Michaelis-Menten equation. 
pH 
equivalents 
of 22 
KM app 
[mM] 
kcat 
[s-1] 
kcat/KM app 
[s-1 mM-1] 
Michaelis-Menten plot 
8.0 1 
20.47 ± 
5.67 
4.45 x 10-3 ± 
0.66 x 10-3 
0.22 x 10-3 ± 
0.07 x 10-3 
Figure S60 
8.0 10 
4.15 ± 
0.29 
5.68 x 10-3 ± 
0.26 x 10-3 
1.37 x 10-3 ± 
0.12 x 10-3 
Figure S61 
8.0 50 
2.14 ± 
0.07 
11.15 x 10-3 ± 
0.34 x 10-3 
5.22 x 10-3 ± 
0.24 x 10-3 
Figure S62 
9.0 1 
10.54 ± 
2.34 
4.31 x 10-3 ± 
0.38 x 10-3 
0.41 x 10-3 ± 
0.10 x 10-3 
Figure S63 
9.0 10 
3.91 ± 
0.43 
5.21 x 10-3 ± 
0.20 x 10-3 
1.33 x 10-3 ± 
0.16 x 10-3 
Figure S64 
9.0 50 
1.94 ± 
0.23 
9.21 x 10-3 ± 
0.56 x 10-3 
4.75 x 10-3 ± 
0.63 x 10-3 
Figure S65 
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Figure 26: Top: Reaction scheme for the steps of the reductive amination reaction of 11 and 22 with R-IRED-Sr (enzyme E). As 
an initial step (k0) the substrate (S) imine 7 has to form by condensation of benzaldehyde 11 and methylamine 22. The equilibrium 
of this reaction then affects the formation (k1) of the enzyme substrate complex ([ES]). The Michaelis-Menten complex is resolved 
by the reduction (k2) to the product (P) 8.  
Bottom: Overlay of the Michaelis-Menten plots for the reductive amination of 11 with different excess amounts of nucleophile 22 
at pH 9.0 with R-IRED-Sr. Conditions that shift the equilibrium towards imine 7 go along with a decreased KM app value, directly 
reflecting the relative amount of substrate the enzyme is exposed to. 
 
3.7 Production of N-heterocycles by enzymatic cascade reactions with IREDs – 
the enzymatic generation of cyclic imines with PuO-Re 
 
Amine oxidases in combination with IREDs could be used in an enzymatic cascade reaction to establish 
the de novo synthesis of N-heterocycles. The irreversible oxidation of a polyamine to an aminoaldehyde 
triggers its spontaneous cyclization to a cyclic imine, thereby generating the substrate for the second 
enzyme (IRED) (Scheme 11 in 1.2.3). However in contrast to the widespread use of MAO-N and variants 
of it,2,115,225,226 polyamine oxidases are not thoroughly investigated for biocatalytic purposes. One of the 
best characterized enzymes in literature is PuO-Re.161,170–173 
In contrast to the initial characterization of the enzyme, with a range of natural polyamines, amino acids 
and amino alcohols tested as substrates,161 nothing is known about the activity with non-natural 
polyamines. The use of such modified polyamines as precursors would directly result in a set of diverse 
heterocyclic compounds in the reaction cascade. To investigate such polyamines as substrates, a panel 
composed of linear- and branched polyamines, including symmetric and asymmetric polyamines with 
oxygen- and nitrogen heteroatoms was investigated. To check for activity with purified PuO-Re the 
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formation of the enzymatic byproduct H2O2 was followed in a spectrophotometric assay with horseradish 
peroxidase (HRP) and a suitable dye system. The substrates were used in excess to ensure the 
saturation of the enzyme and the specific activities, as well as the relative activities compared to the 
natural substrate diaminobutane 28 are given in Table 30. By GC-MS headspace it was also confirmed 
that the aminoaldehydes generated by the oxidation of polyamines 28 and 29 indeed spontaneously 
cyclize to the cyclic imine (Figure S66).  
As it was expected, by far the highest activity was observed with the natural substrate diaminobutane 28. 
Although the enzyme was able to oxidize a wide variety of the selected substrates, a general trend was 
obvious. By increasing the chain length, by using branched polyamines or polyamines with heteroatoms 
in the middle of the chain, a dramatic loss in activity was observed. The same behavior was also already 
described for PuO-Re with natural polyamines besides 28, for example diaminopentane 29 and 
spermidine 34.161 
 
Table 30: Specific activities in [U/mg] and the relative activities in [%] compared to the natural substrate 28 for PuO-Re with a 
range of polyamine substrates. All activities were determined in triplicates by monitoring the formation of the enzymatic byproduct 
H2O2 spectrophotometrically with a suitable dye system and HRP. 
structure of polyamine substrate  # specific activity [U/mg] relative activity [%] 
 
28 12.28 ± 0.33 100.00 
 
29 0.45 ± 0.04 3.69 
 
30 87.36 x 10-3 ± 2.64 x 10-3 0.71 
 
31 0.33 ± 0.04 2.66 
 
32 65.62 x 10-3 ± 3.94 x 10-3 0.53 
 
33 3.75 x 10-3 ± 0.99 x 10-3 0.03 
 
34 2.63 ± 0.07 21.40 
 
35 8.13 x 10-3 ± 0.28 x 10-3 0.07 
 
36 22.59 x 10-3 ± 1.18 x 10-3 0.18 
 
37 9.18 x 10-3 ± 0.21 x 10-3 0.07 
 
38 5.36 x 10-3 ± 5.22 x 10-3 0.04 
 
To investigate the molecular basis for the observed strong loss in activity in more detail, kinetic 
parameters for selected polyamine substrates (28, 29, 31, 34 and 36) were determined. By comparing 
the catalytic efficiency (kcat/KM) of the enzyme with different substrates, it is possible to evaluate the 
performance of the enzyme with different substrates.227,228 The affinities determined for this set of 
polyamine substrates were, with the exception of substrate 34, all in the same order of magnitude. The 
highest affinity was found for the natural substrate 28 with the KM value to be around 15 µM. However, 
although the measured affinities for the other tested substrates increased, it was still feasible to saturate 
the enzyme with them and all measured KM values were in the µM range (Table 31). In contrast, the 
3 RESULTS 
88 
turnover numbers for the non-natural substrates were reduced at least 10-fold and found to be 
about 1000-fold lower with triamine 36 (Table 31). The reasons for the strongly decreased activities 
might be due to limitations in the substrate access to the active site, which is deeply buried in the 
enzyme.171 Also the binding in an unproductive way to the enzyme, not assisting in the formation of a 
proper enzyme-substrate (ES) complex might contribute to the low turnover numbers.229,230 
 
Table 31: Summary of the kinetic constants recorded for PuO-Re with the set of polyamine substrates 28, 29, 31, 34 and 36. All 
specific activities were determined in triplicates for varying concentrations of the substrate. To calculate kcat and KM the data was 
then fitted by nonlinear regression to the Michaelis-Menten equation. 
substrate KM [µM] kcat [s
-1] kcat/KM [s
-1 mM-1] kcat/KM [%] Michaelis-Menten plot 
28 15.54 ± 0.64 16.91 ± 0.19 1088.42 ± 46.52 100.00 Figure S69 
29 22.79 ± 4.37 1.59 ± 0.08 69.58 ± 13.82 6.39 Figure S70 
31 31.45 ± 2.33 1.28 ± 0.02 40.74 ± 3.12 3.74 Figure S71 
34 131.39 ± 15.96 1.33 ± 0.07 10.13 ± 1.35 0.93 Figure S72 
36 42.29 ± 1.76 14.00 x 10-3 ± 0.12 x 10-3 0.33 ± 0.01 0.03 Figure S73 
 
3.8 Directed evolution of PuO-Re to expand the substrate scope 
3.8.1 Random mutagenesis by epPCR 
 
To alter the efficiency of the enzyme for the oxidation of longer and branched polyamine substrates, 
mutants were generated. In a first attempt to shift the substrate spectrum of the enzyme, its “anionic 
point” was modulated.166,171 A glutamic acid in the active site is responsible for the correct positioning of 
the positively charged amine substrate in relation to the flavin cofactor that is in charge of the oxidation 
(Figure 28).171 By mutation of Glu to Asp, ideally more space should be created and the enhanced 
substrate binding pocket might accommodate substrates that have longer chain lengths like 
diaminopentane 29. This mutant was generated by site directed mutagenesis and purified. Although a 
shift in the substrate spectrum towards longer polyamines was observed, overall the specific activity of 
the mutant with all tested substrates was extremely low. It decreased to about 0.3% of the wt activity for 
1,4-diaminobutane 28 and to about 2.7% of the wt activity for 1,5-diaminopentane 29 (Table S15). These 
findings were later also published by Kopacz et al. and the effect of the mutation on kcat and KM analyzed 
in more detail.172 
As this rational approach for the optimization of PuO-Re proved to be unsuccessful, for further 
mutagenesis a random mutagenesis strategy based on an error prone PCR (epPCR) for diversity 
generation was chosen. The required HTS system was based on a solid phase assay adapted from 
Turner and coworkers.110,231 For this assay, the cells were grown on a nylon membrane and after the 
partial lysis by a freeze thaw cycle, HRP, a suitable dye and the substrates of interest were added. Cells 
that expressed active enzyme variants produced H2O2 and by the action of HRP the dye 
diaminobenzidine polymerized to a dark brown precipitate (Figure 27). Using this method libraries from 
directed evolution and metagenome experiments were already screened and led to the identification of 
improved biocatalysts or novel enzymes, including PuO-Re itself.110,111,161,231,232 
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Figure 27: Solid phase assay to screen for oxidase activity. The cells are growing on a nylon membrane and after addition of the 
substrate of interest and HRP, active cells produce H2O2. The dye diaminobenzidine then polymerizes into a complex brown 
precipitate, allowing the visual inspection for activity based on differences in color formation.  
 
From an epPCR library about 60000 – 70000 colonies were screened with this solid phase assay 
towards polyamine substrates 31, 33, 36 and 38. To increase the throughput the substrates screened 
were clustered according to their activity level and used simultaneously. Colonies that developed a 
brown color were picked, transferred to a new membrane und subjected to a second screening round 
to eliminate false positives and refine the screening procedure. Positive mutants after the second 
screening round were grown in 96 deep well plates for the generation of cell lysate. With the lysates 
activity assays were performed for the specific substrates and the best mutants thereof were sequenced, 
purified and characterized in more detail.  
In the sequencing results of several of these mutants one residue was identified that was of special 
interest. Variants that displayed amino acid exchanges at this position also showed the most 
pronounced effects for oxidizing non-natural substrates. The identified amino acid was a glutamic acid 
at position 203 of the enzyme which is in the wt enzyme located in the second shell around the active 
site and its side chain points into one of the 7V channels that end in the deeply buried cave with the 
flavin cofactor responsible for the oxidation (Figure 28).171 This position was independently identified in 
two variants: once it was substituted by a glycine (E203G) and in the second mutant it was replaced by 
valine (E203V). The second mutant possessed also an additional I154V substitution.  
 
 
Figure 28: Active site of PuO-Re with the flavin cofactor in yellow sticks and the substrate 1,4-diaminobutane in blue sticks (pdb 
code: 2YG4).171 The anionic point (E324) responsible for the correct positioning of the substrate in the active site166,171 is shown 
in orange sticks. Position E203 aligning the channel that leads into the active site is highlighted as a red mesh. The identification 
of the channel (blue dots) was done with the CAVER plugin of HotSpot Wizard.233 
                                                                
V: The 7 channels leading into the active site of the enzyme were identified with the CAVER plugin of HotSpot Wizard.233 Except 
for one channel that aligns to the non-covalently bound flavin cofactor170 for none of them a function could be deduced.  
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It is likely that by mutations in this channel, substrates can more easily enter the active site for oxidation. 
Consequently, during the characterization these two mutants (E203G and I154V E203V) displayed 
much higher activities for most of the substrates (Table 32, Figure 29 and Figure 33). However, not only 
the turnover numbers were affected. For longer polyamines like spermidine 34 also the affinity 
determined for the mutant PuO-Re E203G increased (Figure 29). Overall this mutant displayed for 
polyamine substrate 34 an over 10-fold higher kcat/KM value compared to the wt enzyme (Table 31 and 
Table 32). The full characterization of the E203G mutant and the I154V E203V double mutant showed 
that in both mutants the substrate spectrum of the enzyme was shifted (Table 32 and Figure 30). 
Diaminobutane 28 is still the substrate that is transformed with the highest catalytic efficiency, however 
with the mutants the discrimination of polyamine 28 towards longer polyamines is changed and the 
longer substrates are transformed more efficiently. The relative kcat/KM for polyamine 29 increased about 
twofold from 6% to 12% in the I154V E203V double mutant. In case of the E203G mutant the relative 
kcat/KM for polyamine 34 compared to the natural substrate is shifted from around 1% for the wt enzyme 
to about 25% in case of the mutant (Table 31, Table 32 and Figure 30). 
 
 
Figure 29: Comparison of the Michaelis-Menten plots for PuO-Re wt (green) and PuO-Re E203G (blue) with polyamine 34. The 
mutant shows higher affinity and higher activity with this substrate, resulting in an over 10-fold increased catalytic 
efficiency (kcat/KM).  
 
Table 32: Summary of the kinetic constants recorded for PuO-Re mutants E203G and I154V E203V double mutant with the set 
of polyamine substrates 28, 29, 31, 34 and 36. By comparing the relative catalytic efficiencies (28 was always set as 100%) of the 
mutants to the wt, the shift in the substrate spectrum towards the longer polyamines becomes obvious. All specific activities were 
determined in triplicates for varying concentrations of the substrate. To calculate kcat and KM the data was then fitted by nonlinear 
regression to the Michaelis-Menten equation. 
Mutant substrate 
KM 
[µM] 
kcat 
[s-1] 
kcat/KM 
[s-1 mM-1] 
kcat/KM 
[%] 
Michaelis-Menten plot 
E203G 
28 90.49 ± 6.01 45.10 ± 0.63 498.44 ± 33.86 100.00 Figure S74 
29 199.35 ± 3.24 4.27 ± 0.14 21.44 ± 0.80 4.30 Figure S75 
31 94.11 ± 8.16 1.55 ± 0.02 16.44 ± 1.45 3.30 Figure S76 
34 50.23 ± 1.45 6.07 ± 0.04 120.91 ± 3.61 24.26 Figure S77 
36 119.43 ± 17.73 11.39 x 10-3 ± 0.61 x 10-3 0.10 ± 0.02 0.02 Figure S78 
I154V 
E203V 
28 55.00 ± 4.86 32.98 ± 1.25 599.58 ± 57.65 100.00 Figure S79 
29 52.76 ± 5.63 3.82 ± 0.10 72.37 ± 0.48 12.07 Figure S80 
31 48.72 ± 4.64 1.32 ± 0.02 27.04 ± 2.60 4.51 Figure S81 
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Figure 30: Relative catalytic efficiencies for PuO-Re wt and the mutants E203G and I154V E203V, shown on a logarithmic scale. 
1,4-Diaminobutane (28) is still the best substrate for all three enzymes (relative kcat/KM = 1), however the substrate spectrum of 
the mutants is shifted and they show increased activity with longer polyamines like 1,5-diaminopentane (29) and 1,5-diamino-2-
methylpentane (31) for PuO-Re I154V E203V and spermidine (34) in case of PuO-Re E203G. The kinetic constants for PuO-Re 
I154V E203V with polyamines 34 and 36 were not determined (n.d.).  
 
3.8.2 Semi-rational design by site-saturation mutagenesis 
 
Considering the strong impact variations at position E203 had on the activity of PuO-Re, for further 
mutagenesis a more focused strategy was followed. The selected residues targeted for mutagenesis 
were all located within the channel that was suggested by position E203, which was also included for 
the saturation mutagenesis approach. The tertiary structure of the helix around position 203 (shown in 
red in Figure 31) adopts a U-formed shape (colored in brown in Figure 31, right side) and this element 
was targeted by several libraries consisting of single-, double- and triple randomizations with different 
degenerated codons (Table 33). The selection of residues for the simultaneous randomization was done 
(when possible) considering the CASTing criteria postulated by Reetz.189,234,235 Due to this U-shape 
more degrees of freedom are however available than for a simple α-helix or β-sheet and it was not 
possible to consider all potential combinations of positions for mutagenesis. The other libraries that were 
generated targeted the amino acids at position D104 and a double mutant at positions L168 F169 
(Figure 31). These amino acids are either located at the surface and the entrance of the channel (D104, 
colored in purple in Figure 31) or at a turn before the channel approaches the U-shaped helix (L168 
F169, colored in cyan in Figure 31). Finally, two active site residues that might directly influence the 
coordination of the substrate were chosen for mutagenesis (M174 and L207, colored in green in 
Figure 31). The degenerated codons for the individual libraries (NNK, DNK, NNY, NHK and NDT; for 
details see Table 33) were selected based on the library sizes that had to be screened and to provide a 
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balanced mix of amino acids but avoiding or minimizing the number of very bulky amino acids in the 
active site or positively charged amino acids (active site and tunnel) as it is expected that this might lead 
to some repulsion with the positively charged polyamine substrates. The tools CASTER189 and 
AA-Calculator185 were used for selection of the different degenerated codons.  
 
 
Figure 31: Active site of PuO-Re with the flavin cofactor in yellow sticks and the substrate 1,4-diaminobutane in blue sticks (pdb 
code: 2YG4).171 The anionic point (E324) responsible for the correct positioning of the substrate in the active site166,171 is shown 
in orange sticks. The identification of the channel (blue dots) was done with the CAVER plugin of HotSpot Wizard.233 The left side 
shows the active site in more detail with amino acids M174 and L207 (green sicks) that were selected for mutagenesis. The other 
amino acids of the active site (Tyr396 and His433, shown also in orange sticks) constitute the so called aromatic cage of amine 
oxidases and were excluded from mutagenesis as they are highly conserved.161,171,236 The right side shows in more detail the 
amino acids that were targeted for mutagenesis and which align the potential substrate entrance channel (blue dots). The helix 
around position E203 (colored in red) adopts a U-formed shape (highlighed in brown color), resulting in various combinations for 
simulltaneous randomizations at this element. D104 (purple sticks) is at the entrance of this channel and L168 F169 (cyan sticks) 
are located at a turn before the channel reaches the brown U-shape.  
 
Table 33: Amino acids of PuO-Re targeted for site-saturation mutagenesis with degenerated codons. The location of the targeted 
position, the degenerated codon and the number of colonies that have to be screened for a library coverage of 95% are given.  
targeted residue(s) location 
degenerated codon(s) 
used for mutagenesis 
# colonies for 95% coverage 
(calculated with CASTER)189 
D104 channel/surface NNK 94 
L168 F169 channel NNK NNK 3066 
M174 active site NHK 70 
V201 E203 channel DNK NNK 2299 
L207 active site NNY 94 
L200 E203 I206[a] channel NDT NHK NDT 10352 
V201 D204[a] channel NDT NDT 430 
D202 F205[a] channel NDT NDT 430 
degenerated codons:  
N = A, C, G, T; K (“Keto”) = G, T; H (“not G”) = A, C, T; D (“not C”) = A, G, T; Y (“pYrimidine”) = C, T 
amino acids (one letter code, * = stop):  
NNK = all 20; NHK = A, N, D, Q, E, H, I, L, K, M, F, P, S, T, Y, V, *; NDT = R, N, D, C, G, H, I, L, F, S, Y, V; DNK = A, R, N, D, 
C, E, G, I, L, K, M, F, S, T, W, Y, V, *; NNY = A, R, N, D, C, G, H, I, L, F, P, S, T, Y, V 
[a]: The libraries were generated and screened by solid phase assay but no further analysis was done during this project. The 
lysate screening, purification and characterization of these mutants is ongoing work of another PhD project at the Institute of 
Technical Biochemistry.  
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The mutant libraries were generated by a modified Gibson Assembly protocol179 and, after confirming 
the homogeneity of the randomized positions by sequencing, screened with the solid phase assay to a 
coverage of at least 95% as calculated with GLUE.185 Following this, the mutants were grown in 96 well 
plates and the screening was continued as described above. For the last three libraries in Table 33 
however, the expression in 96 well plates, lysate screening, purification and characterization was 
continued in another PhD project at the Institute of Technical Biochemistry.  
Mutants for which the lysate screening resulted in promising activities were then selected for further 
characterization. These mutants were purified and their specific activity with the 11 polyamine substrates 
28 to 38 determined. A summary of the positions and the activities is shown in Figure 32 and Figure 33. 
The specific activities for all variants are also given in [U/mg] in Table S16. Overall the previously 
identified mutation E203G still proved to be the one with the highest influence on activity and it was 
found several times, also in combinations with other smaller amino acids (serine and alanine) at position 
V201 (Figure 33). The most impressive result of the mutation at position E203G was found for the 
oxidation of 1,5-diaminohexane 33. Whereas this substrate is one of the worst for the wt enzyme and 
does hardly show any activity, with the mutant it showed an increase in the oxidation rate of about 
25-fold (Figure 33 and Figure S68). In contrast, mutations at the entrance of this channel (D104) or 
another turn of the channel (L168 F169) showed in most cases diminishing effects on activity 
(Figure 33). Also the library with the mutants for the active site position M174 did not result in any 
potential candidates for further analysis. Solid phase assay screening still indicated that some of the 
colonies were active, but after screening their lysates and comparing the activities to the wt enzyme, no 
candidates remained for follow-up investigation. Interestingly the other position targeted in the active 
site (L207) turned out to be much more promising. The substitution of it with a valine increased the 
activity for most substrates and in some cases even higher activities than with E203G were found 
(Figure 33).  
 
 
Figure 32: Active site of PuO-Re with the flavin cofactor in yellow sticks and the substrate 1,4-diaminobutane in blue sticks (pdb 
code: 2YG4).171 The mutant at position E203 previously generated by an epPCR is shown as red mesh. Novel positions that were 
selected for saturation mutagenesis are shown as green meshes. Position E203 was also inlcuded in the saturation mutagenesis. 
Combinations for simultaneous randomizations were done according to the CASTing criteria.189,234,235 The anionic point (E324) 
responsible for the correct positioning of the substrate in the active site166,171 is shown as orange sticks. The channel that leads 
into the active site is depicted as blue dots. Identification of it was done with the CAVER plugin of HotSpot Wizard.233 
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Figure 33: Summary of the PuO-Re mutants that were generated by epPCR (described above) and saturation mutagenesis. The 
specific activities of the mutants in relation to the wt activity (in [U/mg]) with the polyamine substrates 28 - 38 are given as numbers 
in [%]. For a better overview in addition colors show the change in activity in [%]. The value for the best mutant is always shown 
in bold numbers. In most cases the mutant E203G generated by epPCR proved to be superior. In Table S16 the specific activities 
in [U/mg] are summarized for all variants. 
 
3.9 Cascade reactions to transform polyamines into cyclic amines 
3.9.1 The combination of purified PuO-Re and IREDs 
 
The production of N-heterocycles by the combined action of PuO-Re and IREDs was investigated as a 
proof of concept with both proteins purified using 10 mM of the polyamine substrates 28, 29 and 31. For 
the cascade reaction, both proteins were used in equimolar ratio. As the turnover numbers for 
PuO-Re wt with polyamines 29 and 31 are in the same range than the turnover numbers for the IREDs 
with piperideine substrates, the wild type enzyme of PuO-Re was used (Table 17, Table 18, Table 19 
and Table 31). Thus limitations arising from substrate inhibition of the IREDs or the too high formation 
of H2O2 by PuO-Re are intended to be kept to a minimum. Samples were incubated for 3 h at 25 °C and 
after derivatization analyzed by GC-MS. As controls combinations were done in which always one of 
the enzymes was inactivated by heat treatment. For an initial analysis and to get an estimation about 
the performance of the three IREDs, the peak areas corresponding to the polyamines and the cyclic 
amines were normalized to the internal standard and the relative amounts in [%] in comparison to the 
normalized area of one 10 mM external standard of each compound was calculated. As the imines of 
such unsubstituted heterocycles tend to form dimers and trimers 237,238 with high boiling points they could 
not completely be detected and were therefore not included in this analysis. The further optimization 
and investigation of this reaction cascade is also ongoing work of another PhD project at the Institute of 
Technical Biochemistry. The preliminary results with the comparisons of the three IREDs in combination 
with PuO-Re wt and the polyamine substrates 28, 29 and 31 are summarized in Table 34. 
After oxidation by PuO-Re all three polyamines could successfully be converted with all three IREDs to 
the cyclic amines pyrrolidine 40, piperidine 42 and 3-methylpiperidine 44. The control reactions showed 
that both enzymes had to be active for the complete transformation to the heterocyclic amine. The 
formations of the heterocyclic amines varied, but were always lower in case of 1,4-diaminobutane 28 
(leading to pyrrolidine 40) as substrate, compared to polyamines 29 and 31, which both lead to a six-
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membered piperidine product. In contrast, in the reactions with inactivated PuO-Re the polyamine 
substrate was not converted at all and after inactivation of the IREDs, only parts of the imine 
intermediates (39 corresponding to pyrrolidine 40, 41 to piperidine 42 and 43 to 3-methylpiperidine 44, 
respectively) could be detected, but no heterocyclic amines. In addition in the samples with polyamine 
31 after inactivation of the IREDs, no full substrate consumption was observed. About 10% of the 
residual polyamine could be detected, whereas it was fully consumed in the reaction with both enzymes 
being active. This could be an indicator for potential product inhibition of this cyclic imine on PuO-Re 
activity. Exemplarily this transformation is shown in Figure 34 for PuO-Re and R-IRED-Sr with 
1,5-diamino-2-methylpentane 31 as substrate and the cyclic amine 44 as product in which the 3 h 
reaction time was sufficient for full substrate consumption (Table 34 and Figure 34). 
 
Table 34: Analysis of the reaction cascade with purified proteins (PuO-Re and IREDs) for the conversion of 10 mM of the 
polyamines 28, 29 and 31 into the heterocyclic amines 40, 42 and 44. Single reactions were performed of each biotransformation 
and the reactions stopped after 3 h. Control reactions were done in which always one of each enzymes was inactivated (indicated 
by the red background in Table 34). For analysis the peak areas were normalized to the internal standard and the ratio in [%] 
compared to one external 10 mM standard of the polyamines and heterocyclic amines was calculated. The imine intermediates 
were not examined in this work as they can form dimers and trimers with too high boiling points for the GC based analysis. In 
most reactions with both enzymes being active high conversions to the heterocyclic amines could be found and no residual 
polyamines were detected. In contrast, in the samples with inactivated PuO-Re no conversions of the polyamines were observed. 
After inactivation of the IRED full conversion of polyamines 28 and 29 was observed, but no cyclic amine detected. Also for 31 no 
cyclic amine could be detected, but in addition about 10% of the residual polyamine was found, an indicator for potential product 
inhibition of this imine on the activity of PuO-Re. -: not detected or analyzed as only parts of the imine (monomer/dimer) were 
detected.  
polyamine substrate  
28 
 
29 
 
31 
 
   
cyclic amine product 
 
40 
 
42 
 
44 
enzymes 28 [%] 40 [%] 29 [%] 42 [%] 31 [%] 44 [%] 
PuO-Re (active) 
- 51 - > 99 - 95 
R-IRED-Sr (active) 
PuO-Re (inactive) 
> 99 - > 99 - > 99 - 
R-IRED-Sr (active) 
PuO-Re (active) 
- - - - 13 - 
R-IRED-Sr (inactive) 
PuO-Re (active) 
- 4 - > 99 - > 99 
R-IRED-St (active) 
PuO-Re (inactive) 
> 99 - > 99 - > 99 - 
R-IRED-St (active) 
PuO-Re (active) 
- - - - 9 - 
R-IRED-St (inactive) 
PuO-Re (active) 
- 62 - 84 - 94 
S-IRED-Pe (active) 
PuO-Re (inactive) 
> 99 - > 99 - > 99 - 
S-IRED-Pe (active) 
PuO-Re (active) 
- - - - 9 - 
S-IRED-Pe (inactive) 
 
The GC traces for the conversion of diaminobutane 28 to pyrrolidine 40 and diaminopentane 29 to 
piperidine 42 with PuO-Re and R-IRED-Sr can be found in Figure S82 and Figure S83, respectively. 
The transformations with PuO-Re and R-IRED-St with 28, 29 and 31 to 40, 42 and 44, respectively are 
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shown in Figure S84, Figure S85 and Figure S86. The transformations of the three polyamines with 
PuO-Re and S-IRED-Pe are shown in Figure S87, Figure S88 and Figure S89.  
 
 
Figure 34: Conversion of polyamine 31 to the cyclic amine product 44 by the combination of purified PuO-Re and R-IRED-Sr. In 
the reaction with both enzymes being active (pink) the substrate is fully consumed in the 3 h reaction time and transformed to the 
product 44. After inactivation of one of the enzymes (R-IRED-Sr inactivated in blue or PuO-Re inactivated in brown) either the 
polyamine is not converted (brown) or small amounts of the imine intermediates (blue) could be detected. In addition for this 
substrate after inactivation of the IRED no complete substrate consumption was detected, indicating some kind of product 
inhibition on PuO-Re. The reaction scheme on top assumes that the sterically less demanding amine group of 31 is oxidized, 
however the regioselectivity of PuO-Re has to be determined. Depending on this regioselectivity also different imine intermediates 
are formed, however this information is lost after reduction of the cyclic imine by an IRED. IS = internal standard. 
 
3.9.2 Cascade reaction with whole cells expressing PuO-Re and the IREDs 
 
To avoid the laborious purification of several enzymes, it was finally shown that the reaction cascade 
can be transformed to a host cell expressing both enzymes at the same time. After overnight expression, 
the cells were washed and used as whole cell biocatalyst as described for the IREDs above (see 3.3). 
As model substrate polyamine 31 was selected due to the high conversion by using purified enzymes 
and as it represents an unnatural polyamine in contrast to 1,4-diaminobutane 28 and 
1,5-diaminopentane 29 (see 3.9.1). All three strains were able to transform the polyamine to the cyclic 
amine product 44. As shown in Figure 35 for the E. coli strain JW5510 expressing PuO-Re and 
S-IRED-Pe simultaneously for a reaction time of up to 20 h, the amount of product 44 increased. The 
analysis of the GC peak areasVI underlined this increase in product formation over time (Table 35). 
Nevertheless the overall performance was poor compared to the use of purified enzymes as it is obvious 
by the large peak corresponding to the residual substrate (see Figure 35 and Table 35). The use of the 
                                                                
VI: The ratios of the polyamine substrate 31 and the heterocyclic amine product 44 in [%] were calculated from the GC areas. The 
comparison to the standard, as performed above, was not possible, as the volume of the sample taken was different due to the 
cells.  
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other two IREDs (R-IRED-Sr and R-IRED-St) yielded comparable results (Table 35) and the 
chromatograms for these transformations are shown in Figure S90 and Figure S91.  
 
Table 35: Analysis of the GC areas for the transformation of polyamine 31 into the heterocyclic amine 44 by whole cells expressing 
PuO-Re and an IRED simultaneously. Single reactions were performed and regularly samples taken. After derivatization and GC 
analysis the fractions corresponding to the polyamine substrate and the amine product were calculated in [%]. For the given 
reaction time of 20 h the formed product increased in all cases, however compared to the performance of isolated enzymes the 
overall substrate consumption and product formation was poor. -: not detected.  
 
E. coli JW5510 with 
PuO-Re and R-IRED-Sr 
E. coli JW5510 with 
PuO-Re and R-IRED-St 
E. coli JW5510 with 
PuO-Re and S-IRED-Pe 
time [h] 31 [%] 44 [%] 31 [%] 44 [%] 31 [%] 44 [%] 
0 > 99 - > 99 - > 99 - 
3 94.6 5.4 90.9 9.1 94.1 5.9 
6 93.2 6.8 87.2 12.8 92.4 7.6 
20 92.2 7.8 86.8 13.2 90.5 9.5 
 
 
Figure 35: Whole cell biotransformation of polyamine 31 to the cyclic amine 44 with E. coli JW5510 expressing PuO-Re and 
S-IRED-Pe simultaneously. For the reaction time of 20 h the amount of product slightly increased. Compared to the performance 
of isolated enzymes the consumption of the substrate and transformation to the amine was poor.  
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4 DISCUSSION 
4.1 Identification, selection and definition of enzymes of the IRED family 
4.1.1 The importance of IREDs as novel biocatalysts for the generation of chiral 
amines 
 
Biocatalytic methods for the generation of chiral amines have emerged as promising alternative to 
chemical means. Unfortunately, until recently the amines accessible were limited by the available 
enzymes. Traditionally lipases are employed, also on an industrial scale, for kinetic resolution of racemic 
amines.239,240 Mechanistically however they only provide access to primary amines.60 The same is true 
for ω-TAs, ammonia lyases and amino acid or amine dehydrogenases.50,62,65,92,241 For ω-TAs an 
exception has been described,154,155 and for ammonia lyases by protein engineering the amine 
nucleophile scope was expanded, enabling access to substituted secondary amines, derived from 
aspartic acid.98 As both methods are not broadly applicable, for quite some time deracemizations relying 
on amine oxidases were the biocatalytic method of choice to access secondary and tertiary amines.2,43 
In most cases the (S)- selective MAO-N was applied, which has throughout the last about 15 years 
undergone extensive evolution to broaden its substrate scope.110–113,115 To access the other enantiomer, 
(R)- selective amine oxidases for deracemizations were generated by protein engineering.119,120 Another 
just recently patented enzymatic method for preparation of chiral secondary and tertiary amines involves 
the reductive amination of ketones with opine dehydrogenase variants.106,107  
Alternatively, the novel enzyme class of the IREDs received considerable interest since their first 
description by Mitsukura et al. about 5 years ago.137 In contrast to MAO-N and opine dehydrogenases, 
it was shown for IRED wt enzymes that they are active on imines that lead to chiral primary, secondary 
and tertiary amines.139,142–152 This versatility and the high selectivities that were described for the IREDs 
promoted their use as biocatalysts, what is reflected in a rapid growing number of known and 
characterized enzymes published especially in the last two years.139,142–152 Impressively, in one work 50 
novel enzymes were cloned and tested for the reduction of 3H-indoles150 and in another work the pharma 
company Roche has published their investigations on 20 novel IREDs.149 Within the Chem21 project, 
which started in October 2012242 several research groups and GlaxoSmithKline expressed considerable 
interest in these enzymes and a larger number of IRED genes was ordered and will now be 
characterized in ongoing works. The characterization of them will probably shed more details on the 
mechanism and origin of these enzymes as well as their relation to other enzymes. Overall, keeping the 
enormous potential of the IREDs in mind and the attention they instantly gained, it is expected that the 
number of IREDs and the application of them in biocatalysis will grow even faster. 
 
4.1.2 Defining and expanding the known sequence space of IREDs 
 
The above mentioned rapid increase in known and confirmed IREDs required an in detail analysis how 
to exactly define these enzymes with respect to related enzymes. The early classification in (R)- type 
and (S)- type enzymes from two different superfamilies was based on the transformation of imine 
substrate 1 performed by literature known IREDs138,139,142,143 and the three novel IREDs characterized 
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during this work.145 The selection of these novel IREDs from Streptosporangium roseum DSM 43021 
(R-IRED-Sr), Streptomyces turgidiscabies (R-IRED-St) and Paenibacillus elgii (S-IRED-Pe) was based 
on the combination of biochemical information about the three at this time published IREDs from 
Streptomyces sp.138–142 with bioinformatics sequence analyses. As therefore only few criteria could be 
applied to reduce the sequence space, very stringent sequence thresholds were applied to select the 
members for the first version of the “Imine Reductase Engineering Database” resulting in only about 350 
protein entries.145 The establishment of (R)- type IRED and (S)- type IRED superfamilies resulted also 
in the first classification system of these enzymes. Yet, as the number of characterized IREDs has 
steadily increased a few exceptions from this selectivity pattern were described,148,149 but the overall 
majority of IREDs from these two families follows the classification. As such a designation greatly 
facilitates the communication it will be kept in the current discussion of this work.  
With the proof that even more distantly related enzymes, not part of the two superfamilies of (R)- type 
and (S)- type IREDs are functional,146,149,150 the threshold how to define an IRED had to be reconsidered. 
This resulted in an updated version of the “Imine Reductase Engineering Database”,152 but also 
alternative classification systems were conceived, based on the C-terminal clustering of IRED 
sequences.149 The currently proposed definition of an IRED on a sequence level relies on global 
sequence similarity to known IREDs and the match to two IRED specific motifs.152 The first motif 
describes the IRED specific cofactor binding region (GLGxMGx5[ATS]x4Gx4[VIL]WNR[TS]x2[KR]) and 
the second one characterizes the proposed active site (Gx[DE]x[GDA]x[APS]x3{K}x[ASL]x[LMVIAG]).152 
The combination of these information allows discriminating IREDs from the closest related family, the 
β-HADs (sequence identity up to 35%).152 These two motifs are sufficient to cover all currently described 
IREDs and by the application of them in total more than 1400 sequences encoding for over 1100 putative 
IREDs could be predicted by Fademrecht et al..152 
 
4.1.3 Cofactor binding of IREDs and mechanistic aspects for the enzymatic imine 
reduction 
 
The comparison of the IRED specific cofactor binding motif with the cofactor binding motifs of the IRED 
related family of the β-HADs allowed to predict the preference of all IREDs for NADPH.152 β-HADs were 
described to be either NADH- or NADPH-dependent and the motif of the NADPH-dependent enzyme 
family shares a conserved arginine with IREDs (underlined in the motif described above).152,216,217 This 
preference for NADPH was experimentally confirmed during the characterization of several IREDs with 
IREDs preferring NADPH over NADH for the reduction reaction by a factor of 5 to over 80.138,139,145,146,213 
The yellow color of the purified IREDs shown in Figure 11 for the (R)- selective enzymes might also be 
related to the NADPH binding. A spectral analysis of these proteins indicated a peak at 336 nm, close 
to the generally agreed NADPH maximum of 340 nm. The reason for the (S)- selective IRED to remain 
colorless might be due to some structural differences of the bound NADPH. A highly conserved proline 
in superfamily 2 ((S)- type IREDs) might be the responsible amino acid of the IREDs therefore.152 In the 
crystal structure of the (S)- selective IRED from Streptomyces sp. GF3546 (pdb code: 4OQY)144 the 
NAPDH adopts a bend like structure compared to the NAPDH in the structure of the (R)- selective 
enzyme from Streptomyces kanamyceticus (pdb code: 3ZHB)142 (Figure 36). The color could therefore 
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be just due to the different conformation of the NAPDH, but these difference could also be reflected in 
different affinities for NAPDH. In this concept the yellow colored IREDs should have bound NAPDH and 
the colorless ones not. Preliminary tests to determine the affinity for NADPH of the IREDs were 
performed during this work, however due to the low sensitivity of the assay, based on NAPDH 
absorbance no conclusions could be drawn from these experiments.  
 
 
Figure 36: Cofactor binding sites of an (R)- type (left) and (S)- type (right) IRED. For the comparison the crystal structures of 
R-IRED-Sk (pdb code: 3ZHB)142 and S-IRED-Ss (pdb code: 4OQY),144 both containing the NADPH ligand, were used. The 
conserved proline at standard position 29 in the (S)- type IREDs causes the NAPDH to adopt a bend at the phosphodiester 
linkage, stabilized by different hydrogen bonds (red dashes). This figure was provided by Silvia Fademrecht.152 
 
The active site motif of IREDs can be used to discriminate them further from the closest related enzyme 
family, the β-HADs. While these enzymes are characterized by a conserved lysine in their motif 
representing an essential amino acid for catalysis, this position is only superfamily specific conserved 
in IREDs.152,216 (R)- type IREDs possess mainly an Asp at this position and (S)- type IREDs a Tyr.145,152 
In analogy to the role of the conserved Lys in β-HADs, a mechanism for IREDs was proposed involving 
protonation of the imine to an iminium and hydride transfer from NADPH for the reduction to the 
amine.142 Derived from the mechanistic information about other imine reducing enzymes like 
dihydrofolate reductase (DHFR),128,243,244 pyrroline-2-carboxylate reductase127 and thiazoline reductase 
Irp3,125 there is some debate about the chronology of these steps, but most likely protonation precedes 
the hydride transfer.107 
The differentially conserved active sites of (R)- and (S)- type IREDs however render it questionable 
whether the protonation actually relies on such a “catalytic” amino acid, as suggested for R-IRED-Sk,142 
or not. This is further supported by catalytically active (R)- type IRED mutants (Table 10 and 
Table 11)145,147 and active wild type IREDs with Ala,146 Phe149 and Asn149,VII at this position. In contrast 
however, the (S)- type IREDs all display the conserved Tyr at this position and all of the generated 
mutants were largely inactive (Table 10).145,148 Therefore, different roles of Asp and Tyr, as well as 
variations in the mechanistic aspects between both (R)- and (S)- type IREDs can at the moment also 
not be excluded. This is supported by the fact, that the catalytic constants for the mutants of the 
(R)- selective IREDs decreased only by a factor of about 100 to 400 (Table 11, R-IRED-Sr and 
                                                                
VII: The characterization of an active IRED with Asn in the active site represents currently unpublished work from the group of 
Prof. Dr. Nicholas Turner, University of Manchester. The work was presented during Chem21 project meetings and on a poster 
at the Dechema Summer School “Biotransformations 2014” in Bad Herrenalb, Germany.  
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R-IRED-St, respectively), whereas the knockout of a “true” catalytic residue, the serine in the catalytic 
triade of proteases for example leads to a decrease of kcat/KM by a factor of at least 105.245 Due to the 
very low activity of S-IRED-Pe Y208A the catalytic constants were not determined, but as already 
described in biotransformations the mutant protein was in contrast to the R-IREDs nearly completely 
inactive (Table 10).  
Further observations on the different roles Asp and Tyr might play for catalysis of an IRED were reported 
by Man et al..148 During the characterization of the Tyr containing (S)- selective IRED from 
Streptomyces sp. GF3546 a more narrow pH profile was found than for the (R)- selective Asp containing 
IREDs R-IRED-Ss and R-IRED-Sk.148 According to the authors, the broader pH profile of the Asp 
containing IREDs might be related to the role this residue plays for catalysis.148 Analogously to an Asp 
in DHFR of E. coli, the Asp of the IREDs might function in building up an H-bonding network with H2O 
for the protonation of the substrate, whereas the Tyr might serve as direct proton donor.148 
Taken together, at the moment it seems more likely that at least for the (R)- type IREDs the previously 
designated catalytic residue functions more as an important residue for the correct positioning and 
stabilization of the substrate or in the stabilization of water by building up an H-bonding network, than in 
a direct catalytic way. As described for DHFR,128,244 the source of the proton in the R-IRED mediated 
catalysis might be H2O. Whether this water molecule has to be coordinated by Asp or other amino acids 
remains to be discussed. Considering the weakly basic nature of an imine, having a pKa value of 
about 8 to 9, at neutral pH it should however be per se protonated, alleviating the need for a further 
proton donating step. The function of the IRED would then mainly be in providing a protein environment 
for the correct placement and stabilization of the substrate in close proximity to the NADPH bound to 
the enzyme.  
 
4.2 Biochemical characterization of novel IREDs 
 
After selection of the three novel IREDs (R-IRED-Sr, R-IRED-St and S-IRED-Pe) a basic biochemical 
characterization of these enzymes was performed to be able to define conditions for their application as 
biocatalysts. During this work the pH profile, the thermostability and the effect of organic solvents on 
these enzymes were investigated. Although not that much information about IREDs is available, the 
three enzymes follow some general trends that seem to be similar for all IREDs.  
The reported pH optima for the reduction reaction of the characterized IREDs are all in the neutral range 
around pH 7.0.138,139,146,148,150,151 The same behavior was found for R-IRED-Sr, R-IRED-St and 
S-IRED-Pe (Figure 13, Figure 14 and Figure 15). In addition all IREDs display a relatively broad pH 
profile, especially regarding alkaline conditions. S-IRED-Pe for examples maintained about 50% 
residual activity at pH 9.0 and showed a comparable broad pH profile than the Asp containing (R)- 
selective IREDs. This is in slight contrast to the above mentioned report by Man et al.,148 but the increase 
in pH resistance of S-IRED-Pe might be explained by its generally increased resistance towards non 
physiological conditions and therefore masking the effect described by Man et al..148 
The thermal stability of IREDs is far less investigated than their pH profile. For the first IREDs that were 
characterized by Mitsukura et al.138,139 only rudimentary information about their low thermal stability was 
reported.138,139 For R-IRED-Ss for example it was described that after a 30 min incubation period at 
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35 °C the reduction activity remained stable and for S-IRED-Ss the optimal temperature was 40 °C.138,139 
A more detailed characterization of these properties were done by Li et al. for the (S)- selective IRED 
from Paenibacillus lactis and the half-life times of this enzyme were determined at 30 °C, 40 °C and 
50 °C.150 With a T1/2 of close to 50 h at 50 °C this IRED is assumed to be much more stable than the 
ones from Streptomyces sp., reported by Mitsukura et al..139,150 S-IRED-Pe originates also from a 
Paenibacillus strain and displays an even higher thermal stability. With a half-life time exceeding 400 h 
at 50 °C, it is the IRED with the highest thermal stability known to date. In contrast, the (R)- selective 
IREDs behave most probably comparable to the IREDs characterized by Mitsukura et al. and showed 
significantly lower half-life times and T50
  15
 values than S-IRED-Pe (Table 12 and Table 13). Although the 
genus Paenibacillus was not reported to be thermophilic,246,247 it is interesting that exactly the two IREDs 
from these strains show increased thermal stability compared to the other IREDs.  
The effect of organic solvents on IRED activity was so far only published for S-IRED-Ss by 
Mitsukura et al.139 and again only rudimentary information is available. The enzyme exhibited tolerance 
against MeOH, but not against EtOH, iProp, acetone and DMSO.139 A general relatively high tolerance 
against MeOH could be confirmed for all three IREDs. In addition to MeOH, seven additional organic 
solvents were tested. The resulting residual activities correlate well with the thermostability, which in 
literature is often described to be associated with general stability versus denaturing conditions.49,248 
Whereas for R-IRED-Sr with many solvents at elevated concentrations the residual activities declined 
to less than 1%, again S-IRED-Pe proved to be the IRED resisting more solvents and tolerating also 
higher concentrations of them (see 3.2.4). Displaying hardly any loss of activity in the presence of 20% 
MeOH is an interesting feature of this enzyme as polar organic solvents are usually not very well 
tolerated by enzymes because they show a high ability to strip of the essential water, contributing to the 
hydration shell of the enzyme.249–251 
For the application of these enzymes as biocatalysts, their substrate spectrum was investigated and 
kinetic constants recorded to evaluate the substrate acceptance. These points are discussed separately 
in the following chapter (see 4.3).  
 
4.3 Exploration of the substrate spectrum of the IREDs 
4.3.1 Reduction of cyclic and exocyclic imines 
 
Although neither the physiological role, nor a natural substrate of an IRED are known, these enzymes 
are regarded as promising biocatalysts for the generation of chiral amines. The research that was 
performed during this project and that was also published in the literature by other groups143,146–150 
resulted in the elucidation of many cyclic and exocyclic imines as substrates for IREDs. In these 
biotransformations primary-, secondary- and tertiary amines could be generated, underlining the 
versatility of IREDs for the preparation of chiral amines. In this project the substrate spectrum of the 
three novel IREDs was investigated in biotransformations performed with whole cells expressing these 
enzymes and with purified proteins.  
In the initial reports by Mitsukura et al. the substrate spectrum of the IREDs was described to be very 
narrow.138,139 On the discovery of R-IRED-Ss a small set of imines, ketones and heterocyclic substrates 
was investigated, but activity could only be detected for 2-methylpyrroline (imine 1).138 In contrast, for 
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S-IRED-Ss also activity with the imines 5b, 5c and Δ1-pyrroline-2-carboxylic acid was described.139 
Encouraged by these reports, the group of Turner has synthesized a broad range of substituted 
pyrrolidines, piperideines, isoquinolines and β-carbolines and investigated the reduction of them with 
the two IREDs described by Mitsukura et al..143,147 In their works, published 2013 and 2015, it was shown 
that these IREDs possess a much broader substrate spectrum towards cyclic imines than initially 
thought.143,147 Meanwhile also our145,213 and other groups144,146,149 have investigated pyrrolidines, 
piperideines, isoquinolines and β-carbolines as substrates for IREDs.  
Although the structures of (R)- and (S)- selective IREDs overall share a very similar fold142,144,148 and 
IREDs are also closely related on a sequence level145,152 (the sequence identity of R-IRED-Sr and 
R-IRED-St is > 54% and for both enzymes to S-IRED-Pe ~ 34%III) there are some interesting differences 
in the substrates accepted. These differences were reported independently by various groups working 
with different IREDs, allowing to make some general statements about the IRED substrate scope. Cyclic 
six-membered rings are usually well accepted by both (R)- and (S)- selective IREDs and many 
substituents next to the C=N double bond are tolerated.143,146–149 Piperideines also tend to show higher 
conversion rates than pyrrolidines and azepane-derived imines.143,147,149 Electron-donating and electron-
withdrawing substituents on phenyl rings next to the C=N double bond are usually readily accepted, with 
the substituents in the para position showing beneficial effects on selectivity so far.147 Isoquinolines are 
also well accepted by both, (R)- and (S)- selective IREDs, however giving first indications for a broader 
substrate spectrum for bulky heterocyclic substrates with (S)- selective IREDs.143,144,147,149,150 Imine 5c 
for example is accepted by these enzymes, but no activity was found with (R)- selective IREDs and also 
other groups did not report activity with R-IREDs on this compound.147 For the even bulkier class of 
β-carbolines also only activity with S-IREDs has been reported.143–149,213 The extension of the substrate 
spectrum to indole-derived imines has just recently been described in some of the latest IRED 
publications by Li et al. and Wetzl et al..149,150 In the work performed by Li et al. 50 novel IREDs were 
tested for this reduction, including R-IRED-St and S-IRED-Pe.150 Interestingly, in this report R-IRED-St 
was active, but S-IRED-Pe not.150 The most active IRED, however was again an (S)- selective IRED 
from Paenibacillus lactis, which did surprisingly not show activity on imine 5b.150 As S-IRED-Pe and the 
S-IRED from Paenibacillus lactis are very closely related with a sequence identity of 72.8% and a 
sequence similarity of 84.9% it seems likely that they possess similar properties and the increased 
thermostability of these two enzymes compared to all other described IREDs was already discussed 
above (see 4.2). It might therefore be worth to repeat the experiments reported by Li et al. to confirm 
that S-IRED-Pe does not show activity with 3H-indoles. By such a comparison useful information about 
amino acids of the active site that contribute to substrate binding and recognition might be acquired, but 
otherwise this also indicates that the prediction of substrates for a certain class of IREDs is not easily 
possible. Although altogether S-IREDs seem to have a slightly broader substrate spectrum, higher 
conversion rates in whole cell biotransformations are usually obtained with (R)- selective 
IREDs.107,137,143,145–148,201 An overview about the conversions and selectivities obtained in whole cell 
biotransformations that were performed in this work with R-IRED-Sr, R-IRED-St and S-IRED-Pe and the 
set of cyclic imine substrates is again given in Figure 37.  
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Figure 37: Summary of the product formations in [%] and the enantiomeric excess values in [%] for whole cell biotransformations 
after 24 h performed in this work employing E. coli cells expressing R-IRED-Sr (red), R-IRED-St (blue) and S-IRED-Pe (green). 
The change in the selectivity from the (R)- to the (S)- product for R-IRED-Sr and R-IRED-St and vice versa in the case of 
S-IRED-Pe is caused by a change in the priority of the substituents for the Cahn-Ingold-Prelog assignment. 
 
Work on exocyclic imine substrates is far less reported,138,139,146,151 with the investigation of the oxidation 
reaction on amine substrates by Gand et al. being the most thoroughly published study.146 The 
investigation of amines for the oxidation reaction is an experimentally much more amenable way for the 
exploration of the substrate scope as the amines are not prone to hydrolysis like the imines are. However 
the direct use of exocyclic imine substrates is the synthetically desired reaction and the chemical 
preparation of imines in organic solvents is a straightforward and established method.224 In the studies 
by Mitsukura et al. the imines 18 and 23 (precursor of the dialkylation product dibenzylamine 24 which 
was obtained in small amounts by the repeated reductive amination of benzaldehyde 11 in this work) 
were tested, but no activity reported.138,139 It has therefore to be highlighted that with the IREDs tested 
in this work activity for these compounds was found. Furthermore, for other exocyclic imines like 7, 9 
and 15 the amine products could be obtained. It seems therefore likely that IREDs are also able to 
accept a broad range of exocyclic imines as substrates. Based on this data it is however difficult to make 
some general statements for IRED activity on exocyclic imines as for example imine 7 was accepted by 
all three IREDs in this work, but 9 and 18 could be reduced only by the R-IREDs, with R-IRED-St 
showing much higher activities. In contrast 15 was mainly accepted by R-IRED-Sr, slightly by S-IRED-Pe 
and hardly by R-IRED-St. The broader substrate profile of the R-IREDs could in addition be misleading 
due to a combination of the higher activity these enzymes display and the hydrolytic instability of the 
exocyclic imine substrates. The further investigation and optimization of the reaction conditions for 
example by the inclusion of organic solvents to stabilize the imine substrates is therefore advisable to 
fully exploit IREDs for the reduction of this interesting new class of substrates.  
 
4.3.2 Enantioselectivities for the reduction of imines 
 
The selectivities that were obtained in the IRED-mediated biotransformations with whole cells and 
purified enzymes are often very high and exceed 99% ee.143–147,149,150 The highest selectivities obtained 
with R-IRED-Sr, R-IRED-St and S-IRED-Pe were all observed for the reduction of imine 3a, with no 
traces of the opposite enantiomer detectable. The high selectivities that can be achieved with IREDs 
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again promote their use as biocatalysts for the stereoselective synthesis of chiral amines. Interestingly 
for some substrates large differences in the obtained activity and selectivity were observed, again 
despite the close relationship of the used IREDs. For example the products of the R-IRED catalyzed 
biotransformations performed with isoquinoline 5b differed quite a lot in selectivity (R-IRED-Sr 93.0% ee 
and R-IRED-St 50.7% ee). In other cases already a small modifications of the substrate led to a strong 
change in selectivity as seen for example for piperideines 3b and 3c. As long as no structures with 
bound ligands are available the reasons for these strong differences in selectivity and the possibilities 
how to engineer IREDs for better selectivity are not clear. Preliminary results from crystallizations with 
ligands performed in the group of Prof. Dr. Gideon Grogan at the University of York however suggest 
multiple binding sites for substrates in the active site cleft of the IREDVIII. Having an IRED structure with 
ligand and different binding modes of it available would help to understand some of the currently 
reported unexplained behaviors of these enzymes. Man et al. and Wetzl et al. reported a substrate 
dependent switch in the enantioselectivity of the used IRED148,149 and Hussain et al. reported different 
selectivities of the formed product depending if biotransformations were performed with whole cells or 
with purified protein.147 
 
4.3.3 Reduction of carbonyls 
 
The reduction of carbonyls was observed as byproduct during the investigation of the reduction of 
exocyclic imines with purified IREDs and suspected to originate from contaminants of co-purified 
KREDs. The hydrolytic instability of such imines produces carbonyl byproducts that can be reduced by 
these enzymes. For example imine substrates 7 and 9 hydrolyze to benzaldehyde 11 and methylamine 
22 or aniline 12, respectively. Aldehyde dehydrogenase activity is numerously found in E. coli, with 44 
potential enzyme candidates identified and 13 confirmed ones.252,253 Thereof for at least six enzymes 
activity for the reduction of 11 was confirmed.252 As the investigated substrates most probably do not 
represent natural ones for IREDs and hence the activity was in general rather poor, enough of the IREDs 
had to be used to capture the available (unstable) imine. The enzyme loading in these 
biotransformations was therefore increased over 15-fold compared to the enzyme amount used for the 
reduction of cyclic imine substrates. The strong increase of the biocatalyst loading has to be considered 
as thereby also the amounts of the suspected contaminating KREDs, responsible for the carbonyl 
reduction, are increased. Already slight contaminations like 2% of the total protein will have an enormous 
impact if the enzyme loading is that much increased. To deal with this, the IREDs had to be sufficiently 
pure and indeed, the increase in purity led to higher amounts of the amine product formed (see 3.5.2). 
Together with the biotransformations performed with purified R-IRED-Sr D191A, that did not produce 
any amine product but in which alcohol byproduct formation was observed, it seems likely that the 
aldehyde reduction after the hydrolysis of 7 or 9 was indeed performed by contaminating KREDs. 
However a weak promiscuous activity of IREDs on carbonyls can also not be excluded at the moment, 
although all literature reports on carbonyl reduction were unsuccessful.138,146,147 Producing IREDs with 
                                                                
VIII: The elucidation of IRED structures with bound ligands represents currently unpublished work from the group of Prof. Dr. Gideon 
Grogan, University of York. The presentations of these results were done during an IRED project meeting and on the conference 
Transam 2.0; 2015 in Greifswald, Germany.  
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an in vitro translation system will probably be the most straightforward way to exclude (or confirm) the 
observed KRED activity as thereby also precise control reactions can be included.  
 
4.3.4 Reduction of activated C=C bonds and others 
 
In an attempt to shed more light into the substrate spectrum of IREDs in the diploma thesis of Sebastian 
Hofelzer IRED activity with imines, oximes, oxime ethers, benzoquinolines, amidines, activated C=C 
double bonds and carbonyls was investigated.213 The only substrate of this list that was accepted by the 
IREDs was cinnamaldehyde 45 and in these biotransformations the activated C=C double bond was 
reduced. Carbonyl reduction was also found with this substrate, but was considerably lower than the 
reduction of the C=C double bond. As discussed above this slight reduction might most likely be caused 
by contaminating KREDs in the enzyme preparation (see 4.3.3). To confirm this promiscuous activity 
the reactions were repeated during this work.  
Again, all three IREDs displayed activity towards the C=C double bond in the Michael system. 
R-IRED-Sr and S-IRED-Pe showed only very low activity and the formation of 3-phenylpropanal 46 was 
less than 3-5% in 24 h. R-IRED-St showed the highest activity and about 15% of the product was formed 
(Table S8). In addition to the C=C reduction also small amounts of a byproduct from the aldehyde 
reduction were found. Overall the alcohol byproduct was found to be less than 4% and the fully reduced 
product was not found at all (Table S8). As it was already discussed above, the alcohol formation is 
assumed to be most likely caused by contaminating ketoreductases in the IRED preparation. The only 
ene reductase activity in E. coli is attributed to the N-ethylmaleimide reductase (E. coli gene: 
nemA).44,254–258 In a thorough investigation of biotransformations performed with several ene reductases 
expressed recombinantly in E. coli however the background activity of NemA was negligible, except for 
nitroalkenes.258 As it is also the case for the carbonyl reduction (4.3.3), the further purification of the 
IREDs or the use of a nemA knockout strain175 for production of the enzyme should be performed as 
additional control to ensure that the reduction of the C=C double bond in 45 represents the first 
“promiscuous” activity for IREDs.  
 
4.3.5 Investigation of the substrate preference of IREDs and considerations for the 
search of natural substrates 
 
To get insights in the substrate preference of the IREDs, kinetic constants were recorded with purified 
proteins and the set of cyclic imine model substrates. Comparable results to the ones that were obtained 
during this work were meanwhile also published by other research groups107,143,147,148,201 and are also in 
agreement with the results of the biotransformations. A comparison based solely on biotransformations 
could however be misleading due to differences in the experimental setups that are reported for 
biotransformations and varying expression levels of the IREDs. Piperideines are well accepted as 
substrates and preferred over pyrrolidine rings. The kcat/KM for them is at least 4-fold and up to 160-fold 
higher, meaning that if both substrates would be present at the same time, the IRED preferable would 
transform the piperideine scaffold. Comparing cyclic imines 1 and 3a, 3b and 3c it might also be possible 
that R-IRED-St has a slightly better performance with larger substrates compared to R-IRED-Sr. This 
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could also help to explain the differences in conversion observed during the biotransformation of the 
exocyclic imine substrates 9 and 18. The generally lower turnover numbers determined for S-IRED-Pe 
might then also help to understand the very low conversion of these substrates with this enzyme as they 
probably hydrolyze too fast to be transformed efficiently.  
Isoquinolines are again well accepted by all IREDs and actually 5 is the substrate with the highest kcat/KM 
observed for S-IRED-Pe. This tendency was not that pronounced with the R-IREDs and might again 
reflect the already suspected broader substrate scope of S-IREDs towards more bulky cyclic imine 
substrates (see also 4.3.1). With some of these substrates inhibitions of the used IREDs were observed 
at higher concentrations, however therefore also no clear trend could be obtained. Again as all of the 
three enzymes are closely related (4.3.1) and there are no structures with ligands of them available it is 
not possible to attribute these differences to the architectures of the active sites of these enzymes.  
Further, setting the obtained catalytic efficiencies in relation to the catalytic efficiencies that are assumed 
for enzymes with their natural substrate (they are supposed to be between 105 - 108 M-1 s-1 and thereby 
at least 103 times higher than the typical ones observed for the IREDs)259–261 it is tempting to assume 
that none of the tested substrates so far represents a natural substrate of an IRED. Due to their 
homology IREDs were in most cases wrongly annotated as glycerol-3-phosphate dehydrogenases and 
6-phosphogluconate dehydrogenases, however in none of the literature reports (including R-IRED-Sr, 
R-IRED-St and S-IRED-Pe) where activity with such substrates was tested it could be found.145–147 
Keeping in mind that substrate promiscuity is assumed to be much more widespread than catalytic 
promiscuity262 it seems likely that the C=N reduction represents the natural activity and does not 
represent a promiscuous reaction, but without knowing more about the mechanism of these enzymes 
the confirmation therefore is still outstanding.  
 
4.4 Application of IREDs as whole cell biocatalysts 
 
The use of IREDs in whole cell bioreductions has the advantage of a simple preparation of the 
biocatalyst and the possibility to use the host metabolism for in situ cofactor regeneration, although also 
the use of isolated enzymes might be beneficial to avoid competing side reactions and eliminate 
transport barriers.38,45,46,62 
Most of the biotransformations with the cyclic imine substrates in this work were performed with whole 
cells expressing the IREDs. As cyclic imine substrates are hydrolytically relatively stable, competing 
side reactions like the reductions of the corresponding carbonyl hydrolysis products of exocyclic imines 
were not observed. However other problems that might arise and were also observed, are related to the 
cellular metabolism. The loss of cell fitness is a considerable problem and for whole cell 
biotransformations always fresh cells had to be used as after freezing the activity considerably 
decreased. As IREDs survive several freeze/thaw cycles without any impact on activity, it is most 
probably the case that the host metabolism suffers by this procedure. This then might lead to an 
insufficient cofactor regeneration capacity. The cofactor regeneration capacity is already suspected to 
be limited and the use of glucose as additional energy source is crucial. In the diploma thesis of 
Sebastian Hofelzer it was shown, that otherwise hardly any conversions were obtained.213 Furthermore, 
Nagasawa et al. reported in a patent covering R-IRED-Ss that the co-expression of a glucose 
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dehydrogenase from Bacillus sp. resulted in about twofold higher imine reducing activity.141 This 
limitation is also obvious, when working with R-IRED-Sr and R-IRED-St. During the reduction of 
substrates 1 and 3a in whole cell biotransformations full substrate consumption in less than 3 h and less 
than 0.5 h was observed. Knowing the maximal turnover numbers of the enzymes for these substrates 
(Table 17 and Table 18) however, it is likely that substrate 3a should have been transformed even faster. 
Further information for the inability of the host metabolism to satisfactorily regenerate the NADPH can 
be derived from the biotransformations with the R-IRED mutants (R-IRED-Sr D191A and R-IRED-St 
D193A). In whole cell biotransformations with them, conversion rates decrease to about 15% and 5%, 
respectively. In contrast, the purified enzymes showed 10- to 100-fold decreased turnover numbers. 
This indicates that the whole cell biotransformations employing the wild type enzymes should be faster 
if one considers solely the IRED activity (the expression level of the wt enzymes and the mutants was 
equal, based on SDS gel analysis). Next to limitations of the cofactor regeneration capacity however 
also transport limitations could account for this.  
Another constraint for using whole cells arises from limitations in the recovery of the product, as it was 
observed with amines 4a and 4b. In both cases 10 mM of the imine substrate was used and fully 
consumed during the biotransformation, but the maximal detected product yield was about 70%. Next 
to limitations in the recovery of products from complex biological samples, also the possibility that the 
host strain might metabolize the substrate or product should be considered. Metabolization of the imine 
substrate was detected in case of isoquinoline 5c, where the cells harboring an empty pBAD33 plasmid 
consumed about 20% of the substrate (Figure S12). 
 
4.5 Applications with purified IREDs 
4.5.1 Reduction of exocyclic imine substrates and analytical challenges for their 
detection 
 
The main investigations performed with purified IREDs aimed for the reduction of exocyclic imine 
substrates and their use in reductive amination reactions. For both of these parts it is important to keep 
the hydrolytic sensitive nature of the imine substrate in mind and the therewith associated challenge for 
their detection.  
The hydrolysis of such exocyclic imines is very rapid and for example with imine 7 directly after the setup 
by GC analysis the imine 7 and the aldehyde 11 could be detected in a ratio of about 60/40. As observed 
in the negative control with heat inactivated IRED, this ratio did not change (see also Table 24), 
indicating a potential equilibrium. However the work-up of these samples dramatically influenced the 
conditions and hence the analytical result. First, the extraction into the organic solvent eliminates the 
water and might promote imine formation or at least increase the stability. Second, for extraction of the 
amines the pH of the samples was raised to > 14. The change in pH also changes the protonation status 
of the amine hydrolysis products, with the deprotonated amine being a nucleophile capable of imine 
formation. The combination of these factors led to an overestimation of the imine fraction detected. In 
control experiments it was tested that small amines like methylamine 22 are either not or only poorly 
extracted. Imine formation in the organic phase after extraction is then either not supported by the 
conditions (solvent MTBE) or might be neglected. The GC results for these combinations will therefore 
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most likely give the equilibrium of carbonyl/imine during the workup. In contrast, when working with 
imines 9 and 18 also the amine nucleophile 12 was extracted. In the negative controls for all of these 
electron rich substrates (9, 15 and 18) their hydrolysis could be followed for a period of several hours, 
what could indicate a slightly higher hydrolytic stability. It is however also possible that the amount of 
imine detected by HPLC in these cases is falsified due to re-formation of the imine substrate after the 
sample workup (solvents ammoniumbicarbonate buffer and acetonitrile).  
To get further insights into the imine formation, Maike LenzIX performed NMR experiments.151 By NMR 
spectroscopy directly the imine fraction in the aqueous buffer could be detected without changing the 
conditions for workup as required for GC or HPLC analysis. Being aware of the different acidities of 
hydrogen and deuterium, (pD = pH + 0.4),263,264 it was possible to estimate the true imine fraction. For 
the condensation of aldehyde 11 and amine 22 at the respective pH of 8.2 the imine fraction is about 
32% and not > 80% as detected by GC, thereby confirming the overestimation (Figure 38 and 
Table S11; the reference value with 500 mM of the nucleophile has to be used for the comparison).151  
 
 
Figure 38: 1H-NMR spectra to follow the condensation of aldehyde 11 and amine 22 for the formation of imine 7 at different pH 
conditions, increasing from pH 4.0 to 9.0. As solvent for the NMR experiments D2O was used. The pD was calculated by the 
following correction pD = pH + 0.4.263,264 Above the respective pH of 8.2, substantial amounts of imine 7 could be detected. This 
figure was provided by Maike Lenz.151  
 
Disadvantages of the NMR experiments are the low sensitivity of this technique. For example, for the 
reaction of acetophenone with methylamine no imine formation could be detected, but IREDs are 
capable of product formation (see 3.6.2).151 The detection limit of the 1H-NMR is permissively 
estimated to be above 500 µM, thereby highlighting the potential of IREDs to reduce also low amounts 
of imines.151 
                                                                
IX: Biocatalysis group, Institute of Technical Biochemistry, University of Stuttgart. 
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Summarized it could be said that when working with exocyclic imine substrates, the IRED activity or 
amount of enzyme has to be high enough to capture the available imine substrate before it completely 
hydrolyzes. As already mentioned in 4.3.1, the optimization of the reaction conditions to reduce the 
hydrolysis by performing biotransformations in low water containing media will be advisable, as is the 
engineering of IREDs to show higher activity and stability for these conditions.  
 
4.5.2 Reductive amination reactions – the potential of IREDs 
 
A significant advancement for the use of an IRED is to exploit their reductive potential directly for 
stereoselective intermolecular reactions to generate novel C-N bonds from carbonyls and amines. 
Enzymes to perform such reductive amination reactions (“reductive aminases”) have long been sought 
after and this reaction has been described as one of the most aspirational ones.265 As it is difficult to 
achieve highly selective reductive aminations by chemical catalysts,16,20 enzymes with their exquisite 
selectivity appear to be promising catalysts for such challenging reactions. Indeed, the reductive 
amination of α- and β- keto acids to produce amino acids and derivatives thereof is performed with 
natural and engineered enzymes also on an industrial scale.44,77,83,84,266,267 The enzymatic reductive 
amination of unfunctionalized ketones however was only described in one work with an enzyme from 
Streptomyces virginae IFO 12827,268 without any follow-up results published. The lack of such enzymes 
represented a significant disadvantage and by protein engineering the group of Bommarius has for the 
first time, and later also other groups, promoted to generate amine dehydrogenases from amino acid 
dehydrogenase scaffolds.85–89 Most amino acid dehydrogenase are L-selective and these were used as 
scaffolds for the evolved amine dehydrogenase. In all of these cases the selectivity of the enzymes was 
kept.85–89 To be able to obtain the opposite enantiomers, a D-selective amino acid dehydrogenase with 
broad substrate scope was developed,81 but no such amine dehydrogenase for reductive aminations 
has been described, yet. Still, these enzymes are restricted to ammonia as nitrogen source, as ω-TAs 
are. They are formally also able to perform reductive amination reactions, however require the amine to 
be supplied as a co-substrate and hence are not able to assimilate free ammonia.50,64,65 To overcome 
these limitations researchers from Codexis Inc. have engineered opine dehydrogenase variants with up 
to 29 mutations, acquired over eleven rounds of directed evolution, to perform a wide variety of reductive 
aminations, producing chiral secondary and tertiary amines.106,107  
While Codexis Inc. had to evolve several different enzymes, each for specific reductive amination 
reactions,106,107 results that were obtained during this work with R-IRED-Sr indicated a broad applicability 
of this enzyme with respect to the carbonyl compounds but also the amine nucleophile range.151 
Independently from this work, the reductive amination with IREDs has also been reported in an earlier 
published work by the group of Prof. Dr. Michael Müller, however only with methylamine 22 as 
nucleophile and a maximum of 8.8% conversion and 76% ee was obtained.144 Interestingly for the 
synthetic application of IREDs is that the enantiocomplementary nature of the (R)- and (S)- type IREDs 
was maintained in the reductive amination reactions. Huber et al. used the S-IREDs from 
Streptomyces sp. GF3546 and S. aurantiacus, resulting in the (S)- products,144 whereas the use of 
R-IRED-Sr in this work produced the (R)- enantiomers, with higher enantiomeric excess values and 
higher conversions (see 3.6).151 The progress in using IREDs as catalysts for enzymatic reductive 
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aminations that was obtained during this work and recently published151 underlines the enormous 
potential of these enzymes to fill the gap originating from missing such synthetically desirable enzymes, 
beside the developments of amine dehydrogenases and opine dehydrogenases.  
 
4.5.3 Optimizations for enzymatic reductive amination reactions 
 
Optimization of the reductive amination reaction in this work was mainly done by shifting the equilibrium 
of the carbonyl and amine compound to the imine intermediate. The use of stronger nucleophiles 
resulted in a higher fraction of the imine intermediate. Next, by increasing the amine concentration up 
to a 50-fold molar excess over the carbonyl and by shifting the pH of the reaction media into alkaline 
conditions, the amount of the reactive amine species was increased, again enhancing the imine 
formation.  
The final amine concentration of 500 mM however, does not have to be the optimum for the imine 
forming reaction. Codexis Inc. for example used up to 1.6 M of the amine106,107 and amine 
dehydrogenases were used with up to 5 M NH4Cl.87 As both enzymes, amine dehydrogenases and 
opine dehydrogenases, are described to perform a “true” bimolecular reaction and possess a carbonyl 
and an amine binding site, the high excess of the amine is required to suppress the oxidative 
deamination and to drive the reaction to completion.44,107,241 In contrast, the recent works with IREDs 
indicate that they reduce imines that are formed spontaneously in the aqueous buffer system and hence 
an higher excess of the amine than tested yet, or increase in the pH might further enhance the imine 
fraction151 (see also NMR experiments, discussed in 4.5.1). The optimum however has to be determined 
for each single amine nucleophile and will probably also depend on the used enzyme. With amines 21 
and 22 for example at concentrations up to 500 mM no negative effects on the conversions were 
observed, but with aniline 12 at concentrations of 100 mM conversions decreased, indicating some kind 
of inhibition (3.6.1). The same is true for the pH of the reaction. By increasing it, the fraction of the 
deprotonated amine is enhanced, resulting in an equilibrium shift towards the imine. Work on reductive 
aminations performed in the Müller group was done at pH values ranging from 9.2 to 9.8, without 
systematically investing their effect.144 A further increase in the pH might likely be beneficial for the 
position of this equilibrium, however will also go in line with decreased enzyme activity (see 3.2.1) and 
one has to consider that at higher pH values IREDs are also able to catalyze the oxidation reaction with 
amines as substrates.138,139,146 To further shift the position of the equilibrium, water eliminating or 
reducing conditions by inclusion of organic solvents in the enzymatic reductive amination reaction hold 
great promise for optimization.  
Next to the position of the carbonyl/amine – imine equilibrium also the kinetics of imine formation have 
to be taken into account. In general, the chemistry of imine formation is well understood, but usually 
these reactions are performed in aqueous free media.218,269 Under these conditions slightly acidic pH 
values are reported to be beneficial for the reaction due to the activation of the carbonyl.14 Imine 
formation and hydrolysis in aqueous environment is far less reported in literature218,219,270,271 but from 
investigations in this work it seems possible that the kinetics of imine formation also could become rate 
limiting. During the reductive amination of acetophenone 20 the enzyme loading was increased 4-fold 
but the conversion rates did not increase to the same extent. Determining the kinetic constants for the 
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reductive amination reaction also gave some indications for this. While the maximal determined turnover 
numbers of 11 with 22 at conditions with 1- and 10 equivalents of the nucleophile reach about the same 
level, at 50-fold excess they are increased (Table 29). If the imine formation would become the rate 
limiting step, such an effect could be explained. In this case the determined kcat values should also be 
designated as kcat app (as the rate determining step for this reaction would be k0 for the imine formation 
in the reaction scheme at the top of Figure 26).  
The optimization of the reaction conditions for the reductive amination resulted at the same time in a 
beneficial side effect. Shifting the conditions towards imine formation suppressed the carbonyl reduction. 
This was highest (~ 6%) for nucleophiles 12 and 21 with aldehyde 11 at equimolar concentrations and 
decreased considerably to < 1% for nucleophile 22 (Table S10, Table S11, Table S12). This decrease 
could again be related to different issues. By increasing the fraction of the imine intermediate it might 
be the case that there is less of the carbonyl available for the supposed competing KREDs, or the 
conditions beneficial for imine formation also reduce the suspected KRED activity.  
 
4.5.4 Kinetic characterization of the reductive amination reaction 
 
Although without further knowledge about the reaction mechanism and the true substrate of the IREDs 
the recorded kinetics represent a simplification and the first steps of the reaction (k0 for the formation of 
the imine substrate and k1 for formation of the ES complex, reaction scheme provided in top of Figure 26) 
are treated as a “black box” this data gives valuable information about the reductive amination reaction 
in total. The data was recorded under the premise of a steady state equilibrium and that the imine has 
completely formed before the reaction started. This was ensured by preparation of the substrate solution 
(the mix of aldehyde 11 and amine 22 in buffer with the respective pH) ahead of the reaction start. In 
addition it is expected that the imine is the single substrate for the IRED and that the enzyme does not 
have different binding sites for two substrates. 
The determined apparent KM values correlate with the expected conditions for imine formation indicating 
that they directly reflect the relative amount of substrate the enzyme is exposed to. In this way these 
values represent a very powerful tool to assess the effect of optimizing the reaction conditions. By NMR 
also the actual imine fraction was estimated (data shown in 4.5.1) and thereof the equilibrium constant 
(Keq=
[imine]
[aldehyde] [amine]
) for the imine forming reaction can be calculated. With this Keq it should be possible 
to calculate a “true” imine concentration in the substrate solutions and use this information for data fitting, 
thereby estimating the real affinity (KM) of the enzyme for the substrate. This was done, but problems 
emerged by the insensitivity of the NMR to determine accurately the imine concentration. At unfavorable 
conditions (pH 8.0 and less than 50-fold excess of the amine and pH 9.0 with equimolar amine 
concentrations) no imine formation could be observed and in the other cases the calculated Keq differed 
quite a lot. The correction of the imine fraction with the different calculated Keq resulted in affinities in the 
range of 0.08-0.45 mM of R-IRED-Sr for imine 7 (for details see 7.7).  
As already discussed above the determined turnover numbers might be masked by limitations in the 
kinetics of the imine forming reaction. Further experiments and optimizations should therefore be done 
to clarify this fact. Besides to the spectrophotometric analysis, the turnover numbers can also be 
calculated from the conversion rates of the biotransformations (Table 27, Table S11, Figure S52 and 
4 DISCUSSION 
113 
Figure S53). The values calculated for these experiments (2.23 x 10-3 s-1 for pH 8.0 with an equimolar 
concentration of 22 and 7.77 x 10-3 s-1 in the case of 10-fold excess) resemble quite well the ones 
determined in the photometric assay (Table 29). In the work by Huber et al. also the turnover number 
for the reductive amination of the ketone substrate was calculated and given with 2.8 x 10-6 s-1.144,X 
Calculation of the turnover numbers for the reductive amination of ketone 20 with the amines 21 and 22 
results for the best conditions in about 175 x 10-6 s-1 for the reaction with 21 (see Figure S56) 
and 292 x 10-6 s-1 for the reductive amination employing 22 (see Figure S58). These values are about 
two orders of magnitude higher than the one reported by Huber et al..144 Considering that in the work of 
Huber with ketone 22, no product formation was obtained,272 the results achieved in this work might at 
least partially be owed to the selectivity and activity differences of (R)- type and (S)- type IREDs, but 
could also reflect the further optimized reaction conditions, as ketone 22 is a challenging substrate for 
direct reductive aminations.224 As discussed, the turnover numbers of the IRED catalyzed reductive 
aminations are rather low and most of the optimization steps aimed to enhance the imine formation 
either by higher pH conditions or by increased concentrations of the reactants. Further, the inclusion of 
organic solvents is an option, but all of these steps represent unphysiological conditions and are likely 
to decrease the activity of an IRED. For more efficient applications of IREDs in enzymatic reductive 
amination procedures it is therefore required not only to optimize the reaction conditions, but also the 
activity and stability of the biocatalyst as it was done with many of the nowadays industrially applied 
enzymes.38,39,42,48,156,273 
 
4.6 Establishing cascade reactions with IREDs 
4.6.1 The selection of an amine oxidase and the investigation of its substrate scope 
 
Enzymatic cascade reactions hold great promise for future synthetic challenges as enzymes often 
operate under relatively similar conditions and due to their high selectivity can be combined, avoiding 
unwanted side reactions and laborious isolation steps.257,274–276 Saturated nitrogen containing 
heterocyclic compounds are frequent motifs in pharmaceuticals12 and IREDs show high activity for the 
reduction of cyclic imines, making such a cascade a promising proof of principle showcase. Chemical-
biocatalytical cascades for these targets were already described by the groups of Kroutil and 
Turner.122,154 In these works ω-TAs were employed for the amination of diketones to trigger their self-
cyclization to cyclic imines.122,154 For the subsequent reduction however in both cases chemical reagents 
were used.122,154 As an alternative starting point, based on renewable resources for such a reaction 
cascade polyamines were identified in a “retrobiosynthetic” analysis.277 Polyamines already contain the 
required number of carbon atoms and nitrogen. In addition polyamines or modified version of them are 
well known metabolic intermediates with a wealth of biological functions278–281 and the natural ones are 
easily accessible from amino acids by decarboxylation with overproducing strains described.157,158 The 
difficulty however lies in the cyclization of such an amine, a reaction not directly accessible by chemical 
catalysts or enzymes. The selective transformation of one of the amine groups into a carbonyl to promote 
the formation of a cyclic imine, followed by the reduction with an IRED therefore practically represents 
                                                                
X: The turnover number for this substrate was calculated from the conversion rate, experimental details are given in the PhD thesis 
of T. Huber, online available at the University of Freiburg.272 
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an intramolecular reductive amination. The enzymatic conversion of the amine into the carbonyl is most 
straightforward accomplished by polyamine oxidases (see also Scheme 11) with PuO-Re being the best 
characterized member of this family of enzymes.161,165–173 
To address different polyamines that would directly lead to modified N-heterocycles the substrate scope 
of PuO-Re was investigated with a variety of non-natural polyamine substrates. The substrate panel 
was composed of symmetric and asymmetric polyamines with oxygen and nitrogen heteroatoms, as 
well as methyl-substituted branched polyamines. Next to the activity measurements also the affinities 
for some of these polyamines were determined. In general the trend published in literature could be 
confirmed.161 The enzyme displayed high activity on its natural substrate 1,4-diaminobutane 28 but 
already small modifications of the substrate led to a sharp decrease in activity. After determining the 
kinetic constants it became obvious, that the affinity of the enzyme to these substrates was still high 
enough to facilely saturate it. Without the exception of N-aminopropyl-1,4-diaminobutane 34 which 
shows slightly lower affinities, all KM values were in the low µM range. This exception of amine 34 might 
reflect the challenge arising from longer polyamines to accommodate the active site or the difficulty for 
the enzyme to discriminate between the two highly similar terminal amino groups. In contrast the 
turnover numbers for most non-natural polyamines strongly dropped, indicating that although the affinity 
is high the binding of these substrates does not proceed in a way that supports the path to the transition 
state of the reaction.229,230 The narrow activity profile of the enzyme has already been described with 
natural polyamines and has its origin in the highly evolved active site for polyamine 28. The perfect 
positioning of this substrate in proximity to the flavin cofactor was already 1976 hypothesized by Swain 
and DeSa to be mediated by an anionic point (Glu or Asp residue).166 Later after resolving the crystal 
structure of PuO-Re this hypothesis was confirmed and the anionic point identified as a glutamate at 
position 324.171 
 
4.6.2 Mutagenesis of PuO-Re to enhance the activity for non-natural polyamines 
 
To shift the substrate spectrum of PuO-Re towards longer and non-natural polyamines mutagenesis 
was performed. This has been proven to be a powerful tool for the expansion of the substrate spectrum 
of several enzymes.38,39,42,48,156,273 For example MAO-N initially displayed highest activity with a few 
aliphatic monoamines108,109 but over several rounds of directed evolution it was evolved for the oxidation 
of a broad range of primary-, secondary- and tertiary amines.110–117,282,283 
In a first attempt it was investigated to shift the anionic point by a single point mutation that exchanges 
Glu with Asp. The side chain of this amino acid is one carbon atom shorter and ideally the space that is 
created can then be filled by longer polyamines. The mutant was generated and the activities tested. It 
indeed displayed activity changes for the tested polyamines but the mutation resulted mainly in a 
dramatic loss of activity (28 decreased to 0.3% and 29 to about 2.7%). In 2013 the book of the 
conference “Flavins and Flavoproteins 2011” appeared online and in one chapter a more detailed 
investigation of this mutant was published.172 The affinities and catalytic efficiencies determined by 
Kopacz et al. more clearly demonstrate the shift in the substrate spectrum.172 
For further mutagenesis no rational approach could be outlined. The amino acids in the active site seem 
to be highly specialized and in total 7V channels were identified leading into the active site of the enzyme. 
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Therefore a random mutagenesis strategy starting with an epPCR was pursued, resulting in the 
successful identification of several mutants. Of these mutants, the characterization of two 
(PuO-Re E203G and PuO-Re I154V E203V) is included in this study. The substitution of Glu to Gly 
resulted in strongly increased activities for the tested substrates as did the substitution with Val. It is 
assumed that by the modification with these smaller amino acids the channel leading into the active site 
is enlarged, allowing the easier access of substrates to the active site. In addition this position is located 
at the outer chamber of the active site171 and hence also directly more space for longer polyamines 
like 34 could be created. This additional space might also explain the higher affinity PuO-Re E203G 
displays for 34. The change in activity and affinity compared to the wild type is impressively shown in 
Figure 29 illustrating the over 10-fold increased catalytic efficiency of the mutant. The use of this 
parameter in such a way can however be misleading as two enzymes can possess the same kcat/KM but 
display completely different activities.227,228 In contrast it is best used to evaluate the reaction of one 
enzyme for different substrates, thereby allowing to judge how well an enzyme is able to discriminate 
between them (as done in Figure 30).227,228 By comparing the relative kcat/KM values the achieved shift 
in the substrate spectrum becomes even more obvious. 1,4-diaminobutane 28 is still the best substrate 
for all mutants, but polyamine 34 is converted by the wild type with about 1% of this efficiency and with 
PuO-Re E203G it reaches already 25% (Table 31, Table 32 and Figure 30).  
The successful identification of two mutants at the same position (E203G and E203V) makes it likely 
that this position represents an interesting hotspot that should be targeted for further mutagenesis. The 
fact that this position also aligns one of the channels allowed the generation of more focused libraries, 
surrounding position E203. The second mutagenesis round consisted of site-saturation libraries of two 
residues in the active site and several positions that align this channel. Due to an U-formed shape of 
the tertiary structure at this position however the amino acids surrounding E203 have many potential 
interaction partners (Figure 31) and not all library combinations proposed by Reetz for a CASTing 
process234 could be made during this work. The screening of the saturation mutagenesis libraries 
resulted in much higher “hit” rates of positive candidates than did the screening of the epPCR library. 
Nevertheless, the successful identification of the hotspot and the associated channel relied on the 
random approach and the generation of a glycine substitution would usually be carefully considered as 
due to the high flexibility of this very small amino acid often structural changes are introduced.  
The characterization of the promising mutants identified in the site-saturation approach, underlined the 
versatility of position E203 for increasing the activity of the enzyme. Next to Gly and Val many other 
small amino acids like Ala, Ser, and Cys were found at this position. In addition at the simultaneously 
targeted position V201 also Ser and Ala were found in the sequencing results of the active mutants. The 
characterized mutants summarized in Figure 33 represent the most promising ones and showed for 
many substrates higher activities at saturating conditions. The most impressive increase in activity was 
found for the methyl substituted polyamine 33. Whereas the wt enzyme did hardly show any activity on 
this substrate most mutants displayed activity, with an up to 25-fold increase for PuO-Re E203G. In 
Figure 33 also some mutants with lower activity are shown and they were investigated to confirm the 
importance of these positions. This included mutations in the channel (double mutant L168 F169) or at 
its entrance (D104). Further, the active site position L207 proved to be an interesting target for 
mutagenesis and resulted for most of the substrates in higher activities. In contrast, the other library 
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targeting an active site amino acid (M174) resulted in only poorly active variants. A simultaneous 
saturation mutagenesis approach targeting position E203 and L207 should obviously be made in future 
as these amino acids are in close proximity and interestingly due to the U-formed tertiary structure, the 
side chains of these amino acids point in totally different directions in the crystal structure (Figure 31).  
 
4.6.3 Application of IREDs in cascade reactions 
 
The application of IREDs and PuO-Re in cascade reactions to generate N-heterocycles was investigated 
with purified proteins and with whole cells, expressing both enzymes simultaneously. In this work initial 
experiments for this reaction cascade were performed and are now continued in another PhD project at 
the Institute of Technical Biochemistry.  
For the reactions with purified proteins in most cases fast conversions were obtained, resulting in full 
substrate consumption (Table 34). This confirms that the enzymes in principle work well together. While 
some of these reactions proceeded efficiently (Figure 34: R-IRED-Sr employed in the transformation of 
polyamine 31 to the cyclic amine product 44, full conversion) others worked less well (Figure S84: 
polyamine 28 to the cyclic amine product 40 with R-IRED-St, resulting in only about 4% of the cyclic 
amine). Indeed, it was generally observed, that when starting with polyamines 29 or 31 higher product 
formations were obtained, compared to polyamine 28 as a starting point. Further, with polyamine 31 no 
full substrate consumption was observed with PuO-Re in case the IREDs were inactivated. This could 
indicate some kind of product inhibition of the imine on PuO-Re activity. Also the differences in product 
formation might be explained by the different activities and properties of the enzymes with the 
substrates. PuO-Re prefers polyamine 28, which leads to a pyrroline scaffold, but all IREDs prefer 
piperideine substrates. In addition IREDs tend to be inhibited by too high substrate concentrations and 
this is severe for pyrroline substrates compared to piperideines. A better balancing of the enzymes in 
the reaction might help to avoid bottlenecks and inhibition of the IREDs (substrate) or PuO-Re (product), 
however during this work only equimolar ratios were tested.  
The low amounts of the detected imine intermediate in the reaction with the inactivated IREDs might 
again reflect the analytical difficulties in detection of imines. For unsubstituted pyrrolines and 
piperideines it was described that they tend to form dimers and trimers in solution, with the trimer being 
the most stabile structure.237,238 Such high molecular weight complexes however possess most probably 
too high boiling points and were therefore not detected by GC.  
The simultaneous coexpression of these enzymes and the conversion of polyamine 31 to the 
heterocyclic amine 44 could also be shown with whole cell biocatalysts, albeit in contrast to the reactions 
with purified proteins lower conversions were obtained. As most of the substrate was not consumed 
(Table 35, Figure 35, Figure S90 and Figure S91), it seems likely that the cells did not take up the 
strongly charged polyamines. To overcome this polyamine transporters might be targeted as they are 
reported to be highly specific284,285 and most probably are very inefficient for the uptake of non-natural 
polyamines. Otherwise also permeabilization of the cells by chemical or physical methods can be taken 
into account, but for the redox reaction of the IREDs the cofactor regeneration capacity has to be 
considered. The insufficient ability of the host cells to regenerate the NADPH was already discussed 
above (see 4.4). In addition, in the reactions with purified proteins catalase was included to prevent H2O2 
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damage to the enzyme. A coexpression of such an enzyme might also be beneficial to prevent the host 
strain from oxidative stress.286 Further, the information about the enzyme ratios that can be derived from 
the reaction cascade with purified proteins will help to define and optimize the genetic context. This 
could lead to an optimized expression and better balancing of the enzymes. Finally the combination with 
additional enzymes to decorate the heterocyclic products is an attractive goal. Several steps have to be 
done to reach a full application of such a “designer” bug,287,288 but the proof that this orthogonal pathway 
can be implemented was achieved. 
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5 CONCLUSION AND OUTLOOK 
 
After the discovery of the IRED family in 2010137 the number of enzymes described and the knowledge 
about them has steadily increased, especially in the latest two years. The importance of this novel 
enzyme family is explained by the fact that they represent the first extension of enzymatic reduction 
catalysts for C=N double bonds that can also be used for a broad range of synthetic applications 
(including chiral secondary- and tertiary amines). Together with ketoreductases (KRED, C=O reduction) 
and ene reductases (ERED, reduction of activated C=C bonds) IREDs now comprise the biocatalytic 
reduction toolbox and these enzymes might together simply be summarized as “X”REDs (Figure 39).  
 
 
Figure 39: The “X”RED family composed of KREDs (C=O reduction) and EREDs (reduction of activated C=C bonds; EWG: 
electron withdrawing group) is now extended by the IREDs (C=N reduction).  
 
During this work valuable contributions to this rapidly emerging field were made. For the first time it was 
shown that there are many more functional IREDs stored in the sequence space than initially 
assumed.145 These discoveries were used to assign the IREDs into families and derive information about 
their mechanism.145 Later also the increasing diversity was included and clear criteria defined how to 
discriminate IREDs from their closest related enzymes.152 The characterization of the three selected 
enzymes that was performed in this work and the exploration of their substrate spectrum provided useful 
information, not only for these IREDs but for the whole family as this data extended the molecular 
knowledge about the published IREDs.  
An application of IREDs in cascade reactions for the formation of heterocyclic amines from linear 
precursors was shown and by extending the reaction scope of the IREDs away from the “classical” 
reduction of cyclic imines to reductive aminations the chemical potential of these enzymes was 
investigated.151 Future directions of IRED research will probably include the discovery and 
characterization of many more of these important enzymes. The resolution of new crystal structures with 
bound ligands and the combination of these information with data from their characterization and 
mechanistic studies will help to shed light on how these enzymes work and their physiological role. By 
enzyme engineering the activity, stability, the substrate scope and the selectivity for the products of 
these enzymes could be enhanced but the establishment of a suitable HTS assay is an initially required 
step. The suitability of the IREDs to be integrated in cascade reactions will also increase the number of 
their applications. Finally, further research on the reaction scope of these enzymes could be inspired by 
the reactivity of the imine substrates. The majority of described applications with imines is related to 
reductive aminations,289 but also their enantioselective alkylation and allylation was described.290 
Combining this reactivity with the recent advantages biocatalysis has harvested by engineering non-
natural reactions into protein scaffolds51–56 outlines an exciting future for IREDs.
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7.1 Michaelis-Menten plots of IREDs and mutants with substrate 
2-methylpyrroline 1 
 
 
Figure S1: Determination of kinetic constants for R-IRED-Sr with substrate 1. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation. 
 
 
Figure S2: Determination of kinetic constants for R-IRED-St with substrate 1. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation. 
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Figure S3: Determination of kinetic constants for S-IRED-Pe with substrate 1. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation. 
 
 
Figure S4: Determination of kinetic constants for R-IRED-Sr D191A with substrate 1. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation. 
 
 
Figure S5: Determination of kinetic constants for R-IRED-St D193A with substrate 1. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation. 
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7.2 Biotransformations with IREDs 
7.2.1 IRED catalyzed whole cell biotransformations and chiral GC/HPLC-traces for 
determination of product formations and determination of the enantiomeric 
excess in these biotransformations 
 
Table S1: Product formations and enantiomeric excess values in [%] for the reduction of 1 with whole cells expressing IREDs and 
mutants of them. All biotransformations were performed in triplicates. The values in this table give the average of such a triplicate 
and the errors represent the standard deviation. As the values determined for S-IRED-Pe Y208A after 3 h and 5 h were very low 
and not in the optimal range for detection with the applied method they are given in parentheses. -: not detected.  
 
 
 
IRED 
product formation [%] 
ee [%] after 24 h 
0 h 0.5 h 1 h 3 h 5 h 8 h 24 h 
R-IRED-Sr 
0.77 ± 
0.22 
46.29 ± 
0.42 
89.79 ± 
2.89 
> 99 > 99 > 99 > 99 98.26 ± 0.01 (R) 
R-IRED-St 
0.88 ± 
0.24 
29.58 ± 
1.49 
64.59 ± 
4.19 
> 99 > 99 > 99 > 99 99.02 ± 0.02 (R) 
S-IRED-Pe 
0.58 ± 
0.21 
18.66 ± 
0.12 
38.07 ± 
0.38 
77.25 ± 
1.52 
88.97 ± 
3.92 
94.54 ± 
1.33 
96.84 ± 
1.01 
94.92 ± 0.00 (S) 
R-IRED-Sr D191A < 1 
7.22 ± 
0.14 
14.89 ± 
0.32 
33.25 ± 
1.55 
43.44 ± 
2.79 
58.32 ± 
4.21 
63.73 ± 
3.81 
91.43 ± 0.09 (R) 
R-IRED-St D193A - 
1.11 ± 
0.23 
2.17 ± 
0.06 
5.77 ± 
0.21 
9.07 ± 
0.17 
13.40 ± 
0.35 
17.42 ± 
2.40 
94.13 ± 0.03 (R) 
S-IRED-Pe Y208A - - - (0.08) (0.22) 
0.37 ± 
0.18 
0.88 ± 
0.21 
65.66 ± 0.25 (S) 
 
 
Figure S6: Chiral GC-traces for the separation of the enantiomers of product 2 and determination of the enantiomeric excess in 
IRED catalyzed whole cell biotransformations. Black: racemic 2, pink R-IRED-Sr 98.3% ee; blue: R-IRED-St 99.0% ee and brown: 
S-IRED-Pe 94.9% ee. Assignment of the enantiomers was done by comparison with commercial available samples of (R)-2 and 
(S)-2.  
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Table S2: Product formations and enantiomeric excess values in [%] for IRED catalyzed whole cell biotransformations with 
piperideine substrates 3a, 3b and 3c. All biotransformations were performed in triplicates. The values in this table give the average 
of such a triplicate and the errors represent the standard deviation. Product formation with substrate 3a at 0 h is most probably 
caused by too slow sample preparation after starting the biotransformation. Biotransformations were set up in the order R-IRED-Sr, 
R-IRED-St and S-IRED-Pe last. -: not detected; n.d.: not determined. 
 
 
imine time [h] 
R-IRED-Sr R-IRED-St S-IRED-Pe 
product 
formation [%] ee [%] 
product 
formation [%] ee [%] 
product 
formation [%] ee [%] 
3a 
0 0.37 ± 0.04 n.d. 2.08 ± 0.15 n.d. 5.93 ± 0.00 n.d. 
0.5 63.62 ± 3.94 n.d. 63.67 ± 3.30 n.d. 43.32 ± 4.18 n.d. 
1 64.38 ± 1.48 n.d. 66.99 ± 2.72 n.d. 58.95 ± 4.00 n.d. 
3 67.18 ± 4.47 n.d. 66.17 ± 2.72 n.d. 74.89 ± 8.17 n.d. 
5 66.00 ± 4.15 > 99 (R) 71.52 ± 4.49 > 99 (R) 78.14 ± 4.95 > 99 (S) 
8 64.22 ± 2.21 > 99 (R) 69.86 ± 7.11 > 99 (R) 74.18 ± 6.89 > 99 (S) 
24 64.35 ± 8.15 > 99 (R) 64.81 ± 2.02 > 99 (R) 69.00 ± 1.04 > 99 (S) 
3b 
0 - n.d. 0.05 ± 0.00 n.d. - n.d. 
0.5 10.89 ± 0.21 n.d. 17.77 ± 0.85 58.24 ± 10.43 (S) 0.11 ± 0.00 n.d. 
1 20.88 ± 0.31 32.24 ± 20.66 (S) 29.69 ± 0.84 51.97 ± 8.92 (S) 1.06 ± 0.11 n.d. 
3 36.75 ± 1.96 23.74 ± 0.41 (S) 46.91 ± 1.99 n.d. 4.85 ± 0.08 n.d. 
5 39.95 ± 1.56 22.60 ± 1.94 (S) 48.67 ± 0.99 53.67 ± 3.32 (S) 7.33 ± 0.12 72.31 ± 6.10 (R) 
8 43.62 ± 1.26 20.98 ± 4.24 (S) 50.05 ± 2.09 54.58 ± 1.83 (S) 9.54 ± 0.30 69.32 ± 1.63 (R) 
24 48.02 ± 1.83 23.22 ± 0.41 (S) 47.79 ± 1.20 55.96 ± 0.30 (S) 14.22 ± 0.19 67.89 ± 0.53 (R) 
3c 
0 - n.d. - n.d. - n.d. 
0.5 23.93 ± 1.26 n.d. 52.43 ± 1.61 89.61 ± 0.03 (S) 3.13 ± 0.06 n.d. 
1 46.47 ± 2.34 87.07 ± 0.09 (S) 82.26 ± 4.96 89.92 ± 0.05 (S) 8.17 ± 1.05 n.d. 
3 86.32 ± 4.46 86.52 ± 0.04 (S) 93.83 ± 8.39 89.96 ± 0.01 (S) 24.88 ± 1.98 n.d. 
5 91.68 ± 4.93 86.45 ± 0.02 (S) > 99 n.d. 36.03 ± 3.89 87.20 ± 0.05 (R) 
8 89.79 ± 8.17 n.d. 96.11 ± 3.42 n.d. 49.95 ± 1.39 87.11 ± 0.01 (R) 
24 94.06 ± 4.37 n.d. 94.39 ± 5.22 n.d. 63.00 ± 0.41 87.00 ± 0.02 (R) 
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Figure S7: Chiral GC-traces for the separation of the enantiomers of product 4a (left side) and 4b (right side) to determine the 
enantiomeric excess in IRED catalyzed whole cell biotransformations. Black: racemic 4a or 4b. Examples of biotransformation 
samples are always shown in pink with R-IRED-Sr in the top row, R-IRED-St in the middle and S-IRED-Pe in the bottom row. 
Enantiomeric excess values are given in Table S2. Assignment of the enantiomers was done by comparison with commercial 
available (S)-4a and by analogy to amine product 2a. Assignment for product (R)-4b and (S)-4b is based on literature reference.147 
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Figure S8: Chiral HPLC traces for the separation of the enantiomers of product 4c to determine the enantiomeric excess in IRED 
catalyzed whole cell biotransformations. Blue: racemic 4c, examples of biotransformation samples are always shown in red with 
R-IRED-Sr on top left, R-IRED-St on top right and S-IRED-Pe in the bottom row. Enantiomeric excess values are given in Table S2. 
Assignment of product (R)-4c and (S)-4c is based on literature references.147 
 
 
Figure S9: Exemplarily the whole cell biotransformation for the conversion of substrate 3b into amine product 4b is shown for the 
triplicate of R-IRED-St; R-IRED-Sr yielded comparable results. As explained in the main text, the substrate is fully consumed, but 
the amount of product detected is limited to about 50%. It might be possible that the cells consume the substrate/product or that 
the recovery from the complex biological sample is limited as it is also the case for isoquinoline 5c (Figure S12). 
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Figure S10: Exemplarily the whole cell biotransformation for the conversion of substrate 3c into amine product 4c is shown for the 
triplicate of R-IRED-Sr; R-IRED-St yielded comparable results. In contrast to substrate 3b, which was also fully consumed, this 
product could nearly fully be recovered.  
 
Table S3: Product formations and enantiomeric excess values in [%] for IRED catalyzed whole cell biotransformations with 
isoquinoline substrates 5a, 5b and 5c. All biotransformations were performed in triplicates. The values in this table give the 
average of such a triplicate and the errors represent the standard deviation. Product formation with substrate 5a and 5b at 0 h is 
caused most probably due to the too slow sample preparation after starting the biotransformation. Biotransformations were set up 
in the order R-IRED-Sr, R-IRED-St and S-IRED-Pe last. For the assumed (S)- selectivity of S-IRED-Pe with substrate 5c, please 
see footnoteIV. -: not detected; n.d.: not determined; n.a.: not available.  
 
 
imine time [h] 
R-IRED-Sr R-IRED-St S-IRED-Pe 
product 
formation [%] 
ee [%] 
product 
formation [%] 
ee [%] 
product 
formation [%] 
ee [%] 
5a 
0 0.92 ± 0.74 n.a. 1.52 ± 0.54 n.a. 1.42 ± 0.58 n.a. 
0.5 37.65 ± 0.18 n.a. 41.27 ± 0.31 n.a. 37.57 ± 0.57 n.a. 
1 75.52 ± 4.18 n.a. 83.75 ± 2.91 n.a. 67.14 ± 0.91 n.a. 
3 >99 n.a. 97.27 ± 4.05 n.a. 95.00 ± 2.32 n.a. 
5 >99 n.a. >99 n.a. >99 n.a. 
8 >99 n.a. >99 n.a. >99 n.a. 
24 >99 n.a. >99 n.a. >99 n.a. 
5b 
0 1.87 ± 0.30 n.d. 1.99 ± 0.21 n.d. 1.67 ± 0.21 n.d. 
0.5 28.97 ± 0.87 n.d. 18.32 ± 0.40 n.d. 3.69 ± 0.33 n.d. 
1 51.59 ± 3.32 n.d. 37.14 ± 0.93 n.d. 9.25 ± 0.31 n.d. 
3 80.00 ± 9.23 n.d. 86.51 ± 4.62 n.d. 24.14 ± 2.33 n.d. 
5 95.71 ± 4.72 91.26 ± 1.80 (R) 96.29 ±1.78 51.12 ± 0.18 (R) 40.61 ± 1.30 93.15 ± 0.66 (S) 
8 99.32 ± 6.35 93.02 ± 0.07 (R) 98.06 ± 3.63 50.79 ± 0.16 (R) 54.75 ± 2.45 95.32 ± 0.17 (S) 
24 91.51 ± 6.71 93.02 ± 0.15 (R) 94.18 ± 4.14 50.71 ± 0.09 (R) 79.42 ± 4.75 94.89 ± 0.06 (S) 
5c 
0 - n.d. - n.d. - n.d. (S) 
0.5 - n.d. - n.d. - n.d. (S) 
1 - n.d. - n.d. - n.d. (S) 
3 - n.d. - n.d. 3.22 ± 0.14 n.d. (S) 
5 - n.d. - n.d. 5.69 ± 0.83 n.d. (S) 
8 - n.d. - n.d. 9.62 ± 0.85 n.d. (S) 
24 - n.d. - n.d. 14.82 ± 0.75 n.d. (S) 
30 - n.d. - n.d. 17.44 ± 0.33 n.d. (S) 
48 - n.d. - n.d. 28.09 ± 4.94 n.d. (S) 
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Figure S11: Chiral HPLC traces for the separation of the enantiomers of product 6b to determine the enantiomeric excess in IRED 
catalyzed whole cell biotransformations. Blue: Biotransformation with R-IRED-Sr; red: Biotransformation with R-IRED-St and 
green: Biotransformation with S-IRED-Pe. Enantiomeric excess values are given in Table S3. Assignment of the enantiomers was 
done as described by Leipold et al..143 IS = internal standard. 
 
 
Figure S12: Consumption of substrate 5c by E. coli JW5510 cells harboring an empty pBAD33 plasmid. These cells were used 
as control for IRED catalyzed whole cell biotransformations and the mock biotransformation performed in triplicates. The error 
bars in Figure S12 represent the standard deviation of the triplicate. About 20% of the substrate is consumed (or could not be 
recovered from the complex biological sample), but no formation of product 6c was observed. Negative controls for the other 
imine substrates did not show any substrate consumption.  
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7.2.2 Biotransformations with purified IREDs and GC/HPLC-traces for 
determination of product formations and determination of the enantiomeric 
excess in these biotransformations 
 
Table S4: Reduction of imine 7 to amine 8 by purified IREDs. Hydrolysis of 7 generates aldehyde 11 which further reacted to 13 
and 14. For details see main text. The biotransformations were performed in triplicates with purified proteins from the same 
purification batch. The values in this table give the average of such a triplicate and the error represents the standard deviation. 
Negative controls were performed with heat inactivated proteins and did not result in any product formation. -: not detected.  
 
IRED time [h] 
substrate consumption [%] and product formation [%] 
7 8 11 13 14 
R
-I
R
E
D
-S
r 
0 54.15 ± 1.19 - 45.85 ± 1.11 - - 
0.5 48.50 ± 1.28 6.45 ± 0.19 42.29 ± 2.67 2.76 ± 0.23 - 
1 45.73 ± 1.36 9.81 ± 0.26 40.03 ± 1.54 4.44 ± 0.16 - 
3 34.96 ± 0.59 22.77 ± 0.84 29.54 ± 0.49 12.73 ± 0.86 - 
5 23.40 ± 0.24 30.69 ± 0.92 19.43 ± 0.23 21.64 ± 1.14 4.84 ± 0.47 
8 12.13 ± 0.49 37.61 ± 0.85 8.95 ± 0.51 33.26 ± 1.95 8.04 ± 0.52 
24 - 42.01 ± 0.92 - 46.22 ± 1.95 11.77 ± 0.15 
R
-I
R
E
D
-S
t 
0 52.87 ± 0.09 - 47.13 ± 2.43 - - 
0.5 48.70 ± 0.30 6.02 ± 0.25 45.28 ± 1.49 - - 
1 47.33 ± 0.28 8.26 ± 0.29 44.41 ± 2.39 - - 
3 42.31 ± 0.82 15.26 ± 0.09 40.00 ± 1.53 2.43 ± 0.39 - 
5 38.21 ± 1.05 21.30 ± 0.42 37.66 ± 0.65 2.83 ± 0.09 - 
8 33.59 ± 0.18 29.31 ± 0.86 33.79 ± 0.96 3.30 ± 0.10 - 
24 18.87 ± 0.37 56.67 ± 0.36 20.11 ± 0.69 4.35 ± 0.23 - 
S
-I
R
E
D
-P
e
 
0 51.80 ± 1.65 - 48.20 ± 3.14 - - 
0.5 52.27 ± 1.29 - 47.73 ± 0.92 - - 
1 52.54 ± 1.02 - 47.46 ± 1.39 - - 
3 51.23 ± 0.86 4.22 ± 0.37 44.56 ± 0.67 - - 
5 50.48 ± 1.52 5.50 ± 0.34 44.01 ± 2.60 - - 
8 50.02 ± 1.68 7.19 ± 0.28 42.79 ± 2.46 - - 
24 44.08 ± 1.39 13.92 ± 0.51 38.18 ± 1.77 3.83 ± 0.55 - 
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Figure S13: Exemplary GC-traces overlay for the reduction of imine 7 to amine 8. The samples after 0 h (black), 1 h (pink), 8 h 
(blue) and 24 h (brown) for the reaction catalyzed by purified R-IRED-Sr are shown. The hydrolysis product 11 further reacted to 
13 (benzylalcohol) and 14 (benzylamine). For details see the main text.  
 
Table S5: Reduction of imine 9 to amine 10 by purified IREDs. Hydrolysis of 9 generates aldehyde 11 and amine 12. Aldehyde 11 
further reacted to 13 and 14. For details see main text. The biotransformations were performed in triplicates with purified proteins 
from the same purification batch. The values in this table give the average of such a triplicate and the error represents the standard 
deviation. Negative controls were performed with heat inactivated proteins and did not result in any product formation. -: not 
detected.  
 
IRED time [h] 
substrate consumption [%] and product formation [%] 
9 10 11 12 13 14 
R
-I
R
E
D
-S
r 
0 87.35 ± 5.29 - 12.65 ± 0.51 10.18 ± 0.33 - - 
0.5 36.84 ± 5.76 0.68 ± 0.03 56.96 ± 3.41 51.49 ± 2.50 3.73 ± 0.38 1.80 ± 0.18 
1 9.43 ± 1.79 0.91 ± 0.11 77.97 ± 3.83 76.69 ± 1.50 9.07 ± 0.60 2.61 ± 0.20 
3 15.40 ± 1.91 3.58 ± 0.64 57.87 ± 2.79 72.33 ± 3.30 19.93 ± 1.08 3.21 ± 0.19 
5 4.05 ± 0.96 3.17 ± 0.71 53.65 ± 2.62 88.80 ± 3.01 34.56 ± 2.44 4.56 ± 0.32 
8 4.08 ± 0.66 4.81 ± 0.79 39.87 ± 3.05 87.07 ± 3.36 45.77 ± 1.42 5.47 ± 0.12 
24 1.94 ± 0.43 6.49 ± 2.65 19.84 ± 4.55 87.14 ± 6.33 64.14 ± 2.77 7.59 ± 0.46 
R
-I
R
E
D
-S
t 
0 86.27 ± 1.62 0.79 ± 0.05 12.94 ± 0.25 11.36 ± 0.03 - - 
0.5 35.43 ± 4.71 9.75 ± 0.18 53.07 ± 0.78 47.77 ± 0.95 0.34 ± 0.03 1.41 ± 0.17 
1 7.94 ± 1.09 11.89 ± 0.42 76.54 ± 4.17 71.06 ± 3.66 1.68 ± 0.04 1.96 ± 0.07 
3 16.86 ± 0.31 33.90 ± 1.63 44.68 ± 1.61 43.08 ± 1.42 2.73 ± 0.10 1.83 ± 0.05 
5 4.58 ± 1.34 34.03 ± 4.86 51.75 ± 2.03 57.42 ± 1.94 6.50 ± 0.27 3.15 ± 0.13 
8 5.90 ± 2.59 56.39 ± 11.54 29.17 ± 4.10 33.13 ± 6.38 5.85 ± 1.26 2.69 ± 0.64 
24 1.65 ± 0.28 67.00 ± 13.99 16.56 ± 2.33 25.60 ± 2.74 10.49 ± 0.82 4.30 ± 0.39 
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Figure S14: Graphical representation of the R-IRED-Sr catalyzed biotransformation of imine 9 (dark blue) to amine 10 (red). 
R-IRED-Sr was selected for presentation as in this biotransformation the formation of the byproducts is better visualized than with 
R-IRED-St. The hydrolysis product aniline 12 (green) can react back to form the substrate 9, but the aldehyde 11 (purple) can 
also be further reduced to alcohol 13 (light blue) and reductively aminated to amine 14 (orange).  
 
 
Figure S15: Exemplary HPLC traces for the reduction of imine 9 to amine 10. The reduction catalyzed by purified R-IRED-St 
over 24 h is shown as with this enzyme the formation of product 10 is more pronounced than with R-IRED-Sr. Next to the substrate 
and product also the hydrolysis products (aldehyde 11 and amine 12) and the byproducts (alcohol 13 and amine 14) were 
detected. For a more detailed explanation see main text. The UV signal at 220 nm was used for generation of this Figure as it 
provides in general the highest sensitivity, however note that not all substances have their absorbance maxima at this wavelength. 
Quantification was done at the maximum specific absorbance wavelength. IS = internal standard.  
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Table S6: Full dataset for the formation of benzhydrylamine 16 and the hydrolytic byproduct benzophenone 17 in [%] in a 
biotransformation with purified R-IRED-Sr. For the negative control, the IRED was heat inactivated by treatment at 95 °C for 10 
min. All reactions were performed in triplicates with purified proteins from the same purification batch. The values in this table give 
the average of such a triplicate and the errors represent the standard deviation. Further reduction of 17 to the alcohol was not 
observed. -: not detected.  
 
 product formation [%] 
time [h] 
R-IRED-Sr negative control 
16 17 16 17 
0 - 3.98 ± 0.10 - 3.22 ± 0.34 
0.5 21.60 ± 0.72 21.11 ± 0.32 - 29.20 ± 0.70 
1 34.22 ± 0.98 30.91 ± 0.42 - 45.32 ± 0.19 
3 47.56 ± 0.37 40.75 ± 1.78 - 76.90 ± 2.35 
5 48.71 ± 0.15 41.92 ± 1.41 - 84.78 ± 4.02 
8 49.46 ± 0.24 42.49 ± 1.66 - 81.43 ± 1.27 
24 52.55 ± 2.94 45.84 ± 1.55 - 88.48 ± 2.64 
 
 
Figure S16: Time course for the reduction and the hydrolysis of 10 mM benzophenoneimine 15 to the amine product 16 and the 
ketone 17 in a biotransformation with purified R-IRED-Sr. The biotransformation was performed in triplicates with purified protein 
of the same purification batch. Values in Figure S16 give the average of the triplicate and the error bars represent the standard 
deviation. The pure hydrolysis to ketone 17, visible in the negative control with heat inactivated R-IRED-Sr is shown in Figure S17.  
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Figure S17: Time course for the hydrolysis of 10 mM benzophenoneimine 15 to the ketone 17 in a mock biotransformation with 
heat inactivated R-IRED-Sr. The control reaction was done in triplicates and the error bars represent the standard deviation.  
 
 
Figure S18: Exemplary HPLC traces for the reduction of imine 15 to amine 16 catalyzed by purified R-IRED-Sr over 24 h. Next to 
the substrate and product also the hydrolysis product, ketone 17 was detected. The UV signal at 220 nm was used for generation 
of this Figure as it provides in general the highest sensitivity, however note that not all substances have their absorbance maxima 
at this wavelength. Quantification was done at the maximum specific absorbance wavelength. IS = internal standard. 
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Table S7: Product formations and stereoselectivities in [%] for the reduction of 18 to amine product 19 by (R)- selective IREDs. 
Imine substrate 18 hydrolyzes to the byproducts 12 and 20. Further reduction of 20 to 1-phenylethanol was not observed or is 
below the detection limit. The biotransformations were performed in triplicates with purified proteins from the same purification 
batch. The values in this table give the average of such a triplicate and the errors represent the standard deviation. Negative 
controls were performed with heat inactivated proteins and did not result in any product formation. -: not detected; n.d.: not 
determined.  
 
IRED time [h] 
substrate consumption [%] and product formation [%] 
ee [%] of 19 
18 19 20 12 
R
-I
R
E
D
-S
r 
0 82.30 ± 6.05 - 1.05 ± 0.06 1.01 ± 0.06 n.d. 
0.5 54.61 ± 6.61 - 1.92 ± 0.13 2.00 ± 0.15 n.d. 
1 65.77 ± 11.04 - 3.36 ± 0.15 3.55 ± 0.14 n.d. 
3 43.51 ± 11.30 1.48 ± 0.23 8.60 ± 0.27 9.59 ± 0.28 n.d. 
5 23.20 ± 7.20 2.56 ± 0.96 13.42 ± 0.73 14.97 ± 0.29 91.81 ± 1.57 (R) 
8 19.85 ± 6.65 2.82 ± 0.35 20.81 ± 0.78 24.62 ± 0.44 90.39 ± 2.85 (R) 
24 50.35 ± 17.44 10.18 ± 5.65 38.17 ± 2.47 38.28  ± 0.86 94.24 ± 0.50 (R) 
R
-I
R
E
D
-S
t 
0 59.07 ± 7.78 - 0.63 ± 0.06 0.57 ± 0.06 n.d. 
0.5 54.61 ± 6.61 - 1.92 ± 0.13 2.00 ± 0.15 n.d. 
1 37.19 ± 4.35 21.32 ± 1.08 2.67 ± 0.09 2.78 ± 0.13 n.d. 
3 19.30 ± 3.87 47.71 ± 2.57 5.46 ± 0.33 5.65 ± 0.34 n.d. 
5 5.89 ± 1.57 49.51 ± 4.27 6.39 ± 0.32 6.83 ± 0.41 88.62 ± 0.06 (R) 
8 1.65 ± 0.87 30.22 ± 4.02 7.92 ± 0.42 8.74 ± 0.64 88.23 ± 0.25 (R) 
24 13.44 ± 5.68 83.85 ± 20.47 9.76 ± 2.06 7.96 ± 1.52 87.75 ± 0.33 (R) 
 
 
Figure S19: Chiral HPLC traces for the separation of the enantiomers of product 19 to determine the enantiomeric excess in 
biotransformations with purified R-IREDs. Blue: racemic-19. Red: Biotransformation with R-IRED-Sr; green: Biotransformation 
with R-IRED-St. Enantiomeric excess values are given in Table S7. Assignment of the enantiomers was done as described in 
literature.195–197 As the substrate (imine 18) at high concentrations overlaps with the (S)- enantiomer of the product it was 
hydrolyzed by the addition of acidic Et2O (2 M HCl in Et2O), followed by a washing procedure to remove parts of aniline 12, which 
shows higher water solubility than ketone 20. For the analysis of the sample on HPLC the compounds had to be extracted again 
into an organic solvent, requiring a pH shift to > 14, leading to the potential partial reformation of the imine. By this procedure the 
fraction of imine 18 was reduced and the ratio of 12:20 increased towards the ketone. IS = internal standard. 
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Table S8: Reduction of cinnamaldehyde 45 to 3-phenylpropanal 46 by purified R-IRED-St and formation of the alcohol 
byproduct 46 in [%]. Product formation with the other two IREDs was found to be in the range of 3-5% in 24 h. All 
biotransformations were performed in triplicates with purified proteins from the same purification batch. The values in this table 
give the average of such a triplicate and the errors represent the standard deviation. Negative controls were performed with heat 
inactivated proteins and did not result in any product formation. -: not detected.  
 
 product formation [%] 
time [h] 
R-IRED-St 
46 47 
0 - - 
0.5 0.74 ± 0.06 1.21 ± 0.11 
1 1.55 ± 0.15 1.24 ± 0.11 
3 4.95 ± 0.30 1.94 ± 0.69 
5 7.89 ± 0.54 2.30 ± 1.48 
8 11.18 ± 0.58 3.49 ± 0.79 
24 15.83 ± 0.95 3.56 ± 1.00 
 
 
Figure S20: Exemplary GC-traces for the reduction of the activated C=C double bond in 45 to aldehyde 46 and formation of the 
alcohol byproduct. The samples after 0 h (black), 1 h (pink), 8 h (blue) and 24 h (brown) for the reaction catalyzed by purified 
R-IRED-St are shown. IS = internal standard. 
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7.3 Characterization of the IREDs 
7.3.1 Thermostability 
 
 
Figure S21: Specific activities for the reduction of 1 in [%] to determine the half-life time of R-IRED-Sr for incubation at 30 °C. 
Activities were determined in triplicates and the errors give the standard deviation. The decreasing activities were fitted to an 
exponential decay function of the formula A=A0*e
-λ*t with A0 representing the specific activity at t = 0 h. 
 
 
Figure S22: Specific activities for the reduction of 1 in [%] to determine the half-life time of S-IRED-Pe for incubation at 50 °C. 
Activities were determined in triplicates and the errors give the standard deviation. The decreasing activities were fitted to an 
exponential decay function of the formula A=A0*e
-λ*t with A0 representing the specific activity at t = 0 h.  
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Figure S23: Specific activities for the reduction of 1 in [U/mg] with R-IRED-Sr after incubation at different temperatures for 15 min. 
Activities were determined in triplicates and the errors give the standard deviation. Activities were fitted to a sigmoidal dose-
response curve to determine the T50
  15
. Using the above shown data R-IRED-Sr displayed 50% residual activity when incubated 
at 38.81 °C for a period of 15 min.  
 
 
Figure S24: Specific activities for the reduction of 1 in [U/mg] with R-IRED-St after incubation at different temperatures for 15 min. 
Activities were determined in triplicates and the errors give the standard deviation. Activities were fitted to a sigmoidal dose-
response curve to determine the T50
  15
. Using the above shown data R-IRED-St displayed 50% residual activity when incubated 
at 38.24 °C for a period of 15 min. 
 
 
Figure S25: Specific activities for the reduction of 1 in [U/mg] with S-IRED-Pe recorded at different temperatures. Activities were 
determined in triplicates and the errors give the standard deviation. The maximum activity was found at around 65 °C, followed 
by a rapid loss due to the denaturation of the enzyme. An incrase of about 10 °C resulted in an approximate doubling of the 
reaction rate.   
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7.3.2 Specific activities of the IREDs in the presence of different water miscible 
organic solvents 
 
Table S9: Specific activities in [U/mg] of the three IREDs in the presence of varying (5%-25%) concentrations of water miscible 
organic solvents. All activities were determined in triplicates by photometrically monitoring the decrease of the NADPH absorbance 
for the reduction of 5 mM substrate 1. The solvents tested were: methanol (MeOH), ethanol (EtOH), isopropyl alcohol (iProp), 
acetonitrile (ACN), dimethyl sulfoxide (DMSO), glycerol, acetone and tert-butyl alcohol (t-BuOH). The specific activities of these 
IRED preparations in the solvent free reference system (50 mM NaPi buffer pH 7.0) were for R-IRED-Sr: 3.43 ± 0.02 U/mg, for 
R-IRED-St: 0.97 ± 0.02 U/mg and for S-IRED-Pe: 39.86 x 10-3 ± 1.30 x 10-3 U/mg. -: not detected.  
solvent solvent [%] 
specific activity [U/mg] 
R-IRED-Sr R-IRED-St S-IRED-Pe 
MeOH 
5 % 2.06 ± 0.05 0.52 ± 0.03 48.67 x 10-3 ± 1.68 x 10-3 
10 % 1.44 ± 0.03 0.37 ± 0.02 47.08 x 10-3 ± 2.57 x 10-3 
15 % 0.74 ± 0.11 0.29 ± 0.02 39.30 x 10-3 ± 1.08 x 10-3 
20 % 0.32 ± 0.03 0.20 ± 0.02 40.09 x 10-3 ± 1.11 x 10-3 
25 % 0.11 ± 0.02 0.11 ± 0.02 25.86 x 10-3 ± 0.52 x 10-3 
EtOH 
5 % 0.79 ± 0.05 0.23 ± 0.01 21.82 x 10-3 ± 0.82 x 10-3 
10 % 0.40 ± 0.01 0.10 ± 0.00 14.78 x 10-3 ± 0.29 x 10-3 
15 % 0.09 ±0.01 0.05 ± 0.00 10.22 x 10-3 ± 0.05 x 10-3 
20 % 0.08 ± 0.00 0.06 ± 0.00 11.61 x 10-3 ± 0.69 x 10-3 
25 % - 0.03 ± 0.02 4.83 x 10-3 ± 0.30 x 10-3 
iProp 
5 % 0.38 ± 0.02 0.13 ± 0.01 9.03 x 10-3 ± 0.71 x 10-3 
10 % 0.11 ± 0.00 0.06 ± 0.01 4.75 x 10-3 ± 0.19 x 10-3 
15 % - 0.03 ± 0.00 1.93 x 10-3 ± 0.18 x 10-3 
20 % - 0.02 ± 0.00 1.26 x 10-3 ± 0.06 x 10-3 
25 % - - 0.90 x 10-3 ± 0.47 x 10-3 
ACN 
5 % 1.06 ±0.05 0.27 ± 0.01 15.92 x 10-3 ± 0.31 x 10-3 
10 % 0.26 ± 0.02 0.13 ± 0.01 9.80 x 10-3 ± 0.66 x 10-3 
15 % - 0.03 ± 0.01 4.76 x 10-3 ± 0.38 x 10-3 
20 % - 0.04 ± 0.03 3.22 x 10-3 ± 0.34 x 10-3 
25 % - - 1.97 x 10-3 ± 0.17 x 10-3 
DMSO 
5 % 1.83 ± 0.06 0.38 ± 0.02 25.06 x 10-3 ± 1.64 x 10-3 
10 % 1.34 ± 0.08 0.26 ± 0.01 14.60 x 10-3 ± 2.25 x 10-3 
15 % 0.74 ± 0.03 0.18 ± 0.00 6.92 x 10-3 ± 0.41 x 10-3 
20 % 0.46 ± 0.03 0.12 ± 0.00 4.02 x 10-3 ± 0.22 x 10-3 
25 % 0.30 ± 0.09 0.06 ± 0.00 2.08 x 10-3 ± 0.18 x 10-3 
glycerol 
5 % 2.72 ± 0.12 0.56 ± 0.01 41.51 x 10-3 ± 0.79 x 10-3 
10 % 2.36 ± 0.26 0.49 ± 0.02 38.06 x 10-3 ± 1.57 x 10-3 
15 % 1.61 ± 0.10 0.66 ± 0.05 30.40 x 10-3 ± 0.64 x 10-3 
20 % 1.55 ± 0.15 0.58 ± 0.03 28.55 x 10-3 ± 0.62 x 10-3 
25 % 0.73 ± 0.03 0.43 ± 0.03 25.01 x 10-3 ± 1.08 x 10-3 
acetone 
5 % 0.65 ± 0.05 0.23 ± 0.06 15.88 x 10-3 ± 0.87 x 10-3 
10 % 0.30 ± 0.03 0.13 ± 0.05 9.21 x 10-3 ± 0.94 x 10-3 
15 % 0.12 ± 0.02 0.05 ± 0.01 4.58 x 10-3 ± 0.54 x 10-3 
20 % 0.06 ± 0.02 0.03 ± 0.00 2.85 x 10-3 ± 0.18 x 10-3 
25 % - 0.01 ± 0.01 1.78 x 10-3 ± 0.42 x 10-3 
t-BuOH 
5 % 0.42 ± 0.19 0.12 ± 0.00 10.99 x 10-3 ± 0.29 x 10-3 
10 % 0.05 ± 0.04 0.04 ± 0.02 2.92 x 10-3 ± 0.35 x 10-3 
15 % - - 1.03 x 10-3 ± 0.04 x 10-3 
20 % - - 0.52 x 10-3 ± 0.18 x 10-3 
25 % - - 0.90 x 10-3 ± 0.00 x 10-3 
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7.3.3 HPLC-SEC runs for determination of the IRED purity 
 
 
Figure S26: HPLC-SEC analysis of R-IRED-Sr wild type. 5 µl of the protein diluted to a concentration of 2 µg/µl was injected. The 
purity of the IRED was calculated to be about 90.3%. The peak at 13.89 min indicates that R-IRED-Sr forms a dimer in solution, 
the peak at 18.4 min corresponds to the NADPH added for storage (see also Figure S33).  
 
 
Figure S27: HPLC-SEC analysis of R-IRED-St wild type. 5 µl of the protein diluted to a concentration of 2 µg/µl was injected. The 
purity of the IRED was calculated to be about 87.0%. The peak at 13.94 min indicates that R-IRED-St forms a dimer in solution, 
the peak at 18.4 min corresponds to the NADPH added for storage (see also Figure S33). 
 
 
Figure S28: HPLC-SEC analysis of S-IRED-Pe wild type. 5 µl of the protein diluted to a concentration of 2 µg/µl was injected. The 
purity of the IRED was calculated to be about 91.6%. The peak at 13.69 min indicates that S-IRED-Pe forms a dimer in solution, 
the peak at 18.4 min corresponds to the NADPH added for storage (see also Figure S33). 
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Figure S29: HPLC-SEC analysis of R-IRED-Sr D191A. 5 µl of the protein diluted to a concentration of 2 µg/µl was injected. The 
purity of the IRED was calculated to be about 89.0%. The peak at 13.88 min indicates that R-IRED-Sr D191A forms a dimer in 
solution, the peak at 18.4 min corresponds to the NADPH added for storage (see also Figure S33). 
 
 
Figure S30 HPLC-SEC analysis of R-IRED-St D193A wild type. 5 µl of the protein diluted to a concentration of 2 µg/µl was injected. 
The purity of the IRED was calculated to be about 89.4%. The peak at 13.91 min indicates that R-IRED-St D193A forms a dimer 
in solution, the peak at 18.4 min corresponds to the NADPH added for storage (see also Figure S33). 
 
 
Figure S31: HPLC-SEC analysis of R-IRED-Sr wild type. 5 µl of the protein diluted to a concentration of 2 µg/µl was injected. The 
purity of the IRED was calculated to be about 84.0%. The peak at 13.75 min indicates that R-IRED-Sr forms a dimer in solution, 
the peak at 18.4 min corresponds to the NADPH added for storage (see also Figure S33). Optimization of the Ni2+-NTA purification 
procedure yielded R-IRED-Sr with a purity of close to 90 % (Figure S26).  
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Figure S32: HPLC-SEC analysis of fraction B12 of the MonoQ purified R-IRED-Sr wild type. 5 µl of the protein diluted to a 
concentration of 2 µg/µl was injected. The purity of the IRED was calculated to be about 97.3%. The peak at 13.74 min indicates 
that R-IRED-Sr forms a dimer in solution, the peak at 18.4 min corresponds to the NADPH added for storage (see also Figure S33). 
Note the increase in purity from the R-IRED-Sr preparation in Figure S31 which was used for the ion-exchange chromatography.  
 
 
Figure S33: Injection of 5 µl NADPH solution (150 µM).  
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7.4 Michaelis-Menten plots of IREDs with cyclic imine substrates 3a to 3c and 5a 
to 5b 
 
 
Figure S34: Determination of kinetic constants for R-IRED-Sr with substrate 3a. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation. 
 
 
Figure S35: Determination of kinetic constants for R-IRED-St with substrate 3a. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation.  
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Figure S36: Determination of kinetic constants for S-IRED-Pe with substrate 3a. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation.  
 
 
Figure S37: Determination of kinetic constants for R-IRED-Sr with substrate 3b. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation.  
 
 
Figure S38: Determination of kinetic constants for R-IRED-St with substrate 3b. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation.  
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Figure S39: Determination of kinetic constants for S-IRED-Pe with substrate 3b. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation.  
 
 
Figure S40: Determination of kinetic constants for R-IRED-Sr with substrate 3c. All activities were determined in triplicates and 
the error bars show the standard deviation.  
 
 
Figure S41: Determination of kinetic constants for R-IRED-St with substrate 3c. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation.  
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Figure S42: Determination of kinetic constants for S-IRED-Pe with substrate 3c. All activities were determined in triplicates and 
the error bars show the standard deviation.  
 
 
Figure S43: Determination of kinetic constants for R-IRED-Sr with substrate 5a. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation.  
 
 
Figure S44: Determination of kinetic constants for R-IRED-St with substrate 5a. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation. 
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Figure S45: Determination of kinetic constants for S-IRED-Pe with substrate 5a. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation.  
 
 
Figure S46: Determination of kinetic constants for R-IRED-Sr with substrate 5b. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation.  
 
 
Figure S47: Determination of kinetic constants for R-IRED-St with substrate 5b. Due to lower activities at higher substrate 
concentrations, the Michaelis-Menten equation was adapted to substrate inhibition: v=(vmax×[S])/(KM+[S]×(1+([S]/KI))). All activities 
were determined in triplicates and the error bars show the standard deviation.  
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Figure S48: Determination of kinetic constants for S-IRED-Pe with substrate 5b. All activities were determined in triplicates and 
the error bars show the standard deviation.  
 
7.5 The reductive amination of aldehydes and ketones 
 
 
Scheme S1: reaction scheme for the formation of the dialkylation product 24 by the repeated reductive amination of 11.  
 
Table S10: Product formations in [%] for the reductive amination of benzaldehyde 11 with increasing equivalents of ammonia 21 
as nucleophile. All reactions were done with purified proteins of the same purification batch in triplicates at a pH of 8.0. Negative 
controls were performed with heat inactivated enzyme and did not show any product formation. The errors were calculated from 
the standard deviation. Formation of the imine intermediate might be overestimated as for the extraction the pH was raised. -: not 
detected. 
 
    
product formation [%] 
eq 
21 
1 10 50 1 10 50 1 10 50 1 10 50 
1 h - - < 0.5 
0.70 ± 
0.03 
6.36 ± 
0.11 
13.09 ± 
0.42 
- - - - - - 
3 h - 
5.04 ± 
0.40 
15.29 ± 
0.68 
3.81 ± 
0.02 
16.38 ± 
0.25 
22.53 ± 
0.25 
- - - < 0.5 - - 
5 h 
0.54 ± 
0.13 
12.04 ± 
0.44 
32.79 ± 
0.91 
5.07 ± 
0.18 
20.97 ± 
0.95 
19.58 ± 
0.48 
- - - 
1.58 ± 
0.04 
0.67 < 0.5 
8 h 
1.25 ± 
0.13 
21.43 ± 
0.28 
48.03 ± 
0.76 
6.11 ± 
0.09 
16.02 ± 
0.30 
4.69 ± 
0.26 
< 0.5 < 0.5 - 
2.55 ± 
0.04 
1.54 ± 
0.05 
0.77 ± 
0.02 
24 h 
6.60 ± 
0.25 
51.22 ± 
2.13 
60.66 ± 
1.12 
6.30 ± 
0.16 
2.35 ± 
0.11 
- 
2.18 ± 
0.06 
3.15 ± 
0.03 
< 0.5 
6.94 ± 
0.26 
4.78 ± 
0.18 
1.40 ± 
0.02 
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Figure S49: Time course for the reductive amination of 11 (blue) with 50-fold molar excess of amine nucleophile 21 by R-IRED-Sr. 
The biotransformation was performed in triplicates with purified protein. The initial formed product 14 (green) acts as an additional 
nucleophile leading to the formation of imine intermediate 23 (purple). 23 can be further reduced to the dialkylation product 24. 
Figure S49 illustrates the appearance and the disappearance of the intermediate 23. For a better overview the dialkylation 
product 24 and the formation of byproduct 13 (benzylalcohol) are not shown here.  
 
 
Figure S50: Overlay of chromatograms of the reductive amination of benzaldehyde 11 with ammonia 21 at 10-fold excess after 
0 h (blue), 1 h (pink) and 24 h (black). IS = internal standard. 
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Table S11: Product formations in [%] for the reductive amination of benzaldehyde 11 with different increasing equivalents of 
methylamine 22 as nucleophile. All reactions were done with purified proteins of the same purification batch in triplicates at a pH 
of 8.0. Negative controls were performed with heat inactivated enzyme and did not show any product formation. The errors were 
calculated from the standard deviation. Formation of the imine intermediate might be overestimated as for the extraction the pH 
was raised. -: not detected. 
eq 22 
   
product formation [%] 
1 10 50 1 10 50 1 10 50 
0 h 
55.49 ± 
2.10 
82.50 ± 
6.60 
80.95 ± 
1.73 
- - - - - - 
1 h 
41.60 ± 
0.83 
35.41 ± 
0.74 
10.87 ± 
1.24 
5.54 ± 
0.22 
32.82 ± 
0.56 
57.95 ± 
3.28 
- - - 
3 h 
29.38 ± 
2.16 
1.40 ± 
0.08 
- 
19.40 ± 
1.15 
67.23 ± 
2.21 
75.51 ± 
0.50 
< 0.5 - - 
5 h 
23.69 ± 
2.88 
- - 
30.67 ± 
4.29 
72.01 ± 
2.69 
70.89 ± 
3.18 
1.34 ± 
0.17 
- - 
8 h 
16.04 ± 
0.89 
- - 
34.64 ± 
1.29 
71.56 ± 
3.31 
73.33 ± 
3.80 
2.33 ± 
0.08 
- - 
24 h 
2.05 ± 
0.13 
- - 
51.18 ± 
2.75 
66.19 ± 
0.48 
68.98 ± 
4.08 
5.55 ± 
0.27 
- - 
 
 
Figure S51: Overlay of chromatograms of the reductive amination of benzaldehyde 11 with methylamine 22 at 10-fold excess after 
0 h (blue), 1 h (pink) and 24 h (black). IS = internal standard. 
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Figure S52: Time course for the formation of the amination product in the reductive amination reaction of 10 mM benzaldehyde 11 
with one equivalent of methylamine 22 as nucleophile at pH 8.0, catalyzed by R-IRED-Sr. All biotransformations were done with 
purified proteins of the same purification batch in triplicates. The errors were calculated from the standard deviation. Out of this 
data the turnover number is calculated to be 2.23 x 10-3 s-1. 
 
 
Figure S53: Time course for the formation of the amination product in the reductive amination reaction of 10 mM benzaldehyde 11 
with ten equivalents of methylamine 22 as nucleophile at pH 8.0, catalyzed by R-IRED-Sr. All biotransformations were done with 
purified proteins of the same purification batch in triplicates. The errors were calculated from the standard deviation. Out of this 
data the turnover number is calculated to be 7.77 x 10-3 s-1.  
 
Table S12: Product formations in [%] for the reductive amination of 10 mM benzaldehyde 11 with aniline 12 as nucleophile. All 
reactions were done with purified proteins of the same purification batch in triplicates at a pH of 8.0. Negative controls were 
performed with heat inactivated enzyme and did not show any product formation. The errors were calculated from the standard 
deviation. Formation of the imine intermediate might be overestimated as for the extraction the pH was raised. -: not detected.  
eq 12 
  
 
product formation [%] 
1 1 1 
0 h 2.46 ± 0.20 - - 
1 h 3.02 ± 0.21 4.06 ± 0.16 - 
3 h 2.91 ± 0.10 9.61 ± 0.33 - 
5 h 2.80 ± 0.09 15.08 ± 0.63 1.22 ± 0.03 
8 h 1.02 ± 0.09 13.44 ± 1.30 2.42 ± 0.6 
24 h - 24.97 ± 5.28 7.20 ± 0.45 
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Figure S54: Overlay of chromatograms of the reductive amination of benzaldehyde 11 with aniline 12 at equimolar concentrations 
monitored at 240 nm after 0 h (blue), 1 h (red) and 24 h (green). Due to its poor absorbance at this wavelength and the low 
amounts formed, the byproduct benzylalcohol is not visible in Figure S54. IS = internal standard. 
 
Table S13: Product formations and enantiomeric excess values in [%] for the reductive amination of 10 mM acetophenone 20 with 
ammonia 21 as nucleophile. All reactions were done with purified proteins of the same purification batch in triplicates at a pH of 
8.0, 8.5 and 9.0. The amine nucleophile was used at 50-fold excess in all cases. Negative controls were performed with heat 
inactivated enzyme and did not show any product formation. The errors were calculated from the standard deviation. Byproduct 
formation (reduction of the carbonyl to the alcohol) was detectable only in traces for all conditions. -: not detected; n.d.: not 
determined; [a]: reactions performed with 10 mg/ml R-IRED-Sr.  
 
pH 8.0 8.5 9.0 9.0[a] 
 
product 
[%] 
ee 
[%] 
product 
[%] 
ee 
[%] 
product 
[%] 
ee 
[%] 
product 
[%] 
ee 
[%] 
1 h - n.d. - n.d. - n.d. < 0.5 n.d. 
3 h - n.d. - n.d. < 0.5 n.d. 
0.87 ± 
0.02 
94.11 ± 
4.70 
5 h < 0.5 n.d. < 0.5 n.d. 
0.77 ± 
0.05 
n.d. 
2.28 ± 
0.06 
97.52 ± 
0.34 
8 h 
0.81 ± 
0.02 
91.22 ± 
8.57 
1.16 ± 
0.02 
96.48 ± 
0.37 
2.42 ± 
0.05 
96.85 ± 
0.21 
4.48 ± 
0.09 
97.67 ± 
0.25 
24 h 
5.45 ± 
0.03 
96.55 ± 
0.22 
7.09 ± 
0.07 
97.56 ± 
0.39 
10.12 ± 
0.06 
97.66 ± 
0.16 
15.82 ± 
0.66 
97.07 ± 
0.07 
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Figure S55: Overlay of chiral GC chromatograms for determination of the enantiomeric excess of 1-phenylethylamine 26 in 
biotransformations with R-IRED-Sr. Black: racemic 26 ((S)- enantiomer elutes first, assignment was done with commercially 
available reference material of (R)-26 and (S)-26); pink: biotransformation with R-IRED-Sr, 20 as substrate and 21 as nucleophile; 
blue: negative control (biotransformation with heat inactivated enzyme). Biotransformations with R-IRED-Sr produced (R)-26 with 
an enantiomeric excess of > 97%. 
 
 
Figure S56: Time course for formation of the amination product in the reductive amination reaction of acetophenone 20 with 
50 equivalents of ammonia 21 as nucleophile at pH 9.0 in the reactions catalyzed by 2.5 mg/ml R-IRED-Sr. All biotransformations 
were done with purified proteins of the same purification batch in triplicates. The errors were calculated from the standard 
deviation. Out of this data the turnover number is calculated to be 175 x 10-6 s-1.  
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Table S14: Product formations and enantiomeric excess values in [%] for the reductive amination of 10 mM acetophenone 20 with 
methylamine 22 as nucleophile. All reactions were done with purified proteins of the same purification batch in triplicates at a pH 
of 8.0, 8.5 and 9.0. The amine nucleophile was used at 50-fold excess in all cases. Negative controls were performed with heat 
inactivated enzyme and did not show any product formation. The errors were calculated from the standard deviation. Byproduct 
formation (reduction of the carbonyl to the alcohol), was detectable only in traces for all conditions. -: not detected; n.d.: not 
determined; [a]: reactions performed with 10 mg/ml R-IRED-Sr. 
 
pH 8.0 8.5 9.0 9.0[a] 
 
product 
[%] 
ee 
[%] 
product 
[%] 
ee 
[%] 
product 
[%] 
ee 
[%] 
product 
[%] 
ee 
[%] 
1 h - n.d. < 0.5 n.d. < 0.5 n.d. 
1.37 ± 
0.02 
n.d. 
3 h < 0.5 n.d. 
1.03 ± 
0.03 
n.d. 
1.70 ± 
0.11 
n.d. 
6.90 ± 
0.37 
86.33 ± 
1.64 
5 h 
1.13 ± 
0.03 
n.d. 
2.53 ± 
0.17 
n.d. 
3.38 ± 
0.09 
n.d. 
8.86 ± 
0.20 
86.83 ± 
0.23 
8 h 
2.75 ± 
0.02 
86.46 ± 
2.49 
4.68 ± 
0.06 
86.80 ± 
0.62 
6.49 ± 
0.16 
87.49 ± 
0.48 
13.83 ± 
0.32 
86.54 ± 
0.29 
24 h 
8.57 ± 
0.08 
86.70 ± 
0.37 
15.19 ± 
0.22 
86.33 ± 
0.33 
18.95 ± 
1.02 
86.31 ± 
0.12 
39.18 ± 
1.38 
86.64 ± 
0.04 
 
 
Figure S57: Overlay of chiral GC chromatograms for determination of the enantiomeric excess of N-α-dimethylbenzylamine 27 in 
biotransformations with R-IRED-Sr. Black: (R)-27; pink: (S)-27, blue biotransformation with R-IRED-Sr, 20 as substrate and 22 as 
nucleophile. Biotransformations with R-IRED-Sr produced (R)-27 with an enantiomeric excess of > 86%. 
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Figure S58: Time course for the formation of the amination product in the reductive amination reaction of acetophenone 20 with 
50 equivalents of methylamine 22 as nucleophile at pH 9.0 in the reactions catalyzed by 2.5 mg/ml R-IRED-Sr. All 
biotransformations were done with purified proteins of the same purification batch in triplicates. The errors were calculated from 
the standard deviation. Out of this data the turnover number is calculated to be 292 x 10-6 s-1. 
 
7.6 Michaelis-Menten plots of R-IRED-Sr for the kinetic characterization of the 
reductive amination of 11 with 22 
 
 
Figure S59: Overlay of the Michaelis-Menten plots for the reductive amination of 11 with different excess amounts of nucleophile 
22 at pH 8.0 with R-IRED-Sr. Conditions that shift the equilibrium towards imine 7 go along with a decreased KM app value, directly 
reflecting the relative amount of substrate the enzyme is exposed to. The apparent affinity at an equimolar concentration of 22 
was above the tested conditions and calculated to be 20.47 ± 5.67 mM (Table 29). 
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Figure S60: Michaelis-Menten plot for the reductive amination of 11 with equimolar concentration of nucleophile 22 with R-IRED-Sr 
at pH 8.0. All activities were determined in triplicates and the error bars show the standard deviation. 
 
 
Figure S61: Michaelis-Menten plot for the reductive amination of 11 with 10-fold molar excess of nucleophile 22 with R-IRED-Sr 
at pH 8.0. All activities were determined in triplicates and the error bars show the standard deviation.  
 
 
Figure S62: Michaelis-Menten plot for the reductive amination of 11 with 50-fold molar excess of nucleophile 22 with R-IRED-Sr 
at pH 8.0. All activities were determined in triplicates and the error bars show the standard deviation.  
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Figure S63: Michaelis-Menten plot for the reductive amination of 11 with equimolar concentration of nucleophile 22 with R-IRED-Sr 
at pH 9.0. All activities were determined in triplicates and the error bars show the standard deviation.  
 
 
Figure S64: Michaelis-Menten plot for the reductive amination of 11 with 10-fold molar excess of nucleophile 22 with R-IRED-Sr 
at pH 9.0. All activities were determined in triplicates and the error bars show the standard deviation.  
 
 
Figure S65: Michaelis-Menten plot for the reductive amination of 11 with 50-fold molar excess of nucleophile 22 with R-IRED-Sr 
at pH 9.0. All activities were determined in triplicates and the error bars show the standard deviation.  
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7.7 NMR experiments to determine the actual imine fraction and estimation of a 
“true” KM value 
 
NMR spectra to determine the actual imine concentration in the reductive amination reaction are shown 
in Figure 38. For a pH of 9.0 and 8.0 the Keq was calculated by the following formula (Keq=
[imine]
[aldehyde] [amine]
) 
using the known concentrations for the imine, the aldehyde and the amine. The following Keq were 
calculated from the concentrations derived from the NMR spectra.  
pH 9.0: Keq = 1.36 x 10-2 mM-1 
pH 8.0: Keq = 9.47 x 10-4 mM-1 
 
The calculated Keq were used to correct the imine concentrations in the Michaelis-Menten plots 
(Figure S65 for pH 9.0 and Figure S62 for pH 8.0). Nonlinear regression with the corrected imine 
concentrations resulted in “true” KM values of 0.447 mM for pH 9.0 and 0.081 mM for pH 8.0.  
 
7.8 Oxidation of polyamines by PuO-Re 
7.8.1 Analysis of PuO-Re reaction products by GC-MS headspace 
 
 
Figure S66: GC-MS headspace analysis of PuO-Re reaction products. To avoid misleading information about imine formation 
promoted by a change of the sample conditions due to extraction (high pH, organic solvent and derivatization), GC-MS HS was 
used for analysis. The purified enzyme (10 nM) was incubated with polyamines 1,4-diaminobutane 28 and 1,5-diaminopentane 29 
(each 10 mM) for 1 h at 30 °C and 180 rpm. Negative controls were done with previously heat inactivated PuO-Re. A spontaneous 
cyclization of the formed aminoaldehyde would result in cyclic imines that are much more volatile than the aldehyde or the 
polyamines and can be detected by GC-HS. GC-MS indicated that the formed peaks correspond to the cyclic imines 39 and 41 
resulting from the PuO-Re reaction. Note however that most of the cyclic imines do probably form trimers withstanding detection 
due to their too high boiling points.237,238  
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7.8.2 Activity of purified PuO-Re E324D 
 
Table S15: Specific activities in [U/mg] for PuO-Re E324D catalyzed oxidation of polyamine substrates 28, 29, 31 and 34 and the 
relative activity to the wild type enzyme in [%]. The activities of the wild type enzyme are shown in Table 30 and Table S16. 
substrate and # 
specific activity 
[U/mg] 
activity compared to 
wild type enzyme [%] 
 28 0.041 0.33 
 29 0.012 2.65 
 31 0.003 0.92 
 
34 0.008 0.30 
 
7.8.3 Purification of PuO-Re wt and mutants by ion exchange chromatography 
 
Figure S67: 10% SDS-PAGE of a typical Q-Sepharose HP purification of PuO-Re wt (calculated molecular weight 49.4 kDa) and 
various mutants. 10 µg total protein were loaded for each sample. The purifications yielded protein in about similar purity. 
M = molecular weight Marker (Fermentas PageRulerTM unstained protein ladder).  
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7.8.4 Activity of purified PuO-Re wt and PuO-Re mutants with polyamine substrates 
28 to 38 
 
 
Figure S68: Liquid phase assay with PuO-Re wt, E203G mutant and L207V mutant for the oxidation of polyamines 28 to 38. The 
red color originates from aminoantipyrine and vanillic acid that are converted to a quinoneimine dye by H2O2 and HRP.
187 After 
determining the initial activities in the plate reader, the 96 well plate was stored overnight at room temperature. On the next day 
the picture was taken. As some of the reactions have gone to completion, the color differences are after overnight storage not 
always directly transferable to differences in the activity. Nevertheless for certain substrates the color formation illustrates very 
well the activity increase of the mutants, as it is most pronounced visible for polyamine 33.  
 
Table S16: Specific activities in [U/mg] of purified PuO-Re wt and variants with polyamine substrates 28 to 38. All activities were 
determined in triplicates with 10 mM polyamine substrate by monitoring the formation of the enzymatic byproduct H2O2 in a coupled 
spectrophotometric assay with HRP. The enzyme concentrations in the assay were adjusted according to the activity of the 
polyamine. 1 nM to 4 µM purified PuO-Re wt or mutant were used per reaction. -: not detected.  
 specific activity [U/mg] PuO-Re variant 
polyamine 
substrate # 
wt E203G E203S V201S E203G L207V 
28 
12.28 ± 
0.33 
33.80 ± 
1.52 
18.21 ± 
1.06 
15.20 ± 
1.90 
14.30 ± 
0.93 
29 
0.45 ± 
0.04 
3.32 ± 
0.19 
2.16 ± 
0.18 
2.34 ± 
0.07 
2.07 ± 
0.05 
30 
87.36 x 10-3 ± 
2.64 x 10-3 
0.37 ± 
0.02 
0.29 ± 
0.01 
0.25 ± 
0.00 
0.16 ± 
0.00 
31 
0.33 ± 
0.04 
1.04 ± 
0.09 
0.66 ± 
0.10 
0.98 ± 
0.02 
0.46 ± 
0.02 
32 
65.62 x 10-3 ± 
3.94 x 10-3 
1.02 ± 
0.02 
0.98 ± 
0.01 
0.55 ± 
0 02 
0.17 ± 
0.01 
33 
3.75 x 10-3 ± 
0.99 x 10-3 
97.75 x 10-3 ± 
3.89 x 10-3 
59.28 x 10-3 ± 
7.78 x 10-3 
51.39 x 10-3 ± 
1.88 x 10-3 
6.76 x 10-3 ± 
0.12 x 10-3  
34 
2.63 ± 
0.07 
9.88 ± 
0.34 
5.08 ± 
0.77 
3.38 ± 
0.03 
1.43 ± 
0.02 
35 
8.13 x 10-3 ± 
0.28 x 10-3 
28.39 x 10-3 ± 
0.57 x 10-3 
11.57 x 10-3 ± 
1.63 x 10-3 
20.25 x 10-3 ± 
1.65 x 10-3 
49.09 x 10-3 ± 
1.42 x 10-3 
36 
22.59 x 10-3 ± 
1.18 x 10-3 
13.03 x 10-3 ± 
0.45 x 10-3 
10.93 x 10-3 ± 
1.63 x 10-3 
7.92 x 10-3 ± 
0.54 x 10-3 
37.61 x 10-3 ± 
0.74 x 10-3 
37 
9.18 x 10-3 ± 
0.21 x 10-3 
38.77 x 10-3 ± 
2.26 x 10-3 
17.06 x 10-3 ± 
0.27 x 10-3 
31.17 x 10-3 ± 
3.12 x 10-3 
21.22 x 10-3 ± 
1.24 x 10-3 
38 
5.36 x 10-3 ± 
5.22 x 10-3 
7.59 x 10-3 ± 
2.55 x 10-3 
4.67 x 10-3 ± 
9.96 x 10-3 
0.49 x 10-3 ± 
4.37 x 10-3 
38.83 x 10-3 ± 
8.14 x 10-3 
 
 
 
 
7 SUPPORTING INFORMATION 
176 
Table S16: continued.  
 specific activity [U/mg] PuO-Re variant 
polyamine 
substrate # 
V201A E203P D104L L168S F169Q V201A E203G A24T V201A E203M 
28 
13.72 ± 
0.11 
9.73 ± 
1.38 
3.71 ± 
1.30 
22.87 ± 
1.31 
9.64 ± 
0.51 
29 
1.27 ± 
0.03 
86.52 x 10-3 ± 
72.15 x 10-3 
0.84 ± 
0.29 
2.51 ± 
0.26 
1.36 ± 
0.01 
30 
0.19 ± 
0.00 
53.11 x 10-3 ± 
1.55 x 10-3 
0.15 ± 
0.02 
0.32 ± 
0.02 
0.17 ± 
0.01 
31 
0.48 ± 
0.08 
82.64 x 10-3 ± 
23.63 x 10-3 
0.43 ± 
0.29 
0.73 ± 
0.11 
0.43 ± 
0.04 
32 
0.41 ± 
0.02 
86.27 x 10-3 ± 
5.30 x 10-3 
21.25 x 10-3 ± 
11.89 x 10-3 
0.76 ± 
0.01 
0.64 ± 
0.01 
33 
53.21 x 10-3 ± 
1.31 x 10-3 
0.07 x 10-3 ± 
2.88 x 10-3 
- 
70.07 x 10-3 ± 
4.59 x 10-3 
51.08 x 10-3 ± 
3.38 x 10-3 
34 
0.11 ± 
0.01 
0.74 ± 
0.14 
1.80 ± 
0.17 
4.79 ± 
0.49 
0.46 ± 
0.25 
35 
8.69 x 10-3 ± 
0.31 x 10-3 
2.76 x 10-3 ± 
0.20 x 10-3 
4.35 x 10-3 ± 
0.33 x 10-3 
20.72 x 10-3 ± 
0.90 x 10-3 
14.99 x 10-3 ± 
0.56 x 10-3 
36 
9.29 x 10-3 ± 
0.87 x 10-3 
15.32 x 10-3 ± 
0.82 x 10-3 
7.26 x 10-3 ± 
2.52 x 10-3 
12.31 x 10-3 ± 
2.91 x 10-3 
8.65 x 10-3 ± 
0.38 x 10-3 
37 
16.73 x 10-3 ± 
0.53 x 10-3 
4.82 x 10-3 ± 
0.17 x 10-3 
13.16 x 10-3 ± 
0.47 x 10-3 
42.19 x 10-3 ± 
0.76 x 10-3 
14.84 x 10-3 ± 
0.25 x 10-3 
38 
4.37  x 10-3 ± 
4.50 x 10-3 
9.28 x 10-3 ± 
6.86 x 10-3 
- - - 
 
7.9 Michaelis-Menten plots of putrescine oxidase wild type and mutants 
 
 
Figure S69: Determination of kinetic constants for PuO-Re wild type with substrate 28. All activities were determined in triplicates 
and the error bars show the standard deviation.  
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Figure S70: Determination of kinetic constants for PuO-Re wild type with substrate 29. All activities were determined in triplicates 
and the error bars show the standard deviation. 
 
 
Figure S71: Determination of kinetic constants for PuO-Re wild type with substrate 31. All activities were determined in triplicates 
and the error bars show the standard deviation. 
 
 
Figure S72: Determination of kinetic constants for PuO-Re wild type with substrate 34. All activities were determined in triplicates 
and the error bars show the standard deviation. 
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Figure S73: Determination of kinetic constants for PuO-Re wild type with substrate 36. All activities were determined in triplicates 
and the error bars show the standard deviation. 
 
 
Figure S74: Determination of kinetic constants for PuO-Re E203G with substrate 28. All activities were determined in triplicates 
and the error bars show the standard deviation. 
 
 
Figure S75: Determination of kinetic constants for PuO-Re E203G with substrate 29. All activities were determined in triplicates 
and the error bars show the standard deviation. 
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Figure S76: Determination of kinetic constants for PuO-Re E203G with substrate 31. All activities were determined in triplicates 
and the error bars show the standard deviation. 
 
 
Figure S77: Determination of kinetic constants for PuO-Re E203G with substrate 34. All activities were determined in triplicates 
and the error bars show the standard deviation. 
 
 
Figure S78: Determination of kinetic constants for PuO-Re E203G with substrate 36. All activities were determined in triplicates 
and the error bars show the standard deviation. 
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Figure S79: Determination of kinetic constants for PuO-Re I154V E203V with substrate 28. All activities were determined in 
triplicates and the error bars show the standard deviation. 
 
 
Figure S80: Determination of kinetic constants for PuO-Re I154V E203V with substrate 29. All activities were determined in 
triplicates and the error bars show the standard deviation. 
 
 
Figure S81: Determination of kinetic constants for PuO-Re I154V E203V with substrate 31. All activities were determined in 
triplicates and the error bars show the standard deviation. 
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7.10 GC-traces of the cascade reaction with purified proteins to transform 
polyamines into N-heterocycles 
 
 
Figure S82: Conversion of polyamine 28 to the cyclic amine product 40 by the combination of purified PuO-Re and R-IRED-Sr. In 
the reaction with both enzymes being active (black) the substrate is fully consumed in the 3 h reaction time and transformed to 
the product 40. After inactivation of one of the enzymes (R-IRED-Sr inactivated in pink or PuO-Re inactivated in blue) either the 
polyamine is not converted (blue) or the imine intermediate 39 (pink) could be detected. It is assumed that most of the imine 
intermediate forms a trimer. Due to its too high boiling point, the trimer cannot be detected. IS = internal standard.  
 
 
Figure S83: Conversion of polyamine 29 to the cyclic amine product 42 by the combination of purified PuO-Re and R-IRED-Sr. In 
the reaction with both enzymes being active (black) the substrate is fully consumed in the 3 h reaction time and transformed to 
the product 42. After inactivation of one of the enzymes (R-IRED-Sr inactivated in pink or PuO-Re inactivated in blue) either the 
polyamine is not converted (blue) or small amounts of the imine intermediate (pink) could be detected. It is assumed that most of 
the imine intermediate forms a trimer. Due to its too high boiling point, the trimer cannot be detected. IS = internal standard.  
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Figure S84: Conversion of polyamine 28 to the cyclic amine product 40 by the combination of purified PuO-Re and R-IRED-St. In 
the reaction with both enzymes being active (black) the substrate is fully consumed in the 3 h reaction time and transformed to 
small amounts of product 40. After inactivation of one of the enzymes (R-IRED-St inactivated in pink or PuO-Re inactivated in 
blue) either the polyamine is not converted (blue) or the imine intermediate 39 (pink) could be detected. It is assumed that most 
of the imine intermediate forms a trimer. Due to its too high boiling point, the trimer cannot be detected. IS = internal standard. 
 
 
Figure S85: Conversion of polyamine 29 to the cyclic amine product 42 by the combination of purified PuO-Re and R-IRED-St. In 
the reaction with both enzymes being active (black) the substrate is fully consumed in the 3 h reaction time and transformed to 
the product 42. After inactivation of one of the enzymes (R-IRED-Sr inactivated in pink or PuO-Re inactivated in blue) either the 
polyamine is not converted (blue) or small amounts of the imine intermediate (pink) could be detected. It is assumed that most of 
the imine intermediate forms a trimer. Due to its too high boiling point, the trimer cannot be detected. IS = internal standard.  
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Figure S86: Conversion of polyamine 31 to the cyclic amine product 44 by the combination of purified PuO-Re and R-IRED-St. In 
the reaction with both enzymes being active (black) the substrate is fully consumed in the 3 h reaction time and transformed to 
the product 44. After inactivation of one of the enzymes (R-IRED-St inactivated in pink or PuO-Re inactivated in blue) either the 
polyamine is not converted (blue) or small amounts of the imine intermediates (pink) could be detected. It is assumed that most 
of the imine intermediate forms a trimer. Due to its too high boiling point, the trimer cannot be detected. The reaction scheme on 
top assumes that the sterically less demanding amine group of 31 is oxidized, however the regioselectivity of PuO-Re has to be 
determined. Depending on this regioselectivity also different imine intermediates are formed, however this information is lost after 
reduction of the cyclic imine by an IRED. IS = internal standard. 
 
 
Figure S87: Conversion of polyamine 28 to the cyclic amine product 40 by the combination of purified PuO-Re and S-IRED-Pe. 
In the reaction with both enzymes being active (black) the substrate is fully consumed in the 3 h reaction time and transformed to 
the product 40. After inactivation of one of the enzymes (S-IRED-Pe inactivated in pink or PuO-Re inactivated in blue) either the 
polyamine is not converted (blue) or the imine intermediate 39 (pink) could be detected. It is assumed that most of the imine 
intermediate forms a trimer. Due to its too high boiling point, the trimer cannot be detected. IS = internal standard. 
 
7 SUPPORTING INFORMATION 
184 
 
Figure S88: Conversion of polyamine 29 to the cyclic amine product 42 by the combination of purified PuO-Re and S-IRED-Pe. 
In the reaction with both enzymes being active (black) the substrate is fully consumed in the 3 h reaction time and transformed to 
the product 42. After inactivation of one of the enzymes (R-IRED-Sr inactivated in pink or PuO-Re inactivated in blue) either the 
polyamine is not converted (blue) or small amounts of the imine intermediate (pink) could be detected. It is assumed that most of 
the imine intermediate forms a trimer. Due to its too high boiling point, the trimer cannot be detected. IS = internal standard.  
 
 
Figure S89: Conversion of polyamine 31 to the cyclic amine product 44 by the combination of purified PuO-Re and S-IRED-Pe. 
In the reaction with both enzymes being active (black) the substrate is fully consumed in the 3 h reaction time and transformed to 
the product 44. After inactivation of one of the enzymes (S-IRED-Pe inactivated in pink or PuO-Re inactivated in blue) either the 
polyamine is not converted (blue) or small amounts of the imine intermediates (pink) could be detected. It is assumed that most 
of the imine intermediate forms a trimer. Due to its too high boiling point, the trimer cannot be detected. The reaction scheme on 
top assumes that the sterically less demanding amine group of 31 is oxidized, however the regioselectivity of PuO-Re has to be 
determined. Depending on this regioselectivity also different imine intermediates are formed, however this information is lost after 
reduction of the cyclic imine by an IRED. IS = internal standard.  
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7.11 GC-traces of whole cell biotransformations with E. coli strains expressing 
PuO-Re and an IRED simultaneously to transform polyamines into 
N-heterocycles 
 
 
Figure S90: Whole cell biotransformation of polyamine 31 to the cyclic amine 44 with E. coli JW5510 expressing PuO-Re and 
R-IRED-Sr simultaneously. For the reaction time of 20 h the amount of product slightly increases. Compared to the performance 
of isolated enzymes the consumption of the substrate and transformation to the amine is poor. 
 
 
Figure S91: Whole cell biotransformation of polyamine 31 to the cyclic amine 44 with E. coli JW5510 expressing PuO-Re and 
R-IRED-St simultaneously. For the reaction time of 20 h the amount of product slightly increases. Compared to the performance 
of isolated enzymes the consumption of the substrate and transformation to the amine is poor. 
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7.12 NMR spectra 
 
 
Figure S92: 1H-NMR spectrum of 2-methylpiperideine (3a).  
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Figure S93: 13C-NMR spectrum of 2-methylpiperideine (3a). 
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Figure S94: 1H-NMR spectrum of 2-phenylpiperideine (3b). 
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Figure S95: 13C-NMR spectrum of 2-phenylpiperideine (3b). 
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Figure S96: 1H-NMR spectrum of 2-p-fluorophenylpiperideine (3c). 
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Figure S97: 13C-NMR spectrum of 2-p-fluorophenylpiperideine (3c). 
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Figure S98: 1H-NMR spectrum of 1-methyl-1,2,3,4-tetrahydroisoquinoline (6b). 
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Figure S99: 13C-NMR spectrum of 1-methyl-1,2,3,4-tetrahydroisoquinoline (6b). 
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Figure S100: 1H-NMR spectrum of 1,4-diaminopentane (32). 
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Figure S101: 1H-NMR spectrum of 1,5-diaminohexane (33). 
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